## (19) World Intellectual Property Organization International Bureau





## (43) International Publication Date 25 May 2001 (25.05.2001)

## **PCT**

# (10) International Publication Number WO 01/35726 A1

(51) International Patent Classification<sup>7</sup>: 5/00, C12N 5/14, 15/82

A01H 1/00.

(21) International Application Number: PCT/US00/31418

(22) International Filing Date:

14 November 2000 (14.11.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/166,228 17 November 1999 (17.11.1999) US 60/197,899 17 April 2000 (17.04.2000) US 60/227,439 22 August 2000 (22.08.2000) US

(71) Applicant (for all designated States except US): MENDEL BIOTECHNOLOGY, INC. [US/US]; 21375 Cabot Boulevard, Hayward, CA 94541 (US).

(71) Applicants and

(72) Inventors: HEARD, Jacqueline [US/US]; 810 Guildford Avenue, San Mateo, CA 94402 (US). RATCLIFFE, Oliver [GB/US]; 814 East 21st Street, Oakland, CA 94606 (US). CREELMAN, Robert [US/US]; 2801 Jennifer Drive, Castro Valley, CA 94546 (US). JIANG, Cai-Zhong [CN/US]; 34495 Heathrow Terrace, Fremont, CA 94555 (US). PINEDA, Omaira [CO/US]; 19563 Helen Place, Castro Valley, CA 94546 (US). REUBER, Lynne [US/US]; 2000 Walnut Avenue, Fremont, CA 94538 (US). ADAM, Luc [CA/US]; 25800 Industrial Boulevard, L403, Hayward, CA 94545 (US).

- (74) Agent: GUERRERO, Karen; Mendel Biotechnology, Inc., 21375 Cabot Boulevard, Hayward, CA 94545 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published:

With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

11/35726 A

(54) Title: PATHOGEN TOLERANCE GENES

(57) Abstract: The present invention relates to transgenic plants and methods of making transgenic plant using punitive transcription factors that modulate the transgenic plant's susceptibility to disease.

## PATHOGEN TOLERANCE GENES

#### RELATED APPLICATION INFORMATION

The present invention claims the benefit from US Provisional Patent Application Serial Nos. 60/166,228 filed November 17, 1999 and 60/197,899 filed April 17, 2000 and "Plant Trait Modification III" filed August 22, 2000.

5

10

15

20

25

30

35

#### FIELD OF THE INVENTION

This invention relates to the field of plant biology. More particularly, the present invention pertains to compositions and methods for phenotypically modifying a plant.

#### **BACKGROUND OF THE INVENTION**

Transcription factors can modulate gene expression, either increasing or decreasing (inducing or repressing) the rate of transcription. This modulation results in differential levels of gene expression at various developmental stages, in different tissues and cell types, and in response to different exogenous (e.g., environmental) and endogenous stimuli throughout the life cycle of the organism.

Because transcription factors are key controlling elements of biological pathways, altering the expression levels of one or more transcription factors can change entire biological pathways in an organism. For example, manipulation of the levels of selected transcription factors may result in increased expression of economically useful proteins or metabolic chemicals in plants or to improve other agriculturally relevant characteristics. Conversely, blocked or reduced expression of a transcription factor may reduce biosynthesis of unwanted compounds or remove an undesirable trait. Therefore, manipulating transcription factor levels in a plant offers tremendous potential in agricultural biotechnology for modifying a plant's traits.

The present invention provides novel transcription factors useful for modifying a plant's phenotype in desirable ways, such as modifying a plant's pathogen tolerance.

### SUMMARY OF THE INVENTION

In a first aspect, the invention relates to a recombinant polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence encoding a polypeptide comprising a sequence selected from SEQ ID Nos. 2N, where N=1-29, or a complementary nucleotide sequence thereof; (b) a nucleotide sequence encoding a polypeptide comprising a conservatively substituted variant of a polypeptide of (a); (c) a nucleotide sequence comprising a sequence selected from those of SEQ ID Nos. 2N-1, where N=1-29, or a complementary nucleotide sequence thereof; (d) a nucleotide sequence

comprising silent substitutions in a nucleotide sequence of (c); (e) a nucleotide sequence which hybridizes under stringent conditions over substantially the entire length of a nucleotide sequence of one or more of: (a), (b), (c), or (d); (f) a nucleotide sequence comprising at least 15 consecutive nucleotides of a sequence of any of (a)-(e); (g) a nucleotide sequence comprising a subsequence or fragment of any of (a)-(f), which subsequence or fragment encodes a polypeptide having a biological activity that modifies a plant's pathogen tolerance; (h) a nucleotide sequence having at least 31% sequence identity to a nucleotide sequence of any of (a)-(g); (i) a nucleotide sequence having at least 60% identity sequence identity to a nucleotide sequence of any of (a)-(g); (j) a nucleotide sequence which encodes a polypeptide having at least 31% identity sequence identity to a polypeptide of SEQ ID Nos. 2N, where N=1-29; (k) a nucleotide sequence which encodes a polypeptide having at least 60% identity sequence identity to a polypeptide of SEQ ID Nos. 2N, where N=1-29; and (1) a nucleotide sequence which encodes a conserved domain of a polypeptide having at least 65% sequence identity to a conserved domain of a polypeptide of SEQ ID Nos. 2N, where N=1-29. The recombinant polynucleotide may further comprise a constitutive, inducible, or tissue-active promoter operably linked to the nucleotide sequence. The invention also relates to compositions comprising at least two of the above described polynucleotides.

5

10

15

25

30

35

In a second aspect, the invention is an isolated or recombinant polypeptide comprising a subsequence of at least about 15 contiguous amino acids encoded by the recombinant or isolated polynucleotide described above.

In another aspect, the invention is a transgenic plant comprising one or more of the above described recombinant polynucleotides. In yet another aspect, the invention is a plant with altered expression levels of a polynucleotide described above or a plant with altered expression or activity levels of an above described polypeptide. Further, the invention may be a plant lacking a nucleotide sequence encoding a polypeptide comprising a sequence selected from SEQ ID Nos. 2N, where N=1-29.

The plant may be a soybean, wheat, corn, potato, cotton, rice, oilseed rape, sunflower, alfalfa, sugarcane, turf, banana, blackberry, blueberry, strawberry, raspberry, cantaloupe, carrot, cauliflower, coffee, cucumber, eggplant, grapes, honeydew, lettuce, mango, melon, onion, papaya, peas, peppers, pineapple, spinach, squash, sweet corn, tobacco, tomato, watermelon, rosaceous fruits, or vegetable brassicas plant.

In a further aspect, the invention relates to a cloning or expression vector comprising the isolated or recombinant polynucleotide described above or cells comprising the cloning or expression vector.

In yet a further aspect, the invention relates to a composition produced by incubating a polynucleotide of the invention with a nuclease, a restriction enzyme, a polymerase; a polymerase and a primer; a cloning vector, or with a cell.

Furthermore, the invention relates to a method for producing a plant having improved pathogen tolerance. The method comprises altering the expression of an isolated or recombinant polynucleotide of the invention or altering the expression or activity of a polypeptide of the invention in a plant to produce a modified plant, and selecting the modified plant for modified pathogen tolerance.

5

10

15

20

25

30

35

In another aspect, the invention relates to a method of identifying a factor that is modulated by or interacts with a polypeptide encoded by a polynucleotide of the invention. The method comprises expressing a polypeptide encoded by the polynucleotide in a plant; and identifying at least one factor that is modulated by or interacts with the polypeptide. In one embodiment the method for identifying modulating or interacting factors is by detecting binding by the polypeptide to a promoter sequence, or by detecting interactions between an additional protein and the polypeptide in a yeast two hybrid system, or by detecting expression of a factor by hybridization to a microarray, subtractive hybridization or differential display.

In yet another aspect, the invention is a method of identifying a molecule that modulates activity or expression of a polynucleotide or polypeptide of interest. The method comprises placing the molecule in contact with a plant comprising the polynucleotide or polypeptide encoded by the polynucleotide of the invention and monitoring one or more of the expression level of the polynucleotide in the plant, the expression level of the polypeptide in the plant, and modulation of an activity of the polypeptide in the plant.

In yet another aspect, the invention relates to an integrated system, computer or computer readable medium comprising one or more character strings corresponding to a polynucleotide of the invention, or to a polypeptide encoded by the polynucleotide. The integrated system, computer or computer readable medium may comprise a link between one or more sequence strings to a modified plant pathogen tolerance phenotype.

In yet another aspect, the invention is a method for identifying a sequence similar or homologous to one or more polynucleotides of the invention, or one or more polypeptides encoded by the polynucleotides. The method comprises providing a sequence database; and, querying the sequence database with one or more target sequences corresponding to the one or more polynucleotides or to the one or more polypeptides to identify one or more sequence members of the database that display sequence similarity or homology to one or more of the one or more target sequences.

The method may further comprise of linking the one or more of the polynucleotides of the invention, or encoded polypeptides, to a modified plant pathogen tolerance phenotype.

3

### **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 provides a table of exemplary polynucleotide and polypeptide sequences of the invention. The table includes from left to right for each sequence: the SEQ ID No., the internal code reference number (GID), whether the sequence is a polynucleotide or polypeptide sequence, and identification of any conserved domains for the polypeptide sequences.

Figure 2 provides a table of exemplary sequences that are homologous to other sequences provided in the Sequence Listing and that are derived from *Arabidopsis thaliana*. The table includes from left to right: the SEQ ID No., the internal code reference number (GID), identification of the homologous sequence, whether the sequence is a polynucleotide or polypeptide sequence, and identification of any conserved domains for the polypeptide sequences.

Figure 3 provides a table of exemplary sequences that are homologous to the sequences provided in Figures 1 and 2 and that are derived from plants other than *Arabidopsis thaliana*. The table includes from left to right: the SEQ ID No., the internal code reference number (GID), the unique GenBank sequence ID No. (NID), the probability that the comparison was generated by chance (P-value), and the species from which the homologous gene was identified.

20

25

30

35

10

15

## **DETAILED DESCRIPTION**

The present invention relates to polynucleotides and polypeptides, e.g. for modifying phenotypes of plants.

In particular, the polynucleotides or polypeptides are useful for modifying traits associated with a plant's pathogen tolerance when the expression levels of the polynucleotides or expression levels or activity levels of the polypeptides are altered. Specifically, the polynucleotides and polypeptides are useful for modifying traits associated with a plant's pathogen tolerance, such as alterations in cell wall composition, trichome number or structure, callose induction, phytoalexin induction, alterations in the cell death response, or the like. Transgenic plants employing the polynucleotides or polypeptides of the invention are more tolerant to biotrophic or necrotrophic pathogens such as fungi, bacteria, mollicutes, viruses, nematodes, parasitic higher plants or the like.

The polynucleotides of the invention encode plant transcription factors. The plant transcription factors are derived, e.g., from *Arabidopsis thaliana* and can belong, e.g., to one or more of the following transcription factor families: the AP2 (APETALA2) domain transcription factor family (Riechmann and Meyerowitz (1998) <u>J. Biol. Chem.</u> 379:633-646); the MYB transcription factor family (Martin and Paz-Ares (1997) <u>Trends Genet.</u> 13:67-73); the MADS domain transcription factor family (Riechmann and Meyerowitz (1997) <u>J. Biol.</u>

Chem 378:1079-1101); the WRKY protein family (Ishiguro and Nakamura (1994) Mol. Gen. Genet. 244:563-571); the ankyrin-repeat protein family (Zhang et al. (1992) Plant Cell 4:1575-1588); the miscellaneous protein (MISC) family (Kim et al. (1997) Plant J. 11:1237-1251); the zinc finger protein (Z) family (Klug and Schwabe (1995) FASEB J. 9: 597-604); the homeobox (HB) protein family (Duboule (1994) Guidebook to the Homeobox Genes. Oxford University Press); the CAAT-element binding proteins (Forsburg and Guarente (1989) Genes Dev. 3:1166-1178); the squamosa promoter binding proteins (SPB) (Klein et al. (1996) Mol. Gen. Genet. 1996 250:7-16); the NAM protein family; the IAA/AUX proteins (Rouse et al. (1998) Science 279:1371-1373); the HLH/MYC protein family (Littlewood et al. (1994) Prot. Profile 1:639-709); the DNA-binding protein (DBP) family (Tucker et al. (1994) EMBO J. 13:2994-3002); the bZIP family of transcription factors (Foster et al. (1994) FASEB J. 8:192-200); the BPF-1 protein (Box P-binding factor) family (da Costa e Silva et al. (1993) Plant J. 4:125-135); and the golden protein (GLD) family (Hall et al. (1998) Plant Cell 10:925-936).

In addition to methods for modifying a plant phenotype by employing one or more polynucleotides and polypeptides of the invention described herein, the polynucleotides and polypeptides of the invention have a variety of additional uses. These uses include their use in the recombinant production (i.e, expression) of proteins; as regulators of plant gene expression, as diagnostic probes for the presence of complementary or partially complementary nucleic acids (including for detection of natural coding nucleic acids); as substrates for further reactions, e.g., mutation reactions, PCR reactions, or the like, of as substrates for cloning e.g., including digestion or ligation reactions, and for identifying exogenous or endogenous modulators of the transcription factors.

## **DEFINITIONS**

10

15

20

25

30

35

A "polynucleotide" is a nucleic acid sequence comprising a plurality of polymerized nucleotide residues, e.g., at least about 15 consecutive polymerized nucleotide residues, optionally at least about 30 consecutive nucleotides, at least about 50 consecutive nucleotides. In many instances, a polynucleotide comprises a nucleotide sequence encoding a polypeptide (or protein) or a domain or fragment thereof. Additionally, the polynucleotide may comprise a promoter, an intron, an enhancer region, a polyadenylation site, a translation initiation site, 5' or 3' untranslated regions, a reporter gene, a selectable marker, or the like. The polynucleotide can be single stranded or double stranded DNA or RNA. The polynucleotide optionally comprises modified bases or a modified backbone. The polynucleotide can be, e.g., genomic DNA or RNA, a transcript (such as an mRNA), a cDNA, a PCR product, a cloned DNA, a synthetic DNA or RNA, or the like. The polynucleotide can comprise a sequence in either sense or antisense orientations.

A "recombinant polynucleotide" is a polynucleotide that is not in its native state, e.g., the polynucleotide comprises a nucleotide sequence not found in nature, or the polynucleotide is in a context other than that in which it is naturally found, e.g., separated from nucleotide sequences with which it typically is in proximity in nature, or adjacent (or contiguous with) nucleotide sequences with which it typically is not in proximity. For example, the sequence at issue can be cloned into a vector, or otherwise recombined with one or more additional nucleic acid.

5

10

15

20

25

30

35

An "isolated polynucleotide" is a polynucleotide whether naturally occurring or recombinant, that is present outside the cell in which it is typically found in nature, whether purified or not. Optionally, an isolated polynucleotide is subject to one or more enrichment or purification procedures, e.g., cell lysis, extraction, centrifugation, precipitation, or the like.

A "recombinant polypeptide" is a polypeptide produced by translation of a recombinant polynucleotide. An "isolated polypeptide," whether a naturally occurring or a recombinant polypeptide, is more enriched in (or out of) a cell than the polypeptide in its natural state in a wild type cell, e.g., more than about 5% enriched, more than about 10% enriched, or more than about 20%, or more than about 50%, or more, enriched, i.e., alternatively denoted: 105%, 110%, 120%, 150% or more, enriched relative to wild type standardized at 100%. Such an enrichment is not the result of a natural response of a wild type plant. Alternatively, or additionally, the isolated polypeptide is separated from other cellular components with which it is typically associated, e.g., by any of the various protein purification methods herein.

The term "transgenic plant" refers to a plant that contains genetic material, not found in a wild type plant of the same species, variety or cultivar. The genetic material may include a transgene, an insertional mutagenesis event (such as by transposon or T-DNA insertional mutagenesis), an activation tagging sequence, a mutated sequence, a homologous recombination event or a sequence modified by chimeraplasty. Typically, the foreign genetic material has been introduced into the plant by human manipulation.

A transgenic plant may contain an expression vector or cassette. The expression cassette typically comprises a polypeptide-encoding sequence operably linked (i.e., under regulatory control of) to appropriate inducible or constitutive regulatory sequences that allow for the expression of polypeptide. The expression cassette can be introduced into a plant by transformation or by breeding after transformation of a parent plant. A plant refers to a whole plant as well as to a plant part, such as seed, fruit, leaf, or root, plant tissue, plant cells or any other plant material, e.g., a plant explant, as well as to progeny thereof, and to *in vitro* systems that mimic biochemical or cellular components or processes in a cell.

The phrase "ectopically expression or altered expression" in reference to a polynucleotide indicates that the pattern of expression in, e.g., a transgenic plant or plant

tissue, is different from the expression pattern in a wild type plant or a reference plant of the same species. For example, the polynucleotide or polypeptide is expressed in a cell or tissue type other than a cell or tissue type in which the sequence is expressed in the wild type plant, or by expression at a time other than at the time the sequence is expressed in the wild type plant, or by a response to different inducible agents, such as hormones or environmental signals, or at different expression levels (either higher or lower) compared with those found in a wild type plant. The term also refers to altered expression patterns that are produced by lowering the levels of expression to below the detection level or completely abolishing expression. The resulting expression pattern can be transient or stable, constitutive or inducible. In reference to a polypeptide, the term "ectopic expression or altered expression" further may relate to altered activity levels resulting from the interactions of the polypeptides with exogenous or endogenous modulators or from interactions with factors or as a result of the chemical modification of the polypeptides.

10

15

20

25

30

35

The term "fragment" or "domain," with respect to a polypeptide, refers to a subsequence of the polypeptide. In some cases, the fragment or domain, is a subsequence of the polypeptide which performs at least one biological function of the intact polypeptide in substantially the same manner, or to a similar extent, as does the intact polypeptide. For example, a polypeptide fragment can comprise a recognizable structural motif or functional domain such as a DNA binding domain that binds to a DNA promoter region, an activation domain or a domain for protein-protein interactions. Fragments can vary in size from as few as 6 amino acids to the full length of the intact polypeptide, but are preferably at least about 30 amino acids in length and more preferably at least about 60 amino acids in length. In reference to a nucleotide sequence, "a fragment" refers to any subsequence of a polynucleotide, typically, of at least consecutive about 15 nucleotides, preferably at least about 30 nucleotides, more preferably at least about 50, of any of the sequences provided herein.

The term "trait" refers to a physiological, morphological, biochemical or physical characteristic of a plant or particular plant material or cell. In some instances, this characteristic is visible to the human eye, such as seed or plant size, or can be measured by available biochemical techniques, such as the protein, starch or oil content of seed or leaves or by the observation of the expression level of genes, e.g., by employing Northern analysis, RT-PCR, microarray gene expression assays or reporter gene expression systems, or by agricultural observations such as stress tolerance, yield or pathogen tolerance.

"Trait modification" refers to a detectable difference in a characteristic in a plant ectopically expressing a polynucleotide or polypeptide of the present invention relative to a plant not doing so, such as a wild type plant. In some cases, the trait modification can be evaluated quantitatively. For example, the trait modification can entail at least about a 2%

increase or decrease in an observed trait (difference), at least a 5% difference, at least about a 10% difference, at least about a 20% difference, at least about a 30%, at least about a 50%, at least about a 70%, or at least about a 100%, or an even greater difference. It is known that there can be a natural variation in the modified trait. Therefore, the trait modification observed entails a change of the normal distribution of the trait in the plants compared with the distribution observed in wild type plant.

5

10

15

20

25

35

Trait modifications of particular interest include those to seed ( such as embryo or endosperm), fruit, root, flower, leaf, stem, shoot, seedling or the like, including: enhanced tolerance to environmental conditions including freezing, chilling, heat, drought, water saturation, radiation and ozone; improved tolerance to microbial, fungal or viral diseases; improved tolerance to pest infestations, including nematodes, mollicutes, parasitic higher plants or the like; decreased herbicide sensitivity; improved tolerance of heavy metals or enhanced ability to take up heavy metals; improved growth under poor photoconditions (e.g., low light and/or short day length), or changes in expression levels of genes of interest. Other phenotype that can be modified relate to the production of plant metabolites, such as variations in the production of taxol, tocopherol, tocotrienol, sterols, phytosterols, vitamins, wax monomers, anti-oxidants, amino acids, lignins, cellulose, tannins, prenyllipids (such as chlorophylls and carotenoids), glucosinolates, and terpenoids, enhanced or compositionally altered protein or oil production (especially in seeds), or modified sugar (insoluble or soluble) and/or starch composition. Physical plant characteristics that can be modified include cell development (such as the number of trichomes), fruit and seed size and number, yields of plant parts such as stems, leaves and roots, the stability of the seeds during storage, characteristics of the seed pod (e.g., susceptibility to shattering), root hair length and quantity, internode distances, or the quality of seed coat. Plant growth characteristics that can be modified include growth rate, germination rate of seeds, vigor of plants and seedlings, leaf and flower senescence, male sterility, apomixis, flowering time, flower abscission, rate of nitrogen uptake, biomass or transpiration characteristics, as well as plant architecture characteristics such as apical dominance, branching patterns, number of organs, organ identity, organ shape or size.

### 30 POLYPEPTIDES AND POLYNUCLEOTIDES OF THE INVENTION

The present invention provides, among other things, transcription factors (TFs), and transcription factor homologue polypeptides, and isolated or recombinant polynucleotides encoding the polypeptides. These polypeptides and polynucleotides may be employed to modify a plant's pathogen tolerance.

Exemplary polynucleotides encoding the polypeptides of the invention were identified in the *Arabidopsis thaliana* GenBank database using publicly available sequence

analysis programs and parameters. Sequences initially identified were then further characterized to identify sequences comprising specified sequence strings corresponding to sequence motifs present in families of known transcription factors. Polynucleotide sequences meeting such criteria were confirmed as transcription factors.

Additional polynucleotides of the invention were identified by screening Arabidopsis thaliana and/or other plant cDNA libraries with probes corresponding to known transcription factors under low stringency hybridization conditions. Additional sequences, including full length coding sequences were subsequently recovered by the rapid amplification of cDNA ends (RACE) procedure, using a commercially available kit according to the manufacturer's instructions. Where necessary, multiple rounds of RACE are performed to isolate 5' and 3' ends. The full length cDNA was then recovered by a routine end-to-end polymerase chain reaction (PCR) using primers specific to the isolated 5' and 3' ends. Exemplary sequences are provided in the Sequence Listing.

The polynucleotides of the invention were ectopically expressed in overexpressor or knockout plants and changes in the pathogen tolerance of the plants was observed. Therefore, the polynucleotides and polypeptides can be employed to improve the pathogen resistance of plants.

### Making polynucleotides

5

10

15

20

25

30

35

The polynucleotides of the invention include sequences that encode transcription factors and transcription factor homologue polypeptides and sequences complementary thereto, as well as unique fragments of coding sequence, or sequence complementary thereto. Such polynucleotides can be, e.g., DNA or RNA, e.g., mRNA, cRNA, synthetic RNA, genomic DNA, cDNA synthetic DNA, oligonucleotides, etc. The polynucleotides are either double-stranded or single-stranded, and include either, or both sense (i.e., coding) sequences and antisense (i.e., non-coding, complementary) sequences. The polynucleotides include the coding sequence of a transcription factor, or transcription factor homologue polypeptide, in isolation, in combination with additional coding sequences (e.g., a purification tag, a localization signal, as a fusion-protein, as a pre-protein, or the like), in combination with non-coding sequences (e.g., introns or inteins, regulatory elements such as promoters, enhancers, terminators, and the like), and/or in a vector or host environment in which the polynucleotide encoding a transcription factor or transcription factor homologue polypeptide is an endogenous or exogenous gene.

A variety of methods exist for producing the polynucleotides of the invention. Procedures for identifying and isolating DNA clones are well known to those of skill in the art, and are described in, e.g., Berger and Kimmel, <u>Guide to Molecular Cloning Techniques</u>, <u>Methods in Enzymology</u> volume 152 Academic Press, Inc., San Diego, CA ("Berger");

Sambrook et al., Molecular Cloning - A Laboratory Manual (2nd Ed.), Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989 ("Sambrook") and Current Protocols in Molecular Biology, F.M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (supplemented through 2000) ("Ausubel").

Alternatively, polynucleotides of the invention, can be produced by a variety of in vitro amplification methods adapted to the present invention by appropriate selection of specific or degenerate primers. Examples of protocols sufficient to direct persons of skill through in vitro amplification methods, including the polymerase chain reaction (PCR) the ligase chain reaction (LCR), Qbeta-replicase amplification and other RNA polymerase mediated techniques (e.g., NASBA), e.g., for the production of the homologous nucleic acids of the invention are found in Berger, Sambrook, and Ausubel, as well as Mullis et al., (1987) PCR Protocols A Guide to Methods and Applications (Innis et al. eds) Academic Press Inc. San Diego, CA (1990) (Innis). Improved methods for cloning in vitro amplified nucleic acids are described in Wallace et al., U.S. Pat. No. 5,426,039. Improved methods for amplifying large nucleic acids by PCR are summarized in Cheng et al. (1994) Nature 369: 684-685 and the references cited therein, in which PCR amplicons of up to 40kb are generated. One of skill will appreciate that essentially any RNA can be converted into a double stranded DNA suitable for restriction digestion, PCR expansion and sequencing using reverse transcriptase and a polymerase. See, e.g., Ausubel, Sambrook and Berger, all supra.

Alternatively, polynucleotides and oligonucleotides of the invention can be assembled from fragments produced by solid-phase synthesis methods. Typically, fragments of up to approximately 100 bases are individually synthesized and then enzymatically or chemically ligated to produce a desired sequence, e.g., a polynucleotide encoding all or part of a transcription factor. For example, chemical synthesis using the phosphoramidite method is described, e.g., by Beaucage et al. (1981) Tetrahedron Letters 22:1859-69; and Matthes et al. (1984) EMBO J. 3:801-5. According to such methods, oligonucleotides are synthesized, purified, annealed to their complementary strand, ligated and then optionally cloned into suitable vectors. And if so desired, the polynucleotides and polypeptides of the invention can be custom ordered from any of a number of commercial suppliers.

### **HOMOLOGOUS SEQUENCES**

5

15

25

30

35

Sequences homologous, i.e., that share significant sequence identity or similarity, to those provided in the Sequence Listing, derived from Arabidopsis thaliana or from other plants of choice are also an aspect of the invention. Homologous sequences can be derived from any plant including monocots and dicots and in particular agriculturally important plant species, including but not limited to, crops such as soybean, wheat, com,

potato, cotton, rice, oilseed rape (including canola), sunflower, alfalfa, sugarcane and turf; or fruits and vegetables, such as banana, blackberry, blueberry, strawberry, and raspberry, cantaloupe, carrot, cauliflower, coffee, cucumber, eggplant, grapes, honeydew, lettuce, mango, melon, onion, papaya, peas, peppers, pineapple, spinach, squash, sweet corn, tobacco, tomato, watermelon, rosaceous fruits (such as apple, peach, pear, cherry and plum) and vegetable brassicas (such as broccoli, cabbage, cauliflower, brussel sprouts and kohlrabi). Other crops, fruits and vegetables whose phenotype can be changed include barley, rye, millet, sorghum, currant, avocado, citrus fruits such as oranges, lemons, grapefruit and tangerines, artichoke, cherries, nuts such as the walnut and peanut, endive, leek, roots, such as arrowroot, beet, cassava, turnip, radish, yam, and sweet potato, and beans. The homologous sequences may also be derived from woody species, such pine, poplar and eucalyptus.

10

15

20

25

30

35

Transcription factors that are homologous to the listed sequences will typically share at least about 31% amino acid sequence identity. More closely related transcription factors can share at least about 50%, about 60%, about 65%, about 70%, about 75% or about 80% or about 90% or about 95% or about 98% or more sequence identity with the listed sequences. Factors that are most closely related to the listed sequences share, e.g., at least about 85%, about 90% or about 95% or more % sequence identity to the listed sequences. At the nucleotide level, the sequences will typically share at least about 40% nucleotide sequence identity, preferably at least about 50%, about 60%, about 70% or about 80% sequence identity, and more preferably about 85%, about 90%, about 95% or about 97% or more sequence identity to one or more of the listed sequences. The degeneracy of the genetic code enables major variations in the nucleotide sequence of a polynucleotide while maintaining the amino acid sequence of the encoded protein. Conserved domains within a transcription factor family may exhibit a higher degree of sequence homology, such as at least 65% sequence identity including conservative substitutions, and preferably at least 80% sequence identity.

## Identifying Nucleic Acids by Hybridization

Polynucleotides homologous to the sequences illustrated in the Sequence Listing can be identified, e.g., by hybridization to each other under stringent or under highly stringent conditions. Single stranded polynucleotides hybridize when they associate based on a variety of well characterized physico-chemical forces, such as hydrogen bonding, solvent exclusion, base stacking and the like. The stringency of a hybridization reflects the degree of sequence identity of the nucleic acids involved, such that the higher the stringency, the more similar are the two polynucleotide strands. Stringency is influenced by a variety of factors, including temperature, salt concentration and composition, organic and non-organic additives, solvents, etc. present in both the hybridization and wash solutions and incubations (and number), as described in more detail in the references cited above.

An example of stringent hybridization conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on a filter in a Southern or northern blot is about 5°C to 20°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The T<sub>m</sub> is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Nucleic acid molecules that hybridize under stringent conditions will typically hybridize to a probe based on either the entire cDNA or selected portions, e.g., to a unique subsequence, of the cDNA under wash conditions of 0.2x SSC to 2.0 x SSC, 0.1% SDS at 50-65° C, for example 0.2 x SSC, 0.1% SDS at 65° C. For identification of less closely related homologues washes can be performed at a lower temperature, e.g., 50° C. In general, stringency is increased by raising the wash temperature and/or decreasing the concentration of SSC.

As another example, stringent conditions can be selected such that an oligonucleotide that is perfectly complementary to the coding oligonucleotide hybridizes to the coding oligonucleotide with at least about a 5-10x higher signal to noise ratio than the ratio for hybridization of the perfectly complementary oligonucleotide to a nucleic acid encoding a transcription factor known as of the filing date of the application. Conditions can be selected such that a higher signal to noise ratio is observed in the particular assay which is used, e.g., about 15x, 25x, 35x, 50x or more. Accordingly, the subject nucleic acid hybridizes to the unique coding oligonucleotide with at least a 2x higher signal to noise ratio as compared to hybridization of the coding oligonucleotide to a nucleic acid encoding known polypeptide. Again, higher signal to noise ratios can be selected, e.g., about 5x, 10x, 25x, 35x, 50x or more. The particular signal will depend on the label used in the relevant assay, e.g., a fluorescent label, a colorimetric label, a radio active label, or the like.

Alternatively, transcription factor homologue polypeptides can be obtained by screening an expression library using antibodies specific for one or more transcription factors. With the provision herein of the disclosed transcription factor, and transcription factor homologue nucleic acid sequences, the encoded polypeptide(s) can be expressed and purified in a heterologous expression system (e.g., *E. coli*) and used to raise antibodies (monoclonal or polyclonal) specific for the polypeptide(s) in question. Antibodies can also be raised against synthetic peptides derived from transcription factor, or transcription factor homologue, amino acid sequences. Methods of raising antibodies are well known in the art and are described in Harlow and Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York. Such antibodies can then be used to screen an expression library produced from the plant from which it is desired to clone additional transcription

factor homologues, using the methods described above. The selected cDNAs can be confirmed by sequencing and enzymatic activity.

## SEQUENCE VARIATIONS

5

10

It will readily be appreciated by those of skill in the art, that any of a variety of polynucleotide sequences are capable of encoding the transcription factors and transcription factor homologue polypeptides of the invention. Due to the degeneracy of the genetic code, many different polynucleotides can encode identical and/or substantially similar polypeptides in addition to those sequences illustrated in the Sequence Listing.

For example, Table 1 illustrates, e.g., that the codons AGC, AGT, TCA, TCC, TCG, and TCT all encode the same amino acid: serine. Accordingly, at each position in the sequence where there is a codon encoding serine, any of the above trinucleotide sequences can be used without altering the encoded polypeptide.

Table 1

Amino acids			Codon		-	·		
Alanine	Ala	A	GCA	GCC	GCG	GCU		
Cysteine	Cys	С	TGC	TGT				
Aspartic acid	Asp	D	GAC	GAT				
Glutamic acid	Glu	E	GAA	GAG			•	
Phenylalanine	Phe	F	TTC	TTT				
Glycine	Gly	G	GGA	GGC	GGG	GGT		
Histidine	His	H	CAC	CAT				
Isoleucine	Ile	I	ATA	ATC	ATT			
Lysine	Lys	K	AAA ·	AAG				
Leucine	Leu	L	TTA	TTG	CTA	CTC	CTG	CTT
Methionine	Met	M	ATG					
Asparagine	Asn	N	AAC	AAT			•	
Proline	Pro	P	CCA	CCC	CCG	CCT		
Glutamine	Gln	Q	CAA	CAG				
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG	CGT
Serine	Ser	S	AGC	AGT	TCA	TCC	TCG	TCT
Threonine	Thr	T	ACA	ACC	ACG	ACT		
Valine	Val	V	GTA	GTC	GTG	GTT		
Tryptophan	Trp	W	TGG					
Tyrosine	Tyr	Y	TAC	TAT				

15

20

Sequence alterations that do not change the amino acid sequence encoded by the polynucleotide are termed "silent" variations. With the exception of the codons ATG and TGG, encoding methionine and tryptophan, respectively, any of the possible codons for the same amino acid can be substituted by a variety of techniques, e.g., site-directed mutagenesis, available in the art. Accordingly, any and all such variations of a sequence selected from the above table are a feature of the invention.

In addition to silent variations, other conservative variations that alter one, or a few amino acids in the encoded polypeptide, can be made without altering the function of the polypeptide, these conservative variants are, likewise, a feature of the invention.

For example, substitutions, deletions and insertions introduced into the sequences provided in the Sequence Listing are also envisioned by the invention. Such sequence modifications can be engineered into a sequence by site-directed mutagenesis (Wu (ed.) Meth. Enzymol. (1993) vol. 217, Academic Press) or the other methods noted below. Amino acid substitutions are typically of single residues; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues. In preferred embodiments, deletions or insertions are made in adjacent pairs, e.g., a deletion of two residues or insertion of two residues. Substitutions, deletions, insertions or any combination thereof can be combined to arrive at a sequence. The mutations that are made in the polynucleotide encoding the transcription factor should not place the sequence out of reading frame and should not create complementary regions that could produce secondary mRNA structure. Preferably, the polypeptide encoded by the DNA performs the desired function.

Conservative substitutions are those in which at least one residue in the amino acid sequence has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the Table 2 when it is desired to maintain the activity of the protein. Table 2 shows amino acids which can be substituted for an amino acid in a protein and which are typically regarded as conservative substitutions.

25

5

10

15

20

30

35

Table 2

Residue	Conservative Substitutions
Ala	Ser
Arg	Lys
Asn	Gln; His
Asp	Glu
Gln	Asn
Cys	Ser
Glu	Asp
Gly	Pro
His	Asn; Gln
Ile	Leu, Val
Leu	Ile; Val
Lys	Arg; Gln
Met	Leu; Ile
Phe	Met; Leu; Tyr
Ser	Thr; Gly
Thr	Ser;Val
Тгр	Tyr
Тут	Trp; Phe
Val	Ile; Leu

Substitutions that are less conservative than those in Table 2 can be selected by picking residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in protein properties will be those in which (a) a hydrophilic residue, e.g., seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine.

5

10

## FURTHER MODIFYING SEQUENCES OF THE INVENTION—MUTATION/ FORCED EVOLUTION

In addition to generating silent or conservative substitutions as noted, above, the present invention optionally includes methods of modifying the sequences of the Sequence Listing. In the methods, nucleic acid or protein modification methods are used to alter the given sequences to produce new sequences and/or to chemically or enzymatically modify given sequences to change the properties of the nucleic acids or proteins.

Thus, in one embodiment, given nucleic acid sequences are modified, e.g., according to standard mutagenesis or artificial evolution methods to produce modified sequences. For example, Ausubel, *supra*, provides additional details on mutagenesis methods. Artificial forced evolution methods are described, e.g., by Stemmer (1994) Nature 370:389-391, and Stemmer (1994) Proc. Natl. Acad. Sci. USA 91:10747-10751. Many other mutation and evolution methods are also available and expected to be within the skill of the practitioner.

10

15

20

30

35

Similarly, chemical or enzymatic alteration of expressed nucleic acids and polypeptides can be performed by standard methods. For example, sequence can be modified by addition of lipids, sugars, peptides, organic or inorganic compounds, by the inclusion of modified nucleotides or amino acids, or the like. For example, protein modification techniques are illustrated in Ausubel, *supra*. Further details on chemical and enzymatic modifications can be found herein. These modification methods can be used to modify any given sequence, or to modify any sequence produced by the various mutation and artificial evolution modification methods noted herein.

Accordingly, the invention provides for modification of any given nucleic acid by mutation, evolution, chemical or enzymatic modification, or other available methods, as well as for the products produced by practicing such methods, e.g., using the sequences herein as a starting substrate for the various modification approaches.

For example, optimized coding sequence containing codons preferred by a particular prokaryotic or eukaryotic host can be used e.g., to increase the rate of translation or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, as compared with transcripts produced using a non-optimized sequence. Translation stop codons can also be modified to reflect host preference. For example, preferred stop codons for S. cerevisiae and mammals are TAA and TGA, respectively. The preferred stop codon for monocotyledonous plants is TGA, whereas insects and E. coli prefer to use TAA as the stop codon.

The polynucleotide sequences of the present invention can also be engineered in order to alter a coding sequence for a variety of reasons, including but not limited to, alterations which modify the sequence to facilitate cloning, processing and/or expression of

the gene product. For example, alterations are optionally introduced using techniques which are well known in the art, e.g., site-directed mutagenesis, to insert new restriction sites, to alter glycosylation patterns, to change codon preference, to introduce splice sites, etc.

Furthermore, a fragment or domain derived from any of the polypeptides of the invention can be combined with domains derived from other transcription factors or synthetic domains to modify the biological activity of a transcription factor. For instance, a DNA binding domain derived from a transcription factor of the invention can be combined with the activation domain of another transcription factor or with a synthetic activation domain. A transcription activation domain assists in initiating transcription from a DNA binding site. Examples include the transcription activation region of VP16 or GAL4 (Moore et al. (1998) Proc. Natl. Acad. Sci. USA 95: 376-381; and Aoyama et al. (1995) Plant Cell 7:1773-1785), peptides derived from bacterial sequences (Ma and Ptashne (1987) Cell 51; 113-119) and synthetic peptides (Giniger and Ptashne, (1987) Nature 330:670-672).

## EXPRESSION AND MODIFICATION OF POLYPEPTIDES

15

20

25

5

10

Typically, polynucleotide sequences of the invention are incorporated into recombinant DNA (or RNA) molecules that direct expression of polypeptides of the invention in appropriate host cells, transgenic plants, in vitro translation systems, or the like. Due to the inherent degeneracy of the genetic code, nucleic acid sequences which encode substantially the same or a functionally equivalent amino acid sequence can be substituted for any listed sequence to provide for cloning and expressing the relevant homologue.

Vectors, Promoters and Expression Systems

The present invention includes recombinant constructs comprising one or more of the nucleic acid sequences herein. The constructs typically comprise a vector, such as a plasmid, a cosmid, a phage, a virus (e.g., a plant virus), a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), or the like, into which a nucleic acid sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available.

30

35

General texts which describe molecular biological techniques useful herein, including the use and production of vectors, promoters and many other relevant topics, include Berger, Sambrook and Ausubel, *supra*. Any of the identified sequences can be incorporated into a cassette or vector, e.g., for expression in plants. A number of expression vectors suitable for stable transformation of plant cells or for the establishment of transgenic plants have been described including those described in Weissbach and Weissbach, (1989) Methods for Plant Molecular Biology, Academic Press, and Gelvin et al., (1990) Plant

Molecular Biology Manual, Kluwer Academic Publishers. Specific examples include those derived from a Ti plasmid of *Agrobacterium tumefaciens*, as well as those disclosed by Herrera-Estrella et al. (1983) Nature 303: 209, Bevan (1984) Nucl Acid Res. 12: 8711-8721, Klee (1985) Bio/Technology 3: 637-642, for dicotyledonous plants.

5

Alternatively, non-Ti vectors can be used to transfer the DNA into monocotyledonous plants and cells by using free DNA delivery techniques. Such methods can involve, for example, the use of liposomes, electroporation, microprojectile bombardment, silicon carbide whiskers, and viruses. By using these methods transgenic plants such as wheat, rice (Christou (1991) Bio/Technology 9: 957-962) and corn (Gordon-Kamm (1990) Plant Cell 2: 603-618) can be produced. An immature embryo can also be a good target tissue for monocots for direct DNA delivery techniques by using the particle gun (Weeks et al. (1993) Plant Physiol 102: 1077-1084; Vasil (1993) Bio/Technology 10: 667-674; Wan and Lemeaux (1994) Plant Physiol 104: 37-48, and for Agrobacterium-mediated DNA transfer (Ishida et al. (1996) Nature Biotech 14: 745-750).

15

10

Typically, plant transformation vectors include one or more cloned plant coding sequence (genomic or cDNA) under the transcriptional control of 5' and 3' regulatory sequences and a dominant selectable marker. Such plant transformation vectors typically also contain a promoter (e.g., a regulatory region controlling inducible or constitutive, environmentally-or developmentally-regulated, or cell- or tissue-specific expression), a transcription initiation start site, an RNA processing signal (such as intron splice sites), a transcription termination site, and/or a polyadenylation signal.

20

25

Examples of constitutive plant promoters which can be useful for expressing the TF sequence include: the cauliflower mosaic virus (CaMV) 35S promoter, which confers constitutive, high-level expression in most plant tissues (see, e.g., Odel et al. (1985) Nature 313:810); the nopaline synthase promoter (An et al. (1988) Plant Physiol 88:547); and the octopine synthase promoter (Fromm et al. (1989) Plant Cell 1: 977).

30

35

A variety of plant gene promoters that regulate gene expression in response to environmental, hormonal, chemical, developmental signals, and in a tissue-active manner can be used for expression of a TF sequence in plants. Choice of a promoter is based largely on the phenotype of interest and is determined by such factors as tissue (e.g., seed, fruit, root, pollen, vascular tissue, flower, carpel, etc.), inducibility (e.g., in response to wounding, heat, cold, drought, light, pathogens, etc.), timing, developmental stage, and the like. Numerous known promoters have been characterized and can favorable be employed to promote expression of a polynucleotide of the invention in a transgenic plant or cell of interest. For example, tissue specific promoters include: seed-specific promoters (such as the napin, phaseolin or DC3 promoter described in US Pat. No. 5,773,697), fruit-specific promoters that are active during fruit ripening (such as the dru 1 promoter (US Pat. No. 5,783,393), or the

2A11 promoter (US Pat. No. 4,943,674) and the tomato polygalacturonase promoter (Bird et al. (1988) Plant Mol Biol 11:651), root-specific promoters, such as those disclosed in US Patent Nos. 5,618,988, 5,837,848 and 5,905,186, pollen-active promoters such as PTA29, PTA26 and PTA13 (US Pat. No. 5,792,929), promoters active in vascular tissue (Ringli and Keller (1998) Plant Mol Biol 37:977-988), flower-specific (Kaiser et al, (1995) Plant Mol Biol 28:231-243), pollen (Baerson et al. (1994) Plant Mol Biol 26:1947-1959), carpels (Ohl et al. (1990) Plant Cell 2:837-848), pollen and ovules (Baerson et al. (1993) Plant Mol Biol 22:255-267), auxin-inducible promoters (such as that described in van der Kop et al. (1999) Plant Mol Biol 39:979-990 or Baumann et al. (1999) Plant Cell 11:323-334), cytokinininducible promoter (Guevara-Garcia (1998) Plant Mol Biol 38:743-753), promoters responsive to gibberellin (Shi et al. (1998) Plant Mol Biol 38:1053-1060, Willmott et al. (1998) 38:817-825) and the like. Additional promoters are those that elicit expression in response to heat (Ainley et al. (1993) Plant Mol Biol 22: 13-23), light (e.g., the pea rbcS-3A promoter, Kuhlemeier et al. (1989) Plant Cell 1:471, and the maize rbcS promoter, Schaffner and Sheen (1991) Plant Cell 3: 997); wounding (e.g., wunI, Siebertz et al. (1989) Plant Cell 1: 961); pathogens (such as the PR-1 promoter described in Buchel et al. (1999) Plant Mol. Biol. 40:387-396, and the PDF1.2 promoter described in Manners et al. (1998) Plant Mol. Biol. 38:1071-80), and chemicals such as methyl jasmonate or salicylic acid (Gatz et al. (1997) Plant Mol Biol 48: 89-108). In addition, the timing of the expression can be controlled by using promoters such as those acting at senescence (An and Amazon (1995) Science 270: 1986-1988); or late seed development (Odell et al. (1994) Plant Physiol 106:447-458).

10

15

20

25

30

Plant expression vectors can also include RNA processing signals that can be positioned within, upstream or downstream of the coding sequence. In addition, the expression vectors can include additional regulatory sequences from the 3'-untranslated region of plant genes, e.g., a 3' terminator region to increase mRNA stability of the mRNA, such as the PI-II terminator region of potato or the octopine or nopaline synthase 3' terminator regions.

Additional Expression Elements

Specific initiation signals can aid in efficient translation of coding sequences. These signals can include, e.g., the ATG initiation codon and adjacent sequences. In cases where a coding sequence, its initiation codon and upstream sequences are inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only coding sequence (e.g., a mature protein coding sequence), or a portion thereof, is inserted, exogenous transcriptional control signals including the ATG initiation codon can be separately provided. The initiation codon is provided in the correct reading frame to facilitate transcription. Exogenous transcriptional elements and initiation

codons can be of various origins, both natural and synthetic. The efficiency of expression can be enhanced by the inclusion of enhancers appropriate to the cell system in use.

#### **Expression Hosts**

5

10

15

20

25

30

35

The present invention also relates to host cells which are transduced with vectors of the invention, and the production of polypeptides of the invention (including fragments thereof) by recombinant techniques. Host cells are genetically engineered (i.e, nucleic acids are introduced, e.g., transduced, transformed or transfected) with the vectors of this invention, which may be, for example, a cloning vector or an expression vector comprising the relevant nucleic acids herein. The vector is optionally a plasmid, a viral particle, a phage, a naked nucleic acids, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants, or amplifying the relevant gene. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to those skilled in the art and in the references cited herein, including, Sambrook and Ausubel.

The host cell can be a eukaryotic cell, such as a yeast cell, or a plant cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Plant protoplasts are also suitable for some applications. For example, the DNA fragments are introduced into plant tissues, cultured plant cells or plant protoplasts by standard methods including electroporation (Fromm et al., (1985) Proc. Natl. Acad. Sci. USA 82, 5824, infection by viral vectors such as cauliflower mosaic virus (CaMV) (Hohn et al., (1982) Molecular Biology of Plant Tumors, (Academic Press, New York) pp. 549-560; US 4,407,956), high velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface (Klein et al., (1987) Nature 327, 70-73), use of pollen as vector (WO 85/01856), or use of Agrobacterium tumefaciens or A. rhizogenes carrying a T-DNA plasmid in which DNA fragments are cloned. The T-DNA plasmid is transmitted to plant cells upon infection by Agrobacterium tumefaciens, and a portion is stably integrated into the plant genome (Horsch et al. (1984) Science 233:496-498; Fraley et al. (1983) Proc. Natl. Acad. Sci. USA 80, 4803).

The cell can include a nucleic acid of the invention which encodes a polypeptide, wherein the cells expresses a polypeptide of the invention. The cell can also include vector sequences, or the like. Furthermore, cells and transgenic plants which include any polypeptide or nucleic acid above or throughout this specification, e.g., produced by transduction of a vector of the invention, are an additional feature of the invention.

For long-term, high-yield production of recombinant proteins, stable expression can be used. Host cells transformed with a nucleotide sequence encoding a polypeptide of the invention are optionally cultured under conditions suitable for the

expression and recovery of the encoded protein from cell culture. The protein or fragment thereof produced by a recombinant cell may be secreted, membrane-bound, or contained intracellularly, depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides encoding mature proteins of the invention can be designed with signal sequences which direct secretion of the mature polypeptides through a prokaryotic or eukaryotic cell membrane.

### **Modified Amino Acids**

10

15

25

30

35

Polypeptides of the invention may contain one or more modified amino acids. The presence of modified amino acids may be advantageous in, for example, increasing polypeptide half-life, reducing polypeptide antigenicity or toxicity, increasing polypeptide storage stability, or the like. Amino acid(s) are modified, for example, co-translationally or post-translationally during recombinant production or modified by synthetic or chemical means.

Non-limiting examples of a modified amino acid include incorporation or other use of acetylated amino acids, glycosylated amino acids, sulfated amino acids, prenylated (e.g., farnesylated, geranylgeranylated) amino acids, PEG modified (e.g., "PEGylated") amino acids, biotinylated amino acids, carboxylated amino acids, phosphorylated amino acids, etc. References adequate to guide one of skill in the modification of amino acids are replete throughout the literature.

## 20 <u>IDENTIFICATION OF ADDITIONAL FACTORS</u>

A transcription factor provided by the present invention can also be used to identify additional endogenous or exogenous molecules that can affect a phentoype or trait of interest. On the one hand, such molecules include organic (small or large molecules) and/or inorganic compounds that affect expression of (i.e., regulate) a particular transcription factor. Alternatively, such molecules include endogenous molecules that are acted upon either at a transcriptional level by a transcription factor of the invention to modify a phenotype as desired. For example, the transcription factors can be employed to identify one or more downstream gene with which is subject to a regulatory effect of the transcription factor. In one approach, a transcription factor or transcription factor homologue of the invention is expressed in a host cell, e.g, a transgenic plant cell, tissue or explant, and expression products, either RNA or protein, of likely or random targets are monitored, e.g., by hybridization to a microarray of nucleic acid probes corresponding to genes expressed in a tissue or cell type of interest, by two-dimensional gel electrophoresis of protein products, or by any other method known in the art for assessing expression of gene products at the level of RNA or protein. Alternatively, a transcription factor of the invention can be used to identify promoter sequences (i.e., binding sites) involved in the regulation of a downstream target. After

identifying a promoter sequence, interactions between the transcription factor and the promoter sequence can be modified by changing specific nucleotides in the promoter sequence or specific amino acids in the transcription factor that interact with the promoter sequence to alter a plant trait. Typically, transcription factor DNA binding sites are identified by gel shift assays. After identifying the promoter regions, the promoter region sequences can be employed in double-stranded DNA arrays to identify molecules that affect the interactions of the transcription factors with their promoters (Bulyk et al. (1999) Nature Biotechnology 17:573-577).

The identified transcription factors are also useful to identify proteins that modify the activity of the transcription factor. Such modification can occur by covalent modification, such as by phosphorylation, or by protein-protein (homo or-heteropolymer) interactions. Any method suitable for detecting protein-protein interactions can be employed. Among the methods that can be employed are co-immunoprecipitation, cross-linking and co-purification through gradients or chromatographic columns, and the two-hybrid yeast system.

The two-hybrid system detects protein interactions in vivo and is described in Chien, et al., (1991), Proc. Natl. Acad. Sci. USA 88, 9578-9582 and is commercially available from Clontech (Palo Alto, Calif.). In such a system, plasmids are constructed that encode two hybrid proteins: one consists of the DNA-binding domain of a transcription activator protein fused to the TF polypeptide and the other consists of the transcription activator protein's activation domain fused to an unknown protein that is encoded by a cDNA that has been recombined into the plasmid as part of a cDNA library. The DNA-binding domain fusion plasmid and the cDNA library are transformed into a strain of the yeast Saccharomyces cerevisiae that contains a reporter gene (e.g., lacZ) whose regulatory region contains the transcription activator's binding site. Either hybrid protein alone cannot activate transcription of the reporter gene. Interaction of the two hybrid proteins reconstitutes the functional activator protein and results in expression of the reporter gene, which is detected by an assay for the reporter gene product. Then, the library plasmids responsible for reporter gene expression are isolated and sequenced to identify the proteins encoded by the library plasmids. After identifying proteins that interact with the transcription factors, assays for compounds that interfere with the TF protein-protein interactions can be preformed.

#### **IDENTIFICATION OF MODULATORS**

10

15

20

25

30

35

In addition to the intracellular molecules described above, extracellular molecules that alter activity or expression of a transcription factor, either directly or indirectly, can be identified. For example, the methods can entail first placing a candidate molecule in contact with a plant or plant cell. The molecule can be introduced by topical administration, such as spraying or soaking of a plant, and then the molecule's effect on the

expression or activity of the TF polypeptide or the expression of the polynucleotide monitored. Changes in the expression of the TF polypeptide can be monitored by use of polyclonal or monoclonal antibodies, gel electrophoresis or the like. Changes in the expression of the corresponding polynucleotide sequence can be detected by use of microarrays, Northerns, quantitative PCR, or any other technique for monitoring changes in mRNA expression. These techniques are exemplified in Ausubel et al. (eds) <u>Current Protocols in Molecular Biology</u>, John Wiley & Sons (1998). Such changes in the expression levels can be correlated with modified plant traits and thus identified molecules can be useful for soaking or spraying on fruit, vegetable and grain crops to modify traits in plants.

Essentially any available composition can be tested for modulatory activity of expression or activity of any nucleic acid or polypeptide herein. Thus, available libraries of compounds such as chemicals, polypeptides, nucleic acids and the like can be tested for modulatory activity. Often, potential modulator compounds can be dissolved in aqueous or organic (e.g., DMSO-based) solutions for easy delivery to the cell or plant of interest in which the activity of the modulator is to be tested. Optionally, the assays are designed to screen large modulator composition libraries by automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel (e.g., in microtiter formats on microtiter plates in robotic assays).

10

15

20

25

30

35

In one embodiment, high throughput screening methods involve providing a combinatorial library containing a large number of potential compounds (potential modulator compounds). Such "combinatorial chemical libraries" are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as target compounds.

A combinatorial chemical library can be, e.g., a collection of diverse chemical compounds generated by chemical synthesis or biological synthesis. For example, a combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (e.g., in one example, amino acids) in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound of a set length). Exemplary libraries include peptide libraries, nucleic acid libraries, antibody libraries (see, e.g., Vaughn et al. (1996) Nature Biotechnology, 14(3):309-314 and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al. Science (1996) 274:1520-1522 and U.S. Patent 5,593,853), peptide nucleic acid libraries (see, e.g., U.S. Patent 5,539,083), and small organic molecule libraries (see, e.g., benzodiazepines, Baum C&EN Jan 18, page 33 (1993); isoprenoids, U.S. Patent 5,569,588; thiazolidinones and metathiazanones, U.S. Patent 5,549,974; pyrrolidines, U.S. Patents 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent 5,506,337) and the like.

Preparation and screening of combinatorial or other libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent 5,010,175, Furka, Int. J. Pept. Prot. Res. 37:487-493 (1991) and Houghton et al. Nature 354:84-88 (1991)). Other chemistries for generating chemical diversity libraries can also be used.

5

10

15

20

25

30

35

In addition, as noted, compound screening equipment for high-throughput screening is generally available, e.g., using any of a number of well known robotic systems that have also been developed for solution phase chemistries useful in assay systems. These systems include automated workstations including an automated synthesis apparatus and robotic systems utilizing robotic arms. Any of the above devices are suitable for use with the present invention, e.g., for high-throughput screening of potential modulators. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art.

Indeed, entire high throughput screening systems are commercially available. These systems typically automate entire procedures including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. Similarly, microfluidic implementations of screening are also commercially available.

The manufacturers of such systems provide detailed protocols the various high throughput. Thus, for example, Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like. The integrated systems herein, in addition to providing for sequence alignment and, optionally, synthesis of relevant nucleic acids, can include such screening apparatus to identify modulators that have an effect on one or more polynucleotides or polypeptides according to the present invention.

In some assays it is desirable to have positive controls to ensure that the components of the assays are working properly. At least two types of positive controls are appropriate. That is, known transcriptional activators or inhibitors can be incubated with cells/plants/ etc. in one sample of the assay, and the resulting increase/decrease in transcription can be detected by measuring the resulting increase in RNA/ protein expression, etc., according to the methods herein. It will be appreciated that modulators can also be combined with transcriptional activators or inhibitors to find modulators which inhibit transcriptional activation or transcriptional repression. Either expression of the nucleic acids and proteins herein or any additional nucleic acids or proteins activated by the nucleic acids or proteins herein, or both, can be monitored.

In an embodiment, the invention provides a method for identifying compositions that modulate the activity or expression of a polynucleotide or polypeptide of the invention. For example, a test compound, whether a small or large molecule, is placed in contact with a cell, plant (or plant tissue or explant), or composition comprising the polynucleotide or polypeptide of interest and a resulting effect on the cell, plant, (or tissue or explant) or composition is evaluated by monitoring, either directly or indirectly, one or more of: expression level of the polynucleotide or polypeptide, activity (or modulation of the activity) of the polynucleotide or polypeptide. In some cases, an alteration in a plant phenotype can be detected following contact of a plant (or plant cell, or tissue or explant) with the putative modulator, e.g., by modulation of expression or activity of a polynucleotide or polypeptide of the invention.

#### **SUBSEQUENCES**

10

15

20

25

30

35

Also contemplated are uses of polynucleotides, also referred to herein as oligonucleotides, typically having at least 12 bases, preferably at least 15, more preferably at least 20, 30, or 50 bases, which hybridize under at least highly stringent (or ultra-high stringent or ultra-ultra- high stringent conditions) conditions to a polynucleotide sequence described above. The polynucleotides may be used as probes, primers, sense and antisense agents, and the like, according to methods as noted *supra*.

Subsequences of the polynucleotides of the invention, including polynucleotide fragments and oligonucleotides are useful as nucleic acid probes and primers. An oligonucleotide suitable for use as a probe or primer is at least about 15 nucleotides in length, more often at least about 18 nucleotides, often at least about 21 nucleotides, frequently at least about 30 nucleotides, or about 40 nucleotides, or more in length. A nucleic acid probe is useful in hybridization protocols, e.g., to identify additional polypeptide homologues of the invention, including protocols for microarray experiments. Primers can be annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, and then extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR) or other nucleic-acid amplification methods. See Sambrook and Ausubel, supra.

In addition, the invention includes an isolated or recombinant polypeptide including a subsequence of at least about 15 contiguous amino acids encoded by the recombinant or isolated polynucleotides of the invention. For example, such polypeptides, or domains or fragments thereof, can be used as immunogens, e.g., to produce antibodies specific for the polypeptide sequence, or as probes for detecting a sequence of interest. A

subsequence can range in size from about 15 amino acids in length up to and including the full length of the polypeptide.

### PRODUCTION OF TRANSGENIC PLANTS

5

10

15

20

25

30

35

### Modification of Traits

The polynucleotides of the invention are favorably employed to produce transgenic plants with various traits, or characteristics, that have been modified in a desirable manner, e.g., to improve the pathogen resistance of a plant. For example, alteration of expression levels or patterns (e.g., spatial or temporal expression patterns) of one or more of the transcription factors (or transcription factor homologues) of the invention, as compared with the levels of the same protein found in a wild type plant, can be used to modify a plant's traits. An illustrative example of trait modification, improved pathogen tolerance, by altering expression levels of a particular transcription factor is described further in the Examples and the Sequence Listing.

## Antisense and Cosuppression Approaches

In addition to expression of the nucleic acids of the invention as gene replacement or plant phenotype modification nucleic acids, the nucleic acids are also useful for sense and anti-sense suppression of expression, e.g., to down-regulate expression of a nucleic acid of the invention, e.g., as a further mechanism for modulating plant phenotype. That is, the nucleic acids of the invention, or subsequences or anti-sense sequences thereof, can be used to block expression of naturally occurring homologous nucleic acids. A variety of sense and anti-sense technologies are known in the art, e.g., as set forth in Lichtenstein and Nellen (1997) Antisense Technology: A Practical Approach IRL Press at Oxford University, Oxford, England. In general, sense or anti-sense sequences are introduced into a cell, where they are optionally amplified, e.g., by transcription. Such sequences include both simple oligonucleotide sequences and catalytic sequences such as ribozymes.

For example, a reduction or elimination of expression (i.e., a "knock-out") of a transcription factor or transcription factor homologue polypeptide in a transgenic plant, e.g., to modify a plant trait, can be obtained by introducing an antisense construct corresponding to the polypeptide of interest as a cDNA. For antisense suppression, the transcription factor or homologue cDNA is arranged in reverse orientation (with respect to the coding sequence) relative to the promoter sequence in the expression vector. The introduced sequence need not be the full length cDNA or gene, and need not be identical to the cDNA or gene found in the plant type to be transformed. Typically, the antisense sequence need only be capable of hybridizing to the target gene or RNA of interest. Thus, where the introduced sequence is of shorter length, a higher degree of homology to the endogenous transcription factor sequence will be needed for effective antisense suppression. While antisense sequences of various

lengths can be utilized, preferably, the introduced antisense sequence in the vector will be at least 30 nucleotides in length, and improved antisense suppression will typically be observed as the length of the antisense sequence increases. Preferably, the length of the antisense sequence in the vector will be greater than 100 nucleotides. Transcription of an antisense construct as described results in the production of RNA molecules that are the reverse complement of mRNA molecules transcribed from the endogenous transcription factor gene in the plant cell.

5

10

15

20

25

30

35

Suppression of endogenous transcription factor gene expression can also be achieved using a ribozyme. Ribozymes are RNA molecules that possess highly specific endoribonuclease activity. The production and use of ribozymes are disclosed in U.S. Patent No. 4,987,071 and U.S. Patent No. 5,543,508. Synthetic ribozyme sequences including antisense RNAs can be used to confer RNA cleaving activity on the antisense RNA, such that endogenous mRNA molecules that hybridize to the antisense RNA are cleaved, which in turn leads to an enhanced antisense inhibition of endogenous gene expression.

Vectors in which RNA encoded by a transcription factor or transcription factor homologue cDNA is over-expressed can also be used to obtain co-suppression of a corresponding endogenous gene, e.g., in the manner described in U.S. Patent No. 5,231,020 to Jorgensen. Such co-suppression (also termed sense suppression) does not require that the entire transcription factor cDNA be introduced into the plant cells, nor does it require that the introduced sequence be exactly identical to the endogenous transcription factor gene of interest. However, as with antisense suppression, the suppressive efficiency will be enhanced as specificity of hybridization is increased, e.g., as the introduced sequence is lengthened, and/or as the sequence similarity between the introduced sequence and the endogenous transcription factor gene is increased.

Vectors expressing an untranslatable form of the transcription factor mRNA, e.g., sequences comprising one or more stop codon, or nonsense mutation) can also be used to suppress expression of an endogenous transcription factor, thereby reducing or eliminating it's activity and modifying one or more traits. Methods for producing such constructs are described in U.S. Patent No. 5,583,021. Preferably, such constructs are made by introducing a premature stop codon into the transcription factor gene. Alternatively, a plant trait can be modified by gene silencing using double-strand RNA (Sharp (1999) Genes and Development 13: 139-141).

Another method for abolishing the expression of a gene is by insertion mutagenesis using the T-DNA of Agrobacterium tumefaciens. After generating the insertion mutants, the mutants can be screened to identify those containing the insertion in a transcription factor or transcription factor homologue gene. Plants containing a single

transgene insertion event at the desired gene can be crossed to generate homozygous plants for the mutation (Koncz et al. (1992) Methods in Arabidopsis Research, World Scientific).

Alternatively, a plant phenotype can be altered by eliminating an endogenous gene, such as a transcription factor or transcription factor homologue, e.g., by homologous recombination (Kempin et al. (1997) <u>Nature</u> 389:802).

5

10

15

20

25

30

35

A plant trait can also be modified by using the cre-lox system (for example, as described in US Paent No. 5,658,772). A plant genome can be modified to include first and second lox sites that are then contacted with a Cre recombinase. If the lox sites are in the same orientation, the intervening DNA sequence between the two sites is excised. If the lox sites are in the opposite orientation, the intervening sequence is inverted.

The polynucleotides and polypeptides of this invention can also be expressed in a plant in the absence of an expression cassette by manipulating the activity or expression level of the endogenous gene by other means. For example, by ectopically expressing a gene by T-DNA activation tagging (Ichikawa et al. (1997) Nature 390 698-701; Kakimoto et al. (1996) Science 274: 982-985). This method entails transforming a plant with a gene tag containing multiple transcriptional enhancers and once the tag has inserted into the genome, expression of a flanking gene coding sequence becomes deregulated. In another example, the transcriptional machinery in a plant can be modified so as to increase transcription levels of a polynucleotide of the invention (See, e.g., PCT Publications WO 96/06166 and WO 98/53057 which describe the modification of the DNA binding specificity of zinc finger proteins by changing particular amino acids in the DNA binding motif).

The transgenic plant can also include the machinery necessary for expressing or altering the activity of a polypeptide encoded by an endogenous gene, for example by altering the phosphorylation state of the polypeptide to maintain it in an activated state.

Transgenic plants (or plant cells, or plant explants, or plant tissues) incorporating the polynucleotides of the invention and/or expressing the polypeptides of the invention can be produced by a variety of well established techniques as described above. Following construction of a vector, most typically an expression cassette, including a polynucleotide, e.g., encoding a transcription factor or transcription factor homologue, of the invention, standard techniques can be used to introduce the polynucleotide into a plant, a plant cell, a plant explant or a plant tissue of interest. Optionally, the plant cell, explant or tissue can be regenerated to produce a transgenic plant.

The plant can be any higher plant, including gymnosperms, monocotyledonous and dicotyledenous plants. Suitable protocols are available for Leguminosae (alfalfa, soybean, clover, etc.), Umbelliferae (carrot, celery, parsnip), Cruciferae (cabbage, radish, rapeseed, broccoli, etc.), Curcurbitaceae (melons and cucumber), Gramineae (wheat, corn, rice, barley, millet, etc.), Solanaceae (potato, tomato, tobacco,

peppers, etc.), and various other crops. See protocols described in Ammirato et al. (1984) Handbook of Plant Cell Culture —Crop Species. Macmillan Publ. Co. Shimamoto et al. (1989) Nature 338:274-276; Fromm et al. (1990) Bio/Technology 8:833-839; and Vasil et al. (1990) Bio/Technology 8:429-434.

5

10

15

20

25

30

35

Transformation and regeneration of both monocotyledonous and dicotyledonous plant cells is now routine, and the selection of the most appropriate transformation technique will be determined by the practitioner. The choice of method will vary with the type of plant to be transformed; those skilled in the art will recognize the suitability of particular methods for given plant types. Suitable methods can include, but are not limited to: electroporation of plant protoplasts; liposome-mediated transformation; polyethylene glycol (PEG) mediated transformation; transformation using viruses; microinjection of plant cells; micro-projectile bombardment of plant cells; vacuum infiltration; and Agrobacterium tumeficiens mediated transformation. Transformation means introducing a nucleotide sequence in a plant in a manner to cause stable or transient expression of the sequence.

Successful examples of the modification of plant characteristics by transformation with cloned sequences which serve to illustrate the current knowledge in this field of technology, and which are herein incorporated by reference, include: U.S. Patent Nos. 5,571,706; 5,677,175; 5,510,471; 5,750,386; 5,597,945; 5,589,615; 5,750,871; 5,268,526; 5,780,708; 5,538,880; 5,773,269; 5,736,369 and 5,610,042.

Following transformation, plants are preferably selected using a dominant selectable marker incorporated into the transformation vector. Typically, such a marker will confer antibiotic or herbicide resistance on the transformed plants, and selection of transformants can be accomplished by exposing the plants to appropriate concentrations of the antibiotic or herbicide.

After transformed plants are selected and grown to maturity, those plants showing a modified trait are identified. The modified trait can be any of those traits described above. Additionally, to confirm that the modified trait is due to changes in expression levels or activity of the polypeptide or polynucleotide of the invention can be determined by analyzing mRNA expression using Northern blots, RT-PCR or microarrays, or protein expression using immunoblots or Western blots or gel shift assays.

## INTEGRATED SYSTEMS—SEQUENCE IDENTITY

Additionally, the present invention may be an integrated system, computer or computer readable medium that comprises an instruction set for determining the identity of one or more sequences in a database. In addition, the instruction set can be used to generate or identify sequences that meet any specified criteria. Furthermore, the instruction set may

be used to associate or link certain functional benefits, such improved pathogen tolerance, with one or more identified sequence.

For example, the instruction set can include, e.g., a sequence comparison or other alignment program, e.g., an available program such as, for example, the Wisconsin Package Version 10.0, such as BLAST, FASTA, PILEUP, FINDPATTERNS or the like (GCG, Madision, WI). Public sequence databases such as GenBank, EMBL, Swiss-Prot and PIR or private sequence databases such as PhytoSeq (Incyte Pharmaceuticals, Palo Alto, CA) can be searched.

Alignment of sequences for comparison can be conducted by the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. U.S.A. 85: 2444, by computerized implementations of these algorithms. After alignment, sequence comparisons between two (or more) polynucleotides or polypeptides are typically performed by comparing sequences of the two sequences over a comparison window to identify and compare local regions of sequence similarity. The comparison window can be a segment of at least about 20 contiguous positions, usually about 50 to about 200, more usually about 100 to about 150 contiguous positions. A description of the method is provided in Ausubel et al., supra.

10

15

20

25

30

35

A variety of methods of determining sequence relationships can be used, including manual alignment and computer assisted sequence alignment and analysis. This later approach is a preferred approach in the present invention, due to the increased throughput afforded by computer assisted methods. As noted above, a variety of computer programs for performing sequence alignment are available, or can be produced by one of skill.

One example algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al. J. Mol. Biol 215:403-410 (1990). Software for performing BLAST analyses is publicly available, e.g., through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters

M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, a cutoff of 100, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915).

In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5787). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence (and, therefore, in this context, homologous) if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, or less than about 0.01, and or even less than about 0.001. An additional example of a useful sequence alignment algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments. The program can align, e.g., up to 300 sequences of a maximum length of 5,000 letters.

The integrated system, or computer typically includes a user input interface allowing a user to selectively view one or more sequence records corresponding to the one or more character strings, as well as an instruction set which aligns the one or more character strings with each other or with an additional character string to identify one or more region of sequence similarity. The system may include a link of one or more character strings with a particular phenotype or gene function. Typically, the system includes a user readable output element which displays an alignment produced by the alignment instruction set.

The methods of this invention can be implemented in a localized or distributed computing environment. In a distributed environment, the methods may implemented on a single computer comprising multiple processors or on a multiplicity of computers. The computers can be linked, e.g. through a common bus, but more preferably the computer(s) are nodes on a network. The network can be a generalized or a dedicated local or

wide-area network and, in certain preferred embodiments, the computers may be components of an intra-net or an internet.

Thus, the invention provides methods for identifying a sequence similar or homologous to one or more polynucleotides as noted herein, or one or more target polypeptides encoded by the polynucleotides, or otherwise noted herein and may include linking or associating a given plant phenotype or gene function with a sequence. In the methods, a sequence database is provided (locally or across an inter or intra net) and a query is made against the sequence database using the relevant sequences herein and associated plant phenotypes or gene functions.

5

10

15

25

30

35

Any sequence herein can be entered into the database, before or after querying the database. This provides for both expansion of the database and, if done before the querying step, for insertion of control sequences into the database. The control sequences can be detected by the query to ensure the general integrity of both the database and the query. As noted, the query can be performed using a web browser based interface. For example, the database can be a centralized public database such as those noted herein, and the querying can be done from a remote terminal or computer across an internet or intranet.

#### **EXAMPLES**

The following examples are intended to illustrate but not limit the present invention.

## 20 EXAMPLE I. FULL LENGTH GENE IDENTIFICATION AND CLONING

Putative transcription factor sequences (genomic or ESTs) related to known transcription factors were identified in the *Arabidopsis thaliana* GenBank database using the tblastn sequence analysis program using default parameters and a P-value cutoff threshold of -4 or -5 or lower, depending on the length of the query sequence. Putative transcription factor sequence hits were then screened to identify those containing particular sequence strings. If the sequence hits contained such sequence strings, the sequences were confirmed as transcription factors.

Alternatively, Arabidopsis thaliana cDNA libraries derived from different tissues or treatments, or genomic libraries were screened to identify novel members of a transcription family using a low stringency hybridization approach. Probes were synthesized using gene specific primers in a standard PCR reaction (annealing temperature 60° C) and labeled with <sup>32</sup>P dCTP using the High Prime DNA Labeling Kit (Boehringer Mannheim). Purified radiolabelled probes were added to filters immersed in Church hybridization medium (0.5 M NaPO<sub>4</sub> pH 7.0, 7% SDS, 1 % w/v bovine serum albumin) and hybridized overnight at 60 °C with shaking. Filters were washed two times for 45 to 60 minutes with 1xSCC, 1% SDS at 60° C.

To identify additional sequence 5' or 3' of a partial cDNA sequence in a cDNA library, 5' and 3' rapid amplification of cDNA ends (RACE) was performed using the Marathon<sup>TM</sup> cDNA amplification kit (Clontech, Palo Alto, CA). Generally, the method entailed first isolating poly(A) mRNA, performing first and second strand cDNA synthesis to generate double stranded cDNA, blunting cDNA ends, followed by ligation of the Marathon<sup>TM</sup> Adaptor to the cDNA to form a library of adaptor-ligated ds cDNA.

Gene-specific primers were designed to be used along with adaptor specific primers for both 5' and 3' RACE reactions. Nested primers, rather than single primers, were used to increase PCR specificity. Using 5' and 3' RACE reactions, 5' and 3' RACE fragments were obtained, sequenced and cloned. The process can be repeated until 5' and 3' ends of the full-length gene were identified. Then the full-length cDNA was generated by PCR using primers specific to 5' and 3' ends of the gene by end-to-end PCR.

## EXAMPLE II. CONSTRUCTION OF EXPRESSION VECTORS

5

10

30

35

The sequence was amplified from a genomic or cDNA library using primers specific to sequences upstream and downstream of the coding region. The expression vector 15 was pMEN20 or pMEN65, which are both derived from pMON316 (Sanders et al, (1987) Nucleic Acids Research 15:1543-58) and contain the CaMV 35S promoter to express transgenes. To clone the sequence into the vector, both pMEN20 and the amplified DNA fragment were digested separately with SalI and NotI restriction enzymes at 37° C for 2 hours. The digestion products were subject to electrophoresis in a 0.8% agarose gel and visualized 20 by ethidium bromide staining. The DNA fragments containing the sequence and the linearized plasmid were excised and purified by using a Qiaquick gel extraction kit (Qiagen, CA). The fragments of interest were ligated at a ratio of 3:1 (vector to insert). Ligation reactions using T4 DNA ligase (New England Biolabs, MA) were carried out at 16° C for 16 hours. The ligated DNAs were transformed into competent cells of the E. coli strain 25 DH5alpha by using the heat shock method. The transformations were plated on LB plates containing 50 mg/l kanamycin (Sigma).

Individual colonies were grown overnight in five milliliters of LB broth containing 50 mg/l kanamycin at 37° C. Plasmid DNA was purified by using Qiaquick Mini Prep kits (Qiagen, CA).

# EXAMPLE III. TRANSFORMATION OF AGROBACTERIUM WITH THE EXPRESSION VECTOR

After the plasmid vector containing the gene was constructed, the vector was used to transform Agrobacterium tumefaciens cells expressing the gene products. The stock of Agrobacterium tumefaciens cells for transformation were made as described by Nagel et al. (1990) FEMS Microbiol Letts. 67: 325-328. Agrobacterium strain ABI was grown in 250 ml

LB medium (Sigma) overnight at 28°C with shaking until an absorbance ( $A_{600}$ ) of 0.5 – 1.0 was reached. Cells were harvested by centrifugation at 4,000 x g for 15 min at 4° C. Cells were then resuspended in 250  $\mu$ l chilled buffer (1 mM HEPES, pH adjusted to 7.0 with KOH). Cells were centrifuged again as described above and resuspended in 125  $\mu$ l chilled buffer. Cells were then centrifuged and resuspended two more times in the same HEPES buffer as described above at a volume of 100  $\mu$ l and 750  $\mu$ l, respectively. Resuspended cells were then distributed into 40  $\mu$ l aliquots, quickly frozen in liquid nitrogen, and stored at -80° C.

Agrobacterium cells were transformed with plasmids prepared as described above following the protocol described by Nagel et al. For each DNA construct to be transformed, 50 – 100 ng DNA (generally resuspended in 10 mM Tris-HCl, 1 mM EDTA, pH 8.0) was mixed with 40 μl of Agrobacterium cells. The DNA/cell mixture was then transferred to a chilled cuvette with a 2mm electrode gap and subject to a 2.5 kV charge dissipated at 25 μF and 200 μF using a Gene Pulser II apparatus (Bio-Rad). After electroporation, cells were immediately resuspended in 1.0 ml LB and allowed to recover without antibiotic selection for 2 – 4 hours at 28° C in a shaking incubator. After recovery, cells were plated onto selective medium of LB broth containing 100 μg/ml spectinomycin (Sigma) and incubated for 24-48 hours at 28° C. Single colonies were then picked and inoculated in fresh medium. The presence of the plasmid construct was verified by PCR amplification and sequence analysis.

10

15

20

25

30

35

# EXAMPLE IV. TRANSFORMATION OF ARABIDOPSIS PLANTS WITH AGROBACTERIUM TUMEFACIENS WITH EXPRESSION VECTOR

After transformation of Agrobacterium tumefaciens with plasmid vectors containing the gene, single Agrobacterium colonies were identified, propagated, and used to transform Arabidopsis plants. Briefly, 500 ml cultures of LB medium containing 50 mg/l kanamycin were inoculated with the colonies and grown at 28° C with shaking for 2 days until an absorbance ( $A_{600}$ ) of > 2.0 is reached. Cells were then harvested by centrifugation at 4,000 x g for 10 min, and resuspended in infiltration medium (1/2 X Murashige and Skoog salts (Sigma), 1 X Gamborg's B-5 vitamins (Sigma), 5.0% (w/v) sucrose (Sigma), 0.044  $\mu$ M benzylamino purine (Sigma), 200  $\mu$ l/L Silwet L-77 (Lehle Seeds) until an absorbance ( $A_{600}$ ) of 0.8 was reached.

Prior to transformation, Arabidopsis thaliana seeds (ecotype Columbia) were sown at a density of ~10 plants per 4" pot onto Pro-Mix BX potting medium (Hummert International) covered with fiberglass mesh (18 mm X 16 mm). Plants were grown under continuous illumination (50-75  $\mu$ E/m²/sec) at 22-23° C with 65-70% relative humidity. After about 4 weeks, primary inflorescence stems (bolts) are cut off to encourage growth of

multiple secondary bolts. After flowering of the mature secondary bolts, plants were prepared for transformation by removal of all siliques and opened flowers.

The pots were then immersed upside down in the mixture of Agrobacterium infiltration medium as described above for 30 sec, and placed on their sides to allow draining into a 1' x 2' flat surface covered with plastic wrap. After 24 h, the plastic wrap was removed and pots are turned upright. The immersion procedure was repeated one week later, for a total of two immersions per pot. Seeds were then collected from each transformation pot and analyzed following the protocol described below.

## EXAMPLE V. IDENTIFICATION OF ARABIDOPSIS PRIMARY TRANSFORMANTS

Seeds collected from the transformation pots were sterilized essentially as follows. Seeds were dispersed into in a solution containing 0.1% (v/v) Triton X-100 (Sigma) and sterile H<sub>2</sub>O and washed by shaking the suspension for 20 min. The wash solution was then drained and replaced with fresh wash solution to wash the seeds for 20 min with shaking. After removal of the second wash solution, a solution containing 0.1% (v/v) Triton X-100 and 70% ethanol (Equistar) was added to the seeds and the suspension was shaken for 5 min. After removal of the ethanol/detergent solution, a solution containing 0.1% (v/v) Triton X-100 and 30% (v/v) bleach (Clorox) was added to the seeds, and the suspension was shaken for 10 min. After removal of the bleach/detergent solution, seeds were then washed five times in sterile distilled H2O. The seeds were stored in the last wash water at 4° C for 2 days in the dark before being plated onto antibiotic selection medium (1 X Murashige and Skoog salts (pH adjusted to 5.7 with 1M KOH), 1 X Gamborg's B-5 vitamins, 0.9% phytagar (Life Seeds were germinated under continuous Technologies), and 50 mg/l kanamycin). illumination (50-75 µE/m²/sec) at 22-23° C. After 7-10 days of growth under these conditions, kanamycin resistant primary transformants (T<sub>1</sub> generation) were visible and obtained. These seedlings were transferred first to fresh selection plates where the seedlings continued to grow for 3-5 more days, and then to soil (Pro-Mix BX potting medium).

Primary transformants were crossed and progeny seeds (T<sub>2</sub>) collected; kanamycin resistant seedlings were selected and analyzed. The expression levels of the recombinant polynucleotides in the transformants varies from about a 5% expression level increase to a least a 100% expression level increase. Similar observations are made with respect to polypeptide level expression.

# EXAMPLE VI. IDENTIFICATION OF ARABIDOPSIS PLANTS WITH TRANSCRIPTION FACTOR GENE KNOCKOUTS

5

10

15

20

25

30

The screening of insertion mutagenized *Arabidopsis* collections for null mutants in a known target gene was essentially as described in Krysan et al (1999) <u>Plant Cell</u> 11:2283-2290. Briefly, gene-specific primers, nested by 5-250 bases to each other, were designed from the 5' and 3' regions of a known target gene. Similarly, nested sets of primers were also created specific to each of the T-DNA or transposon ends (the "right" and "left" borders). All possible combinations of gene specific and T-DNA/transposon primers were used to detect by PCR an insertion event within or close to the target gene. The amplified DNA fragments were then sequenced which allows the precise determination of the T-DNA/transposon insertion point relative to the target gene. Insertion events within the coding or intervening sequence of the genes were deconvoluted from a pool comprising a plurality of insertion events to a single unique mutant plant for functional characterization. The method is described in more detail in Yu and Adam, US Application Serial No. 09/177,733 filed October 23, 1998.

#### 15 EXAMPLE VII. IDENTIFICATION OF PATHOGEN INDUCED GENES

5

10

20

25

30

In some instances, expression patterns of the pathogen induced genes (such as defense genes) was monitored by microarray experiments. cDNAs were generated by PCR and resuspended at a final concentration of ~ 100 ng/ul in 3X SSC or 150mM Na-phosphate (Eisen and Brown (1999) *Meth. in Enzymol.* 303:179-205). The cDNAs were spotted on microscope glass slides coated with polylysine. The prepared cDNAs were aliquoted into 384 well plates and spotted on the slides using an x-y-z gantry (OmniGrid) purchased from GeneMachines (Menlo Park, CA) outfitted with quill type pins purchased from Telechem International (Sunnyvale, CA). After spotting, the arrays were cured for a minimum of one week at room temperature, rehydrated and blocked following the protocol recommended by Eisen and Brown (1999).

Sample total RNA (10 ug) samples were labeled using fluorescent Cy3 and Cy5 dyes. Labeled samples were resuspended in 4X SSC/0.03% SDS/4 ug salmon sperm DNA/2 ug tRNA/ 50mM Na-pyrophosphate, heated for 95°C for 2.5 minutes, spun down and placed on the array. The array was then covered with a glass coverslip and placed in a sealed chamber. The chamber was then kept in a water bath at 62°C overnight. The arrays were washed as described in Eisen and Brown (1999) and scanned on a General Scanning 3000 laser scanner. The resulting files are subsequently quantified using Imagene a software purchased from BioDiscovery (Los Angeles, CA).

# EXAMPLE VIII. IDENTIFICATION OF PATHOGEN TOLERANCE PHENOTYPE IN OVEREXPRESSOR OR GENE KNOCKOUT PLANTS

5

10

15

20

25

30

35

Experiments were performed to identify those transformants or knockouts that exhibited an improved pathogen tolerance. For such studies, the transformants were exposed to biotropic fungal pathogens, such as Erisyphe orontii, and necrotropic fungal pathogens, such as Fusarium oxysporum. Fusarium oxysporum isolates cause vascular wilts and damping off of various annual vegetables, perennials and weeds (Mauch-Mani and Slusarenko (1994) Molecular Plant-Microbe Interactions 7: 378-383). For Fusarium oxysporum experiments, plants grown on petri dishes were sprayed with a fresh spore suspension of F. oxysporum. The spore suspension was prepared as follows: A plug of fungal hyphae from a plate culture was placed on a fresh potato dextrose agar plate and allowed to spread for one week. 5 ml sterile water was then added to the plate, swirled, and pipetted into 50 ml Armstrong Fusarium medium. Spores were grown overnight in Fusarium medium and then sprayed onto plants using a Preval paint sprayer. Plant tissue was harvested and frozen in liquid nitrogen 48 hours post infection.

Erysiphe orontii is a causal agent of powdery mildew. For Erysiphe orontii experiments, plants were grown approximately 4 weeks in a greenhouse under 12 hour light (20 C, ~30% relative humidity (rh)). Individual leaves were infected with E. orontii spores from infected plants using a camel's hair brush, and the plants were transferred to a Percival growth chamber (20 C, 80% rh.). Plant tissue was harvested and frozen in liquid nitrogen 7 days post infection.

Botrytis cinerea is a necrotrophic pathogen. Botrytis cinerea was grown on potato dextrose agar in the light. A spore culture was made by spreading 10 ml of sterile water on the fungus plate, swirling and transferring spores to 10 ml of sterile water. The spore inoculum (approx. 105 spores/ml) was used to spray 10 day-old seedlings grown under sterile conditions on MS (-sucrose) media. Symptoms were evaluated every day up to approximately 1 week.

Infection with bacterial pathogens Pseudomonas syringae pv maculicola strain 4326 and pv maculicola strain 4326 was performed by hand inoculation at two doses. Two inoculation doses allows the differentiation between plants with enhanced susceptibility and plants with enhanced resistance to the pathogen. Plants were grown for 3 weeks in the greenhouse, then transferred to the growth chamber for the remainder of their growth. Psm ES4326 was hand inoculated with 1 ml syringe on 3 fully-expanded leaves per plant (4 1/2 wk old), using at least 9 plants per overexpressing line at two inoculation doses, OD=0.005 and OD=0.0005. Disease scoring occured at day 3 post-inoculation with pictures of the plants and leaves taken in parallel.

Table 3 shows the phenotypes observed for particular overexpressor or knockout plants and provides the SEQ ID No., the internal reference code (GID), whether a knockout or overexpressor plant was analyzed and the observed phenotype.

Table 3

SEQ ID No.	GID	Knockout (KO) or overexpressor (OE)	Phenotype
1	G188	KO	Increased susceptibility to Fusarium
3	G616	OE	Increased tolerance to Erysiphe
5	G19	OE	Increased tolerance to Erysiphe
7.	G261	OE .	Increased susceptibility to Botrytis
9	G28	OE	Increased resistance to Erysiphe
11	G869	OE	Increased susceptibility to Fusarium
13	G237	OE	Increased tolerance to Erysiphe
15	G409	OE	Increased tolerance to Erysiphe
17	G418	OE	Increased tolerance to Pseudomonas
19	G591	OE	Increased tolerance to Erysiphe
21	G525	OE	Increased tolerance to Pseudomonas
23	G545	OE	Increased susceptibility to Pseudomonas, Erysiphe and Fusarium
25	G865	OE	Increased susceptibility to Erysiphe and Botrytis
27	G881	OE	Increased susceptibility to Erysiphe and Botrytis
29	G896	KO	Increased susceptibility to Fusarium
31	G378	OE	Increased resistance to Erysiphe
33	G569	OE	Decreased expression of defense genes
35	G558	OE	Increased expression of defense genes

For a particular overexpressor that shows an increased susceptibility to a pathogen, it may be more useful to select a plant with a decreased expression of the particular transcription factor. For a particular knockout that shows an increased susceptibility to a pathogen, it may be more useful to select a plant with an increased expression of the particular transcription factor.

Other than Fusarium oxysporum, Erysyphe orontii, the transgenic plants are more tolerant to Sclerotinia spp., soil-borne oomycetes, foliar oomycetes, Botrytis spp., Rhizoctonia spp, Verticillium dahliae/albo-atrum, Alternaria spp., rusts, Mycosphaerella spp, Fusarium solani, or the like. The transgenic plants are more resistant to fungal diseases such as rusts, smuts, wilts, yellows, root rot, leaf drop, ergot, leaf blight of potato, brown spot of rice, leaf blight, late blight, powdery mildew, downy mildew, and the like; viral diseases such as sugarcane mosaic, cassava mosaic, sugar beet yellows, plum pox, barley yellow dwarf, tomato yellow leaf curl, tomato spotted wilt virus, and the like; bacterial diseases such as citrus canker, bacterial leaf blight, bacterial will, soft rot of vegetables, and the like; nematode diseases such as root knot, sugar beet cyst nematode or the like.

15

5

## EXAMPLE IX. IDENTIFICATION OF HOMOLOGOUS SEQUENCES

10

15

20

25

30

35

Homologous sequences from *Arabidopsis* and plant species other than *Arabidopsis* were identified using database sequence search tools, such as the Basic Local Alignment Search Tool (BLAST) (Altschul et al. (1990) <u>J. Mol. Biol.</u> 215:403-410; and Altschul et al. (1997) <u>Nucl. Acid Res.</u> 25: 3389-3402). The tblastx sequence analysis programs were employed using the BLOSUM-62 scoring matrix (Henikoff, S. and Henikoff, J. G. (1992) <u>Proc. Natl. Acad. Sci. USA</u> 89: 10915-10919).

Identified *Arabidopsis* homologous sequences are provided in Figure 2 and included in the Sequence Listing. The percent sequence identity among these sequences is as low as 47% sequence identity. Additionally, the entire NCBI GenBank database was filtered for sequences from all plants except *Arabidopsis thaliana* by selecting all entries in the NCBI GenBank database associated with NCBI taxonomic ID 33090 (Viridiplantae; all plants) and excluding entries associated with taxonomic ID 3701 (*Arabidopsis thaliana*). These sequences were compared to sequences representing genes of SEQ IDs Nos. 1-58 on 9/26/2000 using the Washington University TBLASTX algorithm (version 2.0a19MP). For each gene of SEQ IDs Nos. 1-58, individual comparisons were ordered by probability score (P-value), where the score reflects the probability that a particular alignment occurred by chance. For example, a score of 3.6e-40 is 3.6 x 10<sup>-40</sup>. For up to ten species, the gene with the lowest P-value (and therefore the most likely homolog) is listed in Figure 3.

In addition to P-values, comparisons were also scored by percentage identity. Percentage identity reflects the degree to which two segments of DNA or protein are identical over a particular length. The ranges of percent identity between the non-Arabidopsis genes shown in Figure 3 and the Arabidopsis genes in the sequence listing are: SEQ ID No. 1: 38%-76%; SEQ ID No. 3: 36%-72%; SEQ ID No. 5: 51%-75%; SEQ ID No. 7: 37%-76%; SEQ ID No. 9: 48%-75%; SEQ ID No. 11: 31%-68%; SEQ ID No. 13: 59%-81%; SEQ ID No. 15: 49%-81%; SEQ ID No. 17: 53%-87%; SEQ ID No. 19: 48%-84%; SEQ ID No. 21: 73%-89%; SEQ ID No. 23: 52%-64%; SEQ ID No. 25: 48%-83%; SEQ ID No. 27: 35%-92%; SEQ ID No. 29: 56%-89%; SEQ ID No. 31: 50%-90%; SEQ ID No. 33: 50%-93%; SEQ ID No. 35: 52%-81%; SEQ ID No. 37: 75%-81%; SEQ ID No. 39: 35%-72%; SEQ ID No. 41: 55%-89%; SEQ ID No. 43: 56%-77%; SEQ ID No. 45: 34%-72%; SEQ ID No. 47: 51%-86%; SEQ ID No. 49: 46%-86%; SEQ ID No. 51: 58%-80%; SEQ ID No. 53: 46%-55%; SEQ ID No. 55: 84%-89%; and SEQ ID No. 57: 43%-71%.

The polynucleotides and polypeptides in the Sequence Listing and the identified homologous sequences may be stored in a computer system and have associated or linked with the sequences a function, such as that the polynucleotides and polypeptides are useful for modifying the pathogen tolerance of a plant.

All references, publications, patents and other documents herein are incorporated by reference in their entirety for all purposes. Although the invention has been described with reference to the embodiments and examples above, it should be understood that various modifications can be made without departing from the spirit of the invention.

#### What is claimed is:

5

15

20

30

1. A transgenic plant with modified pathogen tolerance, which plant comprises a recombinant polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence encoding a polypeptide comprising a sequence selected from SEQ ID Nos. 2N, where N=1-29, or a complementary nucleotide sequence thereof;
  - (b) a nucleotide sequence encoding a polypeptide comprising a conservatively substituted variant of a polypeptide of (a);
- (c) a nucleotide sequence comprising a sequence selected from those of SEQ ID Nos.
   2N-1, where N=1-29, or a complementary nucleotide sequence thereof;
  - (d) a nucleotide sequence comprising silent substitutions in a nucleotide sequence of (c);
  - (e) a nucleotide sequence which hybridizes under stringent conditions to a nucleotide sequence of one or more of: (a), (b), (c), or (d);
  - (f) a nucleotide sequence comprising at least 15 consecutive nucleotides of a sequence of any of (a)-(e);
  - (g) a nucleotide sequence comprising a subsequence or fragment of any of (a)-(f), which subsequence or fragment encodes a polypeptide that modifies a plant's pathogen tolerance;
  - (h) a nucleotide sequence having at least 31% sequence identity to a nucleotide sequence of any of (a)-(g);
  - (i) a nucleotide sequence having at least 60% identity sequence identity to a nucleotide sequence of any of (a)-(g);
- 25 (j) a nucleotide sequence which encodes a polypeptide having at least 31% identity sequence identity to a polypeptide of SEQ ID Nos. 2N, where N=1-29;
  - (k) a nucleotide sequence which encodes a polypeptide having at least 60% identity sequence identity to a polypeptide of SEQ ID Nos. 2N, where N=1-29; and
  - (l) a nucleotide sequence which encodes a polypeptide having at least 65% sequence identity to a conserved domain of a polypeptide of SEQ ID Nos. 2N, where N=1-29.
  - 2. The transgenic plant of claim 1, further comprising a constitutive, inducible, or tissueactive promoter operably linked to said nucleotide sequence.
- 35 3. The transgenic plant of claim 1, wherein the plant is selected from the group consisting of: soybean, wheat, corn, potato, cotton, rice, oilseed rape, sunflower, alfalfa, sugarcane, turf, banana, blackberry, blueberry, strawberry, raspberry, cantaloupe, carrot,

cauliflower, coffee, cucumber, eggplant, grapes, honeydew, lettuce, mango, melon, onion, papaya, peas, peppers, pineapple, spinach, squash, sweet corn, tobacco, tomato, watermelon, rosaceous fruits, and vegetable brassicas.

- 5 4. An isolated or recombinant polynucleotide comprising a nucleotide sequence selected from the group consisting of:
  - (a) a nucleotide sequence encoding a polypeptide comprising a sequence selected from SEQ ID Nos. 2N, where N=1-29, or a complementary nucleotide sequence thereof:
- (b) a nucleotide sequence encoding a polypeptide comprising a conservatively substituted variant of a polypeptide of (a);

15

- (c) a nucleotide sequence comprising a sequence selected from those of SEQ ID Nos. 2N-1, where N=1-29, or a complementary nucleotide sequence thereof;
- (d) a nucleotide sequence comprising silent substitutions in a nucleotide sequence of (c);
- (e) a nucleotide sequence which hybridizes under stringent conditions to a nucleotide sequence of one or more of: (a), (b), (c), or (d);
- (f) a nucleotide sequence comprising at least 15 consecutive nucleotides of a sequence of any of (a)-(e);
- 20 (g) a nucleotide sequence comprising a subsequence or fragment of any of (a)-(f), which subsequence or fragment encodes a polypeptide having a biological activity that modifies a plant's pathogen tolerance;
  - (h) a nucleotide sequence having at least 31% sequence identity to a nucleotide sequence of any of (a)-(g);
- 25 (i) a nucleotide sequence having at least 60% identity sequence identity to a nucleotide sequence of any of (a)-(g);
  - (j) a nucleotide sequence which encodes a polypeptide having at least 31% identity sequence identity to a polypeptide of SEQ ID Nos. 2N, where N=1-29;
  - (k) a nucleotide sequence which encodes a polypeptide having at least 60% identity sequence identity to a polypeptide of SEQ ID Nos. 2N, where N=1-29; and
  - (1) a nucleotide sequence which encodes a conserved domain of a polypeptide having at least 65% sequence identity to a conserved domain of a polypeptide of SEQ ID Nos. 2N, where N=1-29.
- 35 5. The isolated or recombinant polynucleotide of claim 4, further comprising a constitutive, inducible, or tissue-active promoter operably linked to the nucleotide sequence.

6. A cloning or expression vector comprising the isolated or recombinant polynucleotide of claim 4.

- 7. A cell comprising the cloning or expression vector of claim 6.
- 8. A transgenic plant comprising the isolated or recombinant polynucleotide of claim 4.
- 9. A composition produced by one or more of:
  - (a) incubating one or more polynucleotide of claim 4 with a nuclease;
- 10 (b) incubating one or more polynucleotide of claim 4 with a restriction enzyme;
  - (c) incubating one or more polynucleotide of claim 4 with a polymerase;
  - (d) incubating one or more polynucleotide of claim 4 with a polymerase and a primer;
  - (e) incubating one or more polynucleotide of claim 4 with a cloning vector, or
  - (f) incubating one or more polynucleotide of claim 4 with a cell.

15

5

- 10. A composition comprising two or more different polynucleotides of claim 4.
- 11. An isolated or recombinant polypeptide comprising a subsequence of at least about 15 contiguous amino acids encoded by the recombinant or isolated polynucleotide of claim 4.

20

25

- 12. A plant comprising an isolated polypeptide of claim 11.
- 13. A method for producing a plant having a modified pathogen tolerance, the method comprising altering the expression of the isolated or recombinant polynucleotide of claim 4 or the expression levels or activity of a polypeptide of claim 11 in a plant, thereby producing a modified plant, and selecting the modified plant for improved pathogen tolerance thereby providing the modified plant with a modified pathogen tolerance.
  - 14. The method of claim 13, wherein the polynucleotide is a polynucleotide of claim 4.

- 15. A method of identifying a factor that is modulated by or interacts with a polypeptide encoded by a polynucleotide of claim 4, the method comprising:
  - (a) expressing a polypeptide encoded by the polynucleotide in a plant; and
- (b) identifying at least one factor that is modulated by or interacts with the polypeptide.

16. The method of claim 15, wherein the identifying is performed by detecting binding by the polypeptide to a promoter sequence, or detecting interactions between an additional protein and the polypeptide in a yeast two hybrid system.

- 5 17. The method of claim 15, wherein the identifying is performed by detecting expression of a factor by hybridization to a microarray, subtractive hybridization or differential display.
  - 18. A method of identifying a molecule that modulates activity or expression of a polynucleotide or polypeptide of interest, the method comprising:
- (a) placing the molecule in contact with a plant comprising the polynucleotide or polypeptide encoded by the polynucleotide of claim 4; and,
  - (b) monitoring one or more of:
    - (i) expression level of the polynucleotide in the plant;
    - (ii) expression level of the polypeptide in the plant;
    - (iii) modulation of an activity of the polypeptide in the plant; or
    - (iv) modulation of an activity of the polynucleotide in the plant.
- An integrated system, computer or computer readable medium comprising one or more character strings corresponding to a polynucleotide of claim 4, or to a polypeptide
   encoded by the polynucleotide.
  - 20. The integrated system, computer or computer readable medium of claim 19, further comprising a link between said one or more sequence strings to a modified plant pathogen tolerance phenotype.

25

- 21. A method of identifying a sequence similar or homologous to one or more polynucleotides of claim 4, or one or more polypeptides encoded by the polynucleotides, the method comprising:
  - (a) providing a sequence database; and,
- (b) querying the sequence database with one or more target sequences corresponding to the one or more polynucleotides or to the one or more polypeptides to identify one or more sequence members of the database that display sequence similarity or homology to one or more of the one or more target sequences.
- 35 22. The method of claim 21, wherein the querying comprises aligning one or more of the target sequences with one or more of the one or more sequence members in the sequence database.

23. The method of claim 21, wherein the querying comprises identifying one or more of the one or more sequence members of the database that meet a user-selected identity criteria with one or more of the target sequences.

5

- 24. The method of claim 21, further comprising linking the one or more of the polynucleotides of claim 4, or encoded polypeptides, to a modified plant pathogen tolerance phenotype.
- 10 25. A plant comprising altered expression levels of an isolated or recombinant polynucleotide of claim 4.
  - 26. A plant comprising altered expression levels or the activity of an isolated or recombinant polypeptide of claim 11.

15

27. A plant lacking a nucleotide sequence encoding a polypeptide of claim 11.

Figure 1

SEQ ID No.	GID	cDNA or protein	conserved domain
1	G188	cDNA	00.1001.100.001111111
2	G188	protein	175-222
3	G616	cDNA	110-222
4	G616	protein	39-95
5	G19	cDNA	03-30
6	G19	protein	76-145
7	G261	cDNA	10-143
8	G261	protein	16-104
9	G28	cDNA	10-10-
10	G28	protein	145-213
11	G869	cDNA	143-213
12	G869	protein	109-177
13	G237	cDNA	103-111
14	G237		11-113
15		protein cDNA	11-113
	G409		64-124
16	G409	protein	04-124
17	G418	cDNA	F00 F00
18	G418	protein	500-560
19	G591	cDNA	140.040
20	G591	protein	143-240
21	G525	cDNA	00.407
22	G525	protein	23-167
23	G545	cDNA	20 100 100 151
24	G545	protein	82-102, 136-154
25	G865	cDNA	
26	G865	protein	36-103
27	G881	cDNA	
28	G881	protein	176-233
29	G896	cDNA	
30	G896	protein	18-39
31	G378	cDNA	
32	G378	protein	196-237
33	G569	cDNA	
34	G569	protein	90-153
35	G558	cDNA	
36	G558	protein	45-105

Figure 2

SEQ ID No.	GID	homolog	cDNA or protein	conserved domain
37	G1396	homolog of G1394	cDNA	
38	G1396	homolog of G1394	protein	entire protein
39	G265	homolog of G261	cDNA	<u> </u>
40	G265	homolog of G261	protein	14-105
41	G1006	homolog of G28	cDNA	
42	G1006	homolog of G28	protein	114-182
43	G1309	homolog of G237	cDNA	
44	G1309	homolog of G237	protein	9-114
45	G2550	homolog of G418	cDNA	
46	G2550	homolog of G418	protein	348-408
47	G965	homolog of G418	cDNA	
48	G965	homolog of G418	protein	423-486
49	G793	homolog of G591	cDNA	
50	G793	homolog of G591	protein	151-206
51	G764	homolog of G525	cDNA	
52	G764	homolog of G525	protein	27-171
53	G350	homolog of G545	cDNA	
54	G350	homolog of G545	protein	91-113,150-170
55	G986	homolog of G881	cDNA	
56	G986	homolog of G881	protein	146-203
57	G1349	homolog of G896	cDNA	
58	G1349	homolog of G896	protein	13-63

Figure 3A

SEQ ID No.	GID	Genbank NID	P-value	Species
1	G188	7779802	5.20E-36	Lotus japonicus
1	G188	7284340	2.10E-34	Glycine max
1	G188	9361307	1.20E-27	Triticum aestivum
1	G188	7340336	1.10E-22	Oryza sativa
1	G188	6529152	3.60E-22	Lycopersicon esculentum
1	G188	8748477	7.70E-21	Medicago truncatula
1	G188	5456433	7.10E-14	Zea mays
1	G188	9302479	1.60E-12	Sorghum bicolor
1	G188	6696287	4.10E-12	Pinus taeda
1	G188	562242	9.00E-12	Brassica rapa
3	G616	7719440	8.30E-37	Lotus japonicus
3	G616	7692230	5.90E-33	Glycine max
3	G616	7501307	1.10E-21	Gossypium arboreum
3	G616	8071090	1.50E-21	Solanum tuberosum
3	G616	8858771	1.50E-21	Oryza sativa
3	G616	5047315	1.50E-21	
3	G616	· · · · · · · · · · · · · · · · · · ·		Gossypium hirsutum
3	G616	6358532	5.80E-20	Antirrhinum graniticum
3		2826867	7.00E-20	Antirrhinum majus
	G616	6358535	7.40E-20	Antirrhinum majus subsp. linkianum
3	G616	6358538	7.50E-20	Antirrhinum braun-blanquetii
5	G19	8789223	2.80E-34	Citrus x paradisi
5	G19	9434234	4.50E-34	Lycopersicon esculentum
5	G19	7478682	1.30E-30	Glycine max
5	G19	6654934	1.20E-28	Medicago truncatula
5	G19	3264766	5.50E-26	Prunus armeniaca
5	G19	7624302	8.30E-26	Gossypium arboreum
5	G19	9425363	2.90E-25	Triticum aestivum
5	G19	688579	3.60E-25	Ricinus communis
5	G19	9419304	6.00E-25	Hordeum vulgare
5	G19	7720316	8.80E-25	Lotus japonicus
7	G261	5821137	5.10E-93	Nicotiana tabacum
7	G261	7158881	8.80E-86	Medicago sativa
7	G261	886741	1.00E-73	Zea mays
7	G261	5900449	5.20E-47	Lycopersicon esculentum
7	G261	7561318	1.20E-46	Medicago truncatula
7	G261	19491	1.70E-42	Lycopersicon peruvianum
7	G261	7233914	3.50E-41	Glycine max
7	G261	4528238	9.00E-41	Citrus unshiu
7	G261	8903922	4.00E-39	Hordeum vulgare
7	G261	9251913	1.90E-36	Solanum tuberosum
9	G28	7528275	4.20E-62	Mesembryanthemum crystallinum
9	G28	6654776	1.20E-57	Medicago truncatula
9	G28	790362	2.30E-54	Nicotiana tabacum
9	G28	8809570	8.00E-54	Nicotiana sylvestris
9	G28	3342210	8.40E-54	Lycopersicon esculentum
9	G28	6566281	8.40E-47	Glycine max
9	G28	7627061	8.40E-47	Gossypium arboreum
9	G28	7324479	2.00E-44	Lycopersicon pennellii
	G28	6478844	1.80E-35	Matricaria chamomilla
9 1		U-71 UU-77	1.UUL-UU	[manodia onditionilla
9			7 80F-20	Oryza sativa
9 9 11	G28 G869	7273972 2213784	7.80E-29 1.30E-19	Oryza sativa Lycopersicon esculentum

Figure 3B

SEQ ID No.	GID	Genbank NID	P-value	Species
11	G869	8570080	4.20E-18	Oryza sativa
11	G869	7560260	1.50E-17	Medicago truncatula
11	G869	7534890	5.20E-14	Sorghum bicolor
	G869	6455322	1.10E-13	Glycine max
11	G869	9362061	2.70E-13	Triticum aestivum
11		7788764	5.70E-13	Lotus japonicus
11	G869 G869	7624302	2.50E-12	Gossypium arboreum
11	G869	3858036	2.80E-12	Populus balsamifera subsp. trichocarpa
11		8283916	4.70E-42	Glycine max
13	G237	9361969	8.30E-41	Triticum aestivum
13	G237		4.10E-39	Zea mays
13	G237	4753385	4.10E-33	Sorghum bicolor
13	G237	7535969	9.30E-33	Medicago truncatula
13	G237	7566043	2.00E-32	Lycopersicon esculentum
13	G237	7339127	1.10E-28	Pinus taeda
13	G237	5860031		Lotus japonicus
13	G237	7776223	2.20E-28	Oryza sativa
13	G237	6850206	5.10E-28	Gossypium hirsutum
13	G237	5048991	8.50E-28	Medicago truncatula
15	G409	6654773	6.10E-57	Lycopersicon esculentum
15	G409	6531235	2.00E-56	
15	G409	7924152	1.10E-47	Glycine max
15	G409	5006854	6.50E-43.	Oryza sativa
15	G409	8098529	2.10E-41	Hordeum vulgare
15	G409	767697	1.40E-37	Daucus carota
15	G409	8328991	3.30E-37	Mesembryanthemum crystallinum
15	G409	7415613	1.40E-32	Physcomitrella patens
15	G409	7785121	2.80E-32	Lotus japonicus
15	G409	6916941	4.80E-32	Lycopersicon pennellii
17	G418	7239156	1.90E-123	Maius x domestica
17	G418	5892190	2.00E-62	Lycopersicon esculentum
17	G418	7628137	8.70E-58	Gossypium arboreum
17	G418	9205496	3.90E-51	Glycine max
17	G418	6069643	1.50E-45	Oryza sativa
17	G418	7562931	6.90E-45	Medicago truncatula
17	G418	7781695	5.50E-40	Lotus japonicus
17	G418	9298824	7.80E-34	Sorghum bicolor
17	G418	9428023	3.90E-32	Triticum aestivum
17	G418	7244366	1.30E-31	Mentha x piperita
19	G591	7646333	1.90E-55	Lycopersicon esculentum
19	G591	7924288	4.10E-53	Glycine max
19	G591	7722838	1.10E-41	Lotus japonicus
19	G591	5804781	1.40E-24	Nicotiana tabacum
19	G591	9198126	2.50E-23	Medicago truncatula
19	G591	427677	9.50E-15	Oryza sativa
19	G591	7624745	1.80E-14	Gossypium arboreum
19	G591	7535578	8.70E-14	Sorghum bicolor
19	G591	5915205	1.30E-11	Zea mays
19	G591	9249806	2.60E-11	Solanum tuberosum
21	G525	4384535	5.60E-61	Lycopersicon esculentum
21	G525	6454868	2.00E-58	Glycine max
21	G525	6066594	9.30E-54	Petunia x hybrida
21	G525	4977542	8.60E-51	Oryza sativa

Figure 3C

SEQ ID No.	GID	Genbank NID	P-value	Species
21	G525	9361647	2.50E-50	Triticum aestivum
21	G525	4218536	5.20E-50	Triticum sp.
21	G525	6732159	5.20E-50	Triticum monococcum
21	G525	5343151	2.70E-49	Zea mays
21	G525	5049217	4.20E-48	Gossypium hirsutum
21	G525	8708684	8.90E-48	Hordeum vulgare
23	G545	4666359	8.30E-55	Datisca glomerata
23	G545	7228328	3.70E-52	Medicago sativa
23	G545	1763062	1.30E-51	Glycine max
23	G545	7206360	3.10E-44	Medicago truncatula
23	G545	7626808	9.60E-40	Gossypium arboreum
23	G545	439492	3.90E-39	Petunia x hybrida
23	G545	4382658	1.70E-38	Lycopersicon esculentum
23	G545	8486215	8.70E-38	Euphorbia esula
23	G545	7322653	6.80E-37	Lycopersicon hirsutum
23	G545	7785845	1.10E-33	Lotus japonicus
25	G865	9417297	1.70E-32	Triticum aestivum
25	G865	7206394	4.90E-29	Medicago truncatula
25	G865	7796858	5.70E-27	Glycine max
25	G865	4387560	9.20E-25	Lycopersicon esculentum
25	G865	569065	1.50E-23	Oryza sativa
25	G865	7788764	4.10E-23	Lotus japonicus
25	G865	790362	8.40E-22	Nicotiana tabacum
25	G865	7528275	5.90E-21	Mesembryanthemum crystallinum
25	G865	3264766	8.80E-20	Prunus armeniaca
25	G865	8098026	2.00E-19	Hordeum vulgare
27	G881	5820418	9.80E-29	Glycine max
27	G881	8440065	1.00E-27	Gossypium hirsutum
27	G881	4380578	1.50E-27	Lycopersicon esculentum
27	G881	9199620	2.70E-27	Medicago truncatula
27	G881	6472584	2.20E-24	Nicotiana tabacum
27	G881	9250698	3.20E-24	Solanum tuberosum
27	G881	8205146	5.20E-21	Oryza sativa
27	G881	1159878	8.20E-17	Avena fatua
27	G881	9299778	2.70E-16	Sorghum bicolor
27	G881	9444636	1.10E-14	Triticum aestivum
29	G896	9410462	1.90E-101	Hordeum vulgare
29	G896	7628908	3.60E-82	Gossypium arboreum
29	G896	7244408	1.80E-79	Mentha x piperita
29	G896	5046180	2.10E-73	Gossypium hirsutum
29	G896	7678652	1.10E-63	Lotus japonicus
29	G896	8286031	1.40E-60	Glycine max
29	G896	5888938	4.50E-58	Lycopersicon esculentum
29	G896	9298238	9.20E-54	Sorghum bicolor
29	G896	7566414	8.00E-52	Medicago truncatula
29	G896	8845076	1.00E-46	Triticum aestivum
31	G378	5270028	5.10E-73	Lycopersicon esculentum
31	G378	5048335	4.10E-58	Gossypium hirsutum
31	G378	7239521	5.90E-42	Oryza sativa
31	G378	5606120	6.80E-36	Glycine max
31	G378	3853800	3.20E-30	Populus tremula x Populus tremuloides

Figure 3D

SEQ ID No.	GID	Genbank NID	P-value	Species
31	G378	6626305	1.10E-21	Zea mays
31	G378	9412941	9.40E-19	Triticum aestivum
31	G378	3242033	4.30E-17	Mesembryanthemum crystallinum
31	G378	7626259	7.70E-13	Gossypium arboreum
33	G229	7337390	6.60E-51	Lycopersicon esculentum
33	G229	9823237	3.60E-50	Hordeum vulgare
33	G229	7244424	4.90E-50	Mentha x piperita
33	G229	7776053	1.70E-49	Lotus japonicus
33	G229	2921335	5.80E-48	Gossypium hirsutum
33	G229	1491932	4.50E-47	Zea mays
33	G229	6455590	2.80E-44	Glycine max
33	G229	6020191	2.00E-41	Pinus taeda
33	G229	10697236	4.20E-41	Oryza sativa
33	G229	7765706	5.10E-41	Medicago truncatula
35	G663	7673087	5.10E-43	Petunia integrifolia
35	G663	9508051	3.00E-41	Lycopersicon esculentum
35	G663	7673091	3.30E-41	Petunia x hybrida
	G663	7673097	2.40E-36	Petunia axillaris
35 35	G663	5048991	1.20E-33	Gossypium hirsutum
	G663	6455590	2.50E-31	Glycine max
35 35	G663	7560175	1.90E-27	Medicago truncatula
35	G663	7244424	4.10E-26	Mentha x piperita
35	G663	9954117	3.40E-25	Solanum tuberosum
	G663	6020191	3.60E-25	Pinus taeda
35	G1396	498704	5.20E-22	Spinacia oleracea
37		7502400	1.20E-21	Gossypium arboreum
37	G1396 G1396	3857536	3.40E-21	Populus balsamifera subsp. trichocarpa
37	G1396	4385300	1.20E-20	Lycopersicon esculentum
37	G1396	6917249	1.50E-20	Lycopersicon pennellii
37	G1396	6915979	1.70E-20	Glycine max
37	G1396	7674530	2.70E-20	Medicago truncatula
37	G1396	8090319	3.40E-20	Sorghum bicolor
37	G1396	3592182	9.10E-20	Oryza sativa
37	G1396	6654124	1.10E-19	Zea mays
39	G265	5821137	6.50E-83	Nicotiana tabacum
39	G265	7158881	3.80E-79	Medicago sativa
39	G265	886741	1.60E-70	Zea mays
39	G265	5900449	5.60E-43	Lycopersicon esculentum
39	G265	8903922	8.20E-43	Hordeum vulgare
39	G265	7561318	2.10E-41	Medicago truncatula
39	G265	9204445	5.30E-36	Glycine max
39	G265	4528238	5.40E-36	Citrus unshiu
39	G265	19489	2.10E-35	Lycopersicon peruvianum
39	G265	9251913	2.00E-32	Solanum tuberosum
41	G1006	7528275	2.70E-51	Mesembryanthemum crystallinum
41	G1006	3342210	4.90E-49	Lycopersicon esculentum
41	G1006	6654776	1.90E-48	Medicago truncatula
41	G1006	790362	2.30E-47	Nicotiana tabacum
41	G1006	8809570	2.00E-46	Nicotiana sylvestris
41	G1006	7627061	6.40E-41	Gossypium arboreum
41	G1006	7324479	1.20E-35	Lycopersicon pennellii
41	G1006	6478844	1.80E-35	Matricaria chamomilla

Figure 3E

SEQ ID No.	GID	Genbank NID	P-value	Species
41	G1006	6566281	1.30E-34	Glycine max
41	G1006	4716624	3.80E-28	Oryza sativa
43	G1309	9361969	2.40E-45	Triticum aestivum
43	G1309	7566043	9.60E-35	Medicago truncatula
43	G1309	5891104	2.20E-31	Lycopersicon esculentum
43	G1309	5860031	2.10E-30	Pinus taeda
43	G1309	5049507	6.20E-30	Gossypium hirsutum
43	G1309	5139805	1.30E-29	Glycine max
43	G1309	6850206	2.50E-29	Oryza sativa
43	G1309	7721017	3.40E-29	Lotus japonicus
43	G1309	8368245	5.20E-28	Zea mays
43	G1309	20560	9.50E-27	Petunia x hybrida
45	G2550	4380729	2.80E-51	Lycopersicon esculentum
45	G2550	5667196	2.20E-49	Oryza sativa
45	G2550	8669454	1.40E-48	Glycine max
45	G2550	9298824	1.50E-48	Sorghum bicolor
45	G2550	7239156	9.90E-46	Malus x domestica
45	G2550	7570704	5.70E-45	Medicago truncatula
45	G2550	7628137	3.30E-42	Gossypium arboreum
- 45	G2550	7244366	6.00E-41	Mentha x piperita
45	G2550	9428023	4.70E-40	Triticum aestivum
45	G2550	9250642	3.50E-39	Solanum tuberosum
47	G965	7239156	3.10E-126	Malus x domestica
47	G965	5892190	2.00E-62	Lycopersicon esculentum
47	G965	7628137	1.60E-56	Gossypium arboreum
47	G965	9205496	2.60E-49	Glycine max
47	G965	6069643	1.70E-45	Oryza sativa
47	G965	7562931	2.50E-44	Medicago truncatula
47	G965	7781695	1.60E-41	Lotus japonicus
47	G965	9298824	6.30E-33	Sorghum bicolor
47	G965	9428023	1.50E-31	Triticum aestivum
47	G965	7244366	1.20E-29	Mentha x piperita
49	G793	6976712	3.60E-43	Lycopersicon esculentum
49	G793	7924288	2.00E-41	Glycine max
49	G793	7614163	3.90E-34	Lotus japonicus
49	G793	9198126	5.70E-23	Medicago truncatula
49	G793	5804781	1.10E-22	Nicotiana tabacum
49	G793	7535578	1.60E-14	Sorghum bicolor
49	G793	427677	6.10E-14	Oryza sativa
49	G793	5915205	2.90E-10	Zea mays
49	G793	9249806	4.20E-10	Solanum tuberosum
49	G793 .	7624745	1.30E-09	Gossypium arboreum
51	G764	4384535	7.00E-70	Lycopersicon esculentum
51	G764	5049217	1.80E-65	Gossypium hirsutum
51	G764	6454868	1.90E-64	Glycine max
51	G764	6066594	5.20E-59	Petunia x hybrida
51	G764	4218536	2.30E-52	Triticum sp.
51	G764	6732159	2.30E-52	Triticum monococcum
51	G764	9361647	7.50E-52	Triticum aestivum
51	G764	4977542	4.10E-49	Oryza sativa
51	G764	6799764	4.40E-49	Medicago truncatula
51	G764	9296257	1.00E-48	Sorghum bicolor

Figure 3F

SEQ ID No.	GID	Genbank NID	P-value	Species
53	G350	439492	5.20E-53	Petunia x hybrida
53	G350	7228328	8.90E-51	Medicago sativa
53	G350	4666359	3.10E-48	Datisca glomerata
53	G350	1763062	8.30E-48	Glycine max
53	G350	7626808	9.10E-44	Gossypium arboreum
53	G350	7206360	2.20E-43	Medicago truncatula
53	G350	2981168	2.10E-38	Nicotiana tabacum
53	G350	7322653	2.00E-37	Lycopersicon hirsutum
53	G350	5276755	2.40E-37	Lycopersicon esculentum
53	G350	2058503	1.10E-31	Brassica rapa
55	G986	6472584	1.00E-34	Nicotiana tabacum
55	G986	8440065	8.80E-33	Gossypium hirsutum
55	G986	4385167	1.50E-32	Lycopersicon esculentum
55	G986	8205146	5.50E-30	Oryza sativa
55	G986	5820418	8.80E-26	Glycine max
55	G986	1159878	2.30E-23	Avena fatua
55	G986	9250698	4.60E-22	Solanum tuberosum
55	G986	9413507	7.90E-21	Triticum aestivum
55	G986	7748539	2.30E-20	Lotus japonicus
55	G986	9199620	1.30E-16	Medicago truncatula
57	G1349	8904043	1.50E-47	Hordeum vulgare
57	G1349	7244408	2.40E-47	Mentha x piperita
57	G1349	8286031	3.60E-46	Glycine max
57	G1349	9298238	9.10E-36	Sorghum bicolor
. 57	G1349	7628908	4.70E-34	Gossypium arboreum
57	G1349	5046180	1.50E-33	Gossypium hirsutum
57	G1349	5888938	1.30E-30	Lycopersicon esculentum
57	G1349	5043924	6.20E-30	Pinus taeda
57	G1349	8845076	4.40E-29	Triticum aestivum
57	G1349	7678652	4.20E-27	Lotus japonicus

## MBI15 Sequence Listing.ST25 SEQUENCE LISTING

	Heard, Keddie Yu, Gu Ratcli Creelm Jiang, Pineda Reuber Adam,	, Jar o-Lia ffe, an, l Cai , Oma , Lyr	mes ang Oli Robe zho aira	ver rt ng											:
<120>	Patho	gen 1	Resi	stan	ce G	enes	3								
<130>	MBI-0	015					·								
<150> <151>	60/16 1999-											• .			٠
<150> <151>	Plant 2000-			lodif	icat	ion	III								
<150> <151>	60/19 2000-	-													
<160>	58										•				
<170>	Paten	tIn ·	vers	ion	3.0							•			
<210><211><211><212><213>	1 1187 DNA Arabi	dops	is t	hali	.ana					٠					
<220><221><222><223>	CDS (50). G188	. (10	96)												
<400> ctctca	l nccaa c	ataa	tcaa	ıa ga	agct	ttc	e tea	ıcgaa	ittc	aaga	itege	cc at Me 1	g to	cc tcc er Ser	58
ctctca	l accaa c at tgg ap Trp	gat	ctc	ttc	acc	atc	atc	aga	aqc	tqc	agc	Me 1 tct	tct	er Ser gtt	58 106
gag ga Glu As 5	accaa c	gat Asp	ctc Leu tct	ttc Phe tqt	gcc Ala 10 qct	gtc Val qqt	gtc Val cat	aga Arg qaa	agc Ser gac	tgc Cys 15 gac	agc Ser	tct Ser	tct Ser	gtt Val	
gag ga Glu As 5 tcc ac Ser Th 20	at tgg ap Trp	gat Asp aat Asn caa Gln	ctc Leu tct Ser	ttc Phe tgt Cys 25	gcc Ala 10 gct Ala	gtc Val ggt Gly	gtc Val cat His	aga Arg gaa Glu	agc Ser gac Asp 30	tgc Cys 15 gac Asp	agc Ser ata Ile	tct Ser gga Gly	tct Ser aac Asn	gtt Val tgt Cys 35	106
gag ga Glu As 5 tcc ac Ser Th 20 aaa ca Lys Gl	at tgg ap Trp cc acc ar Thr	gat Asp aat Asn caa Gln	ctc Leu tct Ser gat Asp 40	ttc Phe tgt Cys 25 cct Pro	gcc Ala 10 gct Ala cct Pro	gtc Val ggt Gly cct Pro	gtc Val cat His cct Pro	aga Arg gaa Glu cct Pro 45	agc Ser gac Asp 30 ctg Leu	tgc Cys 15 gac Asp ttt Phe	agc Ser ata Ile caa Gln	tct Ser gga Gly gct Ala	tct Ser aac Asn tct Ser 50	gtt Val tgt Cys 35 tct Ser	106
gag ga Glu As 5 tcc ac Ser Th 20 aaa ca Lys Gl tct tg Ser Cy	at tgg sp Trp cc acc nr Thr aa caa ln Gln	gat Asp aat Asn caa Gln gag Glu 55	ctc Leu tct Ser gat Asp 40 tta Leu	ttc Phe tgt Cys 25 cct Pro caa Gln	gcc Ala 10 gct Ala cct Pro gat Asp	gtc Val ggt Gly cct Pro tct ser	gtc Val cat His cct Pro tgc Cys 60	aga Arg gaa Glu cct Pro 45 aaa Lys	agc Ser gac Asp 30 ctg Leu cca Pro	tgc Cys 15 gac Asp ttt Phe ttt	agc Ser ata Ile caa Gln tta Leu	tct Ser gga Gly gct Ala ccc Pro 65	tct Ser aac Asn tct Ser 50 gtt Val	gtt Val tgt Cys 35 tct Ser act Thr	106 154 202
gag ga Glu As 5 tcc ac Ser Th 20 aaa ca Lys Gl tct tg Ser Cy	at tgg ap Trp ac acc ar Thr ac caa an Gln gc aac ys Asn ct act Thr 70 cc tca la Ser	gat Asp aat Asn caa Gln gag Glu 55 act Thr	ctc Leu tct Ser gat Asp 40 tta Leu act Thr	ttc Phe tgt Cys 25 cct Pro caa Gln	gcc Ala 10 gct Ala cct Pro gat Asp	gtc Val ggt Gly cct Pro tct Ser tct Ser 75	gtc Val cat His cct Pro tgc Cys 60 cct Pro	aga Arg gaa Glu cct Pro 45 aaa Lys	agc Ser gac Asp 30 ctg Leu cca Pro	tgc Cys 15 gac Asp ttt Phe ttt Phe	agc Ser ata Ile caa Gln tta Leu ctt Leu 80	tct Ser gga Gly gct Ala ccc Pro 65 cct Pro	tct Ser aac Asn tct Ser tct Val cct Pro	gtt Val tgt Cys 35 tct Ser act Thr	106 154 202 250
gag gag gag Glu As 5 tcc ac Ser Th 20 aaa ca Lys Gl tct tg Ser Cy act ac Thr Th	at tgg ap Trp ac acc ar Thr ac caa an Gln gc aac ys Asn ct act Thr 70 cc tca la Ser	gat Asp aat Asn caa Gln gag Glu 55 act Thr	ctc Leu tct Ser gat Asp 40 tta act Thr cca Pro	ttc Phe tgt Cys 25 cct Pro caa Gln act Thr	gcc Ala 10 gct Ala cct Pro gat Asp tgg Trp ccc Pro 90 caa	gtc Val ggt Gly cct Pro tct Ser tct Ser 75 aat Asn	gtc Val cat His cct Pro tgc Cys 60 cct Pro	aga Arg gaa Glu cct Pro 45 aaa Lys cct Pro	agc Ser gac Asp 30 ctg Leu cca Pro ctt Leu ctt	tgc Cys 15 gac Asp ttt Phe ttt Leu aaa Lys 95 agt	agc Ser ata Ile caa Gln tta Leu ctt Leu 80 caa Gln	Me 1 tct Ser gga Gly gct Ala ccc Pro cct Pro gaa Glu agg	tct Ser aac Asn tct Ser tct Yal cct Pro caa Gln gtt	gtt Val tgt Cys 35 tct Ser act Thr	106 154 202 250

				120			MBII	.5 Se	equer 125	ice 1	List	ing.S	ST25	130		
cag Gln	ctt Leu	ctt Leu	caa Gln 135	caa Gln	caa Gln	tcc Ser	caa Gln	cct Pro 140	ccc Pro	ctt Leu	cga Arg	tct Ser	aga Arg 145	aaa Lys	aga Arg	490
aag Lys	aat Asn	cag Gln 150	caa Gln	aaa Lys	aga Arg	acc Thr	ata Ile 155	tgt Cys	cat His	gta Val	acg Thr	caa Gln 160	gag Glu	aat Asn	ctt Leu	538
tct Ser	tct Ser 165	gat Asp	ttg Leu	tgg Trp	gct Ala	tgg Trp 170	cgt Arg	aaa Lys	tac Tyr	ggt Gly	caa Gln 175	aaa Lys	ccc Pro	atc Ile	aaa Lys	586
ggc Gly 180	tct Ser	cct Pro	tat Tyr	cca Pro	agg Arg 185	aat Asn	tat Tyr	tac Tyr	aga Arg	tgt Cys 190	agt Ser	agc Ser	tca Ser	aaa Lys	gga Gly 195	634
tgt Cys	tta Leu	gca Ala	cga Arg	aaa Lys 200	caa Gln	gtt Val	gaa Glu	aga Arg	agt Ser 205	aat Asn	tta Leu	gat Asp	cct Pro	aat Asn 210	atc Ile	682
ttc Phe	atc Ile	gtt Val	act Thr 215	tac Tyr	acc Thr	gga Gly	gaa Glu	cac His 220	1111	cat His	cca Pro	cgt Arg	cct Pro 225	act Thr	cac His	730
cgg Arg	aac Asn	tct Ser 230	Leu	gcc	gga Gly	agt Ser	act Thr 235	ALG	aac Asn	aaa Lys	tct Ser	cag Gln 240		gtt Val	aac Asn	778
ccg Pro	gtt Val 245	Pro	aaa Lys	ccg Pro	gac Asp	aca Thr 250	Ser	cct Pro	tta Leu	tcg Ser	gat Asp 255	, 1111	gta Val	aaa Lys	gaa Glu	826
gag Glu 260	ı Ile	cat His	ctt Lev	tct Ser	ccg Pro 265	Thr	aca Thr	ccg Pro	ttg Leu	aaa Lys 270	, Gr	aac Asn	gat Asp	gac Asp	gtt Val 275	874
caa Glr	gaa Glu	ace Thi	g aat r Ası	gga Gly 280	, Ast	gaa Glu	gat Asp	ato Met	gtt Val 285		caa Glr	a gaa a Glu	gto Val	aac Asr 290	e atg n Met )	922
Gli	ı Glı	ı Glı	u Gli 29	1 GIV 5	1 GIU	GIU	ı Gıt	300	)	1 61		,,	305	5	gaa Glu	970
ga: Gl:	a gat u As	ga p As 31	p As	t gad p Asj	gtg y Val	g gat L Asj	gat Asj 31!	5 nei	t ttg 1 Lei	ata 1 Il	a cca e Pr	a aat o <b>A</b> si 320		a gcç ı Ala	g gtg a Val	1018
Ar	g As	p Ar 5	g As	p As	р Ге	33	e Pno	e Al	a GI	y se	33	5		,	g tcc p Ser	1066
A1 34	a GI O	y se	T AL	c gg a Gl	34	5	y GI	, 01	1							1116
at	ttac	aatt	tac	aaaa	aga i	aaaa	agtc	ag t	tttt	aatt	a tt	attt	ttgt	ttg	ttaaaac	1176
	gaca															1187
<2 <2	10> 11> 12> 13>	2 348 PRT Ara	ľ	psis	tha	lian	ıa									
<4	00>	2														
Me 1	et Se	er Se	er G	lu As 5	p Tr	p As	p Le	eu Ph	ne Al	a Va	al Va	al Ar	g Se	r Cy	s Ser	

Ser Ser Val Ser Thr Thr Asn Ser Cys Ala Gly His Glu Asp Asp Ile Page 2 20

#### MBI15 Sequence Listing.ST25 25 30

Gly Asn Cys Lys Gln Gln Gln Asp Pro Pro Pro Pro Pro Leu Phe Gln  $_{35}$ 

Ala Ser Ser Ser Cys Asn Glu Leu Gln Asp Ser Cys Lys Pro Phe Leu
50 55 60

Pro Val Thr Thr Thr Thr Thr Thr Thr Thr Trp Ser Pro Pro Pro Leu Leu 65 70 75

Pro Pro Pro Lys Ala Ser Ser Pro Ser Pro Asn Ile Leu Leu Lys Gln
85 90 95

Glu Gln Val Leu Leu Glu Ser Gln Asp Gln Lys Pro Pro Leu Ser Val 100 105 110

Arg Val Phe Pro Pro Ser Thr Ser Ser Ser Val Phe Val Phe Arg Gly
115 120 125

Gln Arg Asp Gln Leu Leu Gln Gln Gln Ser Gln Pro Pro Leu Arg Ser 130 135 140

Arg Lys Arg Lys Asn Gln Gln Lys Arg Thr Ile Cys His Val Thr Gln 145 150 155 160

Glu Asn Leu Ser Ser Asp Leu Trp Ala Trp Arg Lys Tyr Gly Gln Lys 165 170 175

Pro Ile Lys Gly Ser Pro Tyr Pro Arg Asn Tyr Tyr Arg Cys Ser Ser 180 185 190

Ser Lys Gly Cys Leu Ala Arg Lys Gln Val Glu Arg Ser Asn Leu Asp 195 200 205

Pro Asn Ile Phe Ile Val Thr Tyr Thr Gly Glu His Thr His Pro Arg 210 215 220

Pro Thr His Arg Asn Ser Leu Ala Gly Ser Thr Arg Asn Lys Ser Gln 225 230 240

Pro Val Asn Pro Val Pro Lys Pro Asp Thr Ser Pro Leu Ser Asp Thr 245 250 255

Val Lys Glu Glu Ile His Leu Ser Pro Thr Thr Pro Leu Lys Gly Asn 260 265 270

Asp Asp Val Glu Glu Thr Asn Gly Asp Glu Asp Met Val Gly Glu Glu 275 280 285

Val Asn Met Glu Glu Glu Glu Glu Glu Glu Val Glu Glu Asp Asp 290 295 300

Glu Glu Glu Glu Asp Asp Asp Asp Val Asp Asp Leu Leu Ile Pro Asn 305 310 315 320

Leu Ala Val Arg Asp Arg Asp Leu Phe Phe Ala Gly Ser Phe Pro 325

Ser Trp Ser Ala Gly Ser Ala Gly Asp Gly Gly Gly 340

<210: <211: <212	> 1	431 NA															
<213			aqob	is t	hali	ana											
<220 <221 <222 <223	> C > (	DS 129) 616	(1	211)													
	aaat														aaaaa	60	כ
aaac	aaaa	.cc c	taat	tttt	t tt	cttt	agtg	atg	agat	tat	tggt	gatg	at g	aaat	gattg	120	3
gaga	tcta	atg Met 1	aag Lys	aat Asn	aac Asn	aac Asn 5	aat Asn	ggc	gac Asp	gtt Val	gtg Val 10	gat Asp	aac Asn	gaa Glu	gtg Val	170	כ
aac Asn 15	aac Asn	cgg Arg	tta Leu	agc Ser	cgg Arg 20	tgg Trp	cat His	cac His	aat Asn	tct Ser 25	tcc Ser	cgg Arg	ata Ile	TIE	agg Arg 30	21	В
gtt Val	tca Ser	cga Arg	gct Ala	tcc Ser 35	ggt Gly	ggt Gly	aaa Lys	gat Asp	cga Arg 40	cac His	agc Ser	aaa Lys	gtc Val	ttg Leu 45	act Thr	26	5
tct Ser	aaa Lys	gga Gly	cca Pro 50	cgt Arg	gac Asp	cgt Arg	cgt Arg	gtc Val 55	cgg Arg	tta Leu	tca Ser	gtc Val	tcc Ser 60	acc Thr	gct Ala	31	4
ctt Leu	caa Gln	ttc Phe 65	tat Tyr	gat Asp	ctt Leu	caa Gln	gat Asp 70	cgg Arg	tta Leu	ggt Gly	tat Tyr	gat Asp 75	caa Gln	cct Pro	agc Ser	36	2
aaa Lys	gct Ala 80	gtt Val	gaa Glu	tgg Trp	tta Leu	atc Ile 85	aaa Lys	gct Ala	gct Ala	gaa Glu	gat Asp 90	tca Ser	atc Ile	tct. Ser	gag Glu	41	0
ctt Leu 95	cct Pro	tca Ser	ctc Leu	aac Asn	aac Asn 100	act Thr	cat His	ttt Phe	ccg Pro	acc Thr 105	gat Asp	gac Asp	gag Glu	aat Asn	cac His 110	45	8
cag Gln	aat Asn	cag Gln	aca Thr	tta Leu 115	aca Thr	aca Thr	gtt Val	gct Ala	gct Ala 120	aat Asn	tcc Ser	ttg Leu	tct Ser	aaa Lys 125	tct Ser	50	6
gct Ala	tgt Cys	agt Ser	agc Ser 130	aat Asn	tca Ser	gac Asp	acg Thr	agc Ser 135	aag Lys	aac Asn	tct Ser	tct Ser	ggt Gly 140	ttg Leu	tct Ser	55	4
tta Leu	tca Ser	aga Arg 145	tcg Ser	gag Glu	ctt Leu	aga Arg	gat Asp 150	aaa Lys	gct Ala	aga Arg	GIU	agg Arg 155	ATA	aga Arg	gag Glu	60	2
aga Arg	aca Thr 160	gct Ala	aaa Lys	gag Glu	acc Thr	aag Lys 165	gaa Glu	aga Arg	gat Asp	cat His	aac Asn 170	cac His	act Thr	tcg Ser	ttt Phe	65	0
acg Thr 175	qaA	ttg Leu	tta Leu	aat Asn	tcc Ser 180	ggt Gly	tca Ser	gat Asp	ccg Pro	gtt Val 185	aac Asn	tca Ser	aac Asn	cgg Arg	caa Gln 190	69	8 (
tgg Trp	atg Met	gct Ala	tca Ser	gct Ala 195	cct Pro	tct Ser	tca Ser	tct Ser	cca Pro 200	Met	gag Glu	tat Tyr	ttc Phe	agt Ser 205	tcg Ser	74	16

#### MBI15 Sequence Listing.ST25

MBII5 Sequence Listing. \$125	
ggt tta att ctc ggg tcg ggt caa caa acc cat ttc cct att tca aca Gly Leu Ile Leu Gly Ser Gly Gln Gln Thr His Phe Pro Ile Ser Thr 210 215 220	794
aat tot cat cot tto toa toa ato too gat cat cat cat cat cot Asn Ser His Pro Phe Ser Ser Ile Ser Asp His His His His Pro 225 230 235	842
cat cat cag cat caa gag ttt tca ttc gtt ccc gac cat ttg ata tca His His Gln His Gln Glu Phe Ser Phe Val Pro Asp His Leu Ile Ser 240 245 250	890
ccg gca gaa tcc aac ggc gga gca ttc aat ctt gat ttt aat atg tca Pro Ala Glu Ser Asn Gly Gly Ala Phe Asn Leu Asp Phe Asn Met Ser 255 260 265 270	938
aca ccc tcc ggc gcc gga gct gcc gtc tcc gcc gca tca ggt ggc ggc Thr Pro Ser Gly Ala Gly Ala Ala Val Ser Ala Ala Ser Gly Gly 275 280 285	986
ttc agt ggt ttc aac agg ggg acc ctt cag tcc aat tca aca aat cag Phe Ser Gly Phe Asn Arg Gly Thr Leu Gln Ser Asn Ser Thr Asn Gln 290 295 300	1034
cat cag tca ttc ctc gct aat cta cag agg ttt cca aca tca gaa agt His Gln Ser Phe Leu Ala Asn Leu Gln Arg Phe Pro Thr Ser Glu Ser 305 310 315	1082
gga gga ggt cca cag ttc tta ttc ggt gca ctg cct gca gag aat cac Gly Gly Pro Gln Phe Leu Phe Gly Ala Leu Pro Ala Glu Asn His 320 325 330	1130
Cac cac aat cac cag ttt cag ctt tac tat gaa aat gga tgc aga aac His His Asn His Gln Phe Gln Leu Tyr Tyr Glu Asn Gly Cys Arg Asn 335 340 345 350	1178
tca tca gaa cat aag ggt aaa ggc aag aac tga tgatattaat tattgcatct Ser Ser Glu His Lys Gly Lys Gly Lys Asn 355 360	1231
ttggttttgt tcaaatgctc attttgtatg tttatctttg gtttatttca aaacaaatgt	1291
taatotottt ogttgtotga tgtgtgttag ggttttgttt tatgtattga gggtotttgg	1351
aaatcttttt gcattgtgct tgtaatgttg tatttgtgat aatagcattt tgtttgtgag	1411
ttaaaaaaaa aaaaaaaaaa	1431

<210> 4

<211> 360

<212> PRT <213> Arabidopsis thaliana

<400> 4

Met Lys Asn Asn Asn Gly Asp Val Val Asp Asn Glu Val Asn Asn 1 5 10 15

Arg Leu Ser Arg Trp His His Asn Ser Ser Arg Ile Ile Arg Val Ser 20 25 30

Arg Ala Ser Gly Gly Lys Asp Arg His Ser Lys Val Leu Thr Ser Lys 35 40 45

Gly Pro Arg Asp Arg Arg Val Arg Leu Ser Val Ser Thr Ala Leu Gln 50 60

Phe Tyr Asp Leu Gln Asp Arg Leu Gly Tyr Asp Gln Pro Ser Lys Ala 65 70 75 80

#### MBI15 Sequence Listing.ST25

Val Glu Trp Leu Ile Lys Ala Ala Glu Asp Ser Ile Ser Glu Leu Pro 85 90 95

Ser Leu Asn Asn Thr His Phe Pro Thr Asp Asp Glu Asn His Gln Asn 100 105 110

Gln Thr Leu Thr Thr Val Ala Ala Asn Ser Leu Ser Lys Ser Ala Cys 115 120 125

Ser Ser Asn Ser Asp Thr Ser Lys Asn Ser Ser Gly Leu Ser Leu Ser 130 135 • 140

Arg Ser Glu Leu Arg Asp Lys Ala Arg Glu Arg Ala Arg Glu Arg Thr 145 150 155 160

Ala Lys Glu Thr Lys Glu Arg Asp His Asn His Thr Ser Phe Thr Asp 165 170 175

Leu Leu Asn Ser Gly Ser Asp Pro Val Asn Ser Asn Arg Gln Trp Met 180 185 190

Ala Ser Ala Pro Ser Ser Ser Pro Met Glu Tyr Phe Ser Ser Gly Leu 195 200 205

Ile Leu Gly Ser Gly Gln Gln Thr His Phe Pro Ile Ser Thr Asn Ser 210 225

His Pro Phe Ser Ser Ile Ser Asp His His His His Pro His His 225 230 235 240

Gln His Gln Glu Phe Ser Phe Val Pro Asp His Leu Ile Ser Pro Ala 245 250 255

Glu Ser Asn Gly Gly Ala Phe Asn Leu Asp Phe Asn Met Ser Thr Pro 260 265 270

Ser Gly Ala Gly Ala Ala Val Ser Ala Ala Ser Gly Gly Phe Ser 275 280 285

Gly Phe Asn Arg Gly Thr Leu Gln Ser Asn Ser Thr Asn Gln His Gln 290 295 300

Ser Phe Leu Ala Asn Leu Gln Arg Phe Pro Thr Ser Glu Ser Gly Gly 305 310 315 320

Gly Pro Gln Phe Leu Phe Gly Ala Leu Pro Ala Glu Asn His His His 325 330 335

Asn His Gln Phe Gln Leu Tyr Tyr Glu Asn Gly Cys Arg Asn Ser Ser 340 350

Glu His Lys Gly Lys Gly Lys Asn 355 360

<210> 5

### MBI15 Sequence Listing.ST25

<211> 1055 <212> DNA <213> Arabidopsis thaliana	
<220> <221> CDS <222> (70)(816) <223> G19	
<400> 5 ataaaggcat ttcagctcca ccgtaggaaa ctttctcttg aaagaaaccc acagcaacaa	60
acagagaaa atg tgt ggc ggt gct att att tcc gat tat gcc cct ctc gtc Met Cys Gly Gly Ala Ile Ile Ser Asp Tyr Ala Pro Leu Val 1 5 10	111
acc aag gcc aag ggc cgt aaa ctc acg gct gag gaa ctc tgg tca gag Thr Lys Ala Lys Gly Arg Lys Leu Thr Ala Glu Glu Leu Trp Ser Glu 15 20 25 30	159
ctc gat gct tcc gcc gcc gac gac ttc tgg ggt ttc tat tcc acc tcc Leu Asp Ala Ser Ala Ala Asp Asp Phe Trp Gly Phe Tyr Ser Thr Ser 35 40 45	207
aaa ctc cat ccc acc aac caa gtt aac gtg aaa gag gag gca gtg aag Lys Leu His Pro Thr Asn Gln Val Asn Val Lys Glu Glu Ala Val Lys 50 55 60	255
aag gag cag gca aca gag ccg ggg aaa cgg agg a	303
tat aga ggg ata cgt aag cgt cca tgg gga aaa tgg gcg gct gag att Tyr Arg Gly Ile Arg Lys Arg Pro Trp Gly Lys Trp Ala Ala Glu Ile 80 85 90	351
cga gat cca cga aaa ggt gtt aga gtt tgg ctt ggt acg ttc aac acg Arg Asp Pro Arg Lys Gly Val Arg Val Trp Leu Gly Thr Phe Asn Thr 95 100 105 110	399
gcg gag gaa gct gcc atg gct tat gat gtt gcg gcc aag cag atc cgt Ala Glu Glu Ala Ala Met Ala Tyr Asp Val Ala Ala Lys Gln Ile Arg 115 120 125	447
ggt gat aaa gcc aag ctc aac ttc cca gat ctg cac cat cct cct cct Gly Asp Lys Ala Lys Leu Asn Phe Pro Asp Leu His His Pro Pro Pro 130 135 140	495
cct aat tat act cct ccg ccg tca tcg cca cga tca acc gat cag cct Pro Asn Tyr Thr Pro Pro Pro Ser Ser Pro Arg Ser Thr Asp Gln Pro 145 150 155	543
ccg gcg aag aag gtc tgc gtt gtc tct cag agt gag agc gag tta agt Pro Ala Lys Lys Val Cys Val Val Ser Gln Ser Glu Ser Glu Leu Ser 160 165 170	591
cag ccg agt ttc ccg gtg gag tgt ata gga ttt gga aat ggg gac gag Gln Pro Ser Phe Pro Val Glu Cys Ile Gly Phe Gly Asn Gly Asp Glu 175 180 185 190	639
ttt cag aac ctg agt tac gga ttt gag ccg gat tat gat ctg aaa cag Phe Gln Asn Leu Ser Tyr Gly Phe Glu Pro Asp Tyr Asp Leu Lys Gln 195 200 205	687
cag ata tcg agc ttg gaa tcg ttc ctt gag ctg gac ggt aac acg gcg Gln Ile Ser Ser Leu Glu Ser Phe Leu Glu Leu Asp Gly Asn Thr Ala 210 215 220	735
gag caa ccg agt cag ctt gat gag tcc gtt tcc gag gtg gat atg tgg Glu Gln Pro Ser Gln Leu Asp Glu Ser Val Ser Glu Val Asp Met Trp 225 230 235	783
atg ctt gat gat gtc att gcg tcg tat gag taa aagaaaaaaa ataagtttaa Met Leu Asp Asp Val Ile Ala Ser Tyr Glu Page 7	836

896

956 1016

1055

MBI15 Sequence Listing.ST25 aaaaagttaa ataaagtctg taatatatat gtaaccgccg ttacttttaa aaggttttta ccgtcgcatt ggactgctga tgatgtctgt tgtgtaatgt gtagaatgtg accaaatgga cgttatatta cggtttgtgg tattattagt ttcttagatg gaaaaactta catgtgtaaa taagatttgt aatgtaagac gaagtactta taacttctt <210> 248 <211> PRT <212> <213> Arabidopsis thaliana <400> 6 Met Cys Gly Gly Ala Ile Ile Ser Asp Tyr Ala Pro Leu Val Thr Lys Ala Lys Gly Arg Lys Leu Thr Ala Glu Glu Leu Trp Ser Glu Leu Asp 20 25 30 Ala Ser Ala Ala Asp Asp Phe Trp Gly Phe Tyr Ser Thr Ser Lys Leu 35 40 45 His Pro Thr Asn Gln Val Asn Val Lys Glu Glu Ala Val Lys Glu
50 55 60 Gln Ala Thr Glu Pro Gly Lys Arg Lys Arg Lys Asn Val Tyr Arg Gly Ile Arg Lys Arg Pro Trp Gly Lys Trp Ala Ala Glu Ile Arg Asp 85 90 95 Pro Arg Lys Gly Val Arg Val Trp Leu Gly Thr Phe Asn Thr Ala Glu 100 105 110 Glu Ala Ala Met Ala Tyr Asp Val Ala Ala Lys Gln Ile Arg Gly Asp 115 120 125 Lys Ala Lys Leu Asn Phe Pro Asp Leu His His Pro Pro Pro Pro Asn 130 135 140 Tyr Thr Pro Pro Pro Ser Ser Pro Arg Ser Thr Asp Gln Pro Pro Ala 145 150 155 160 Lys Lys Val Cys Val Val Ser Gln Ser Glu Ser Glu Leu Ser Gln Pro 165 170 175 Ser Phe Pro Val Glu Cys Ile Gly Phe Gly Asn Gly Asp Glu Phe Gln 180 185 190 Asn Leu Ser Tyr Gly Phe Glu Pro Asp Tyr Asp Leu Lys Gln Gln Ile 195 200 205 Ser Ser Leu Glu Ser Phe Leu Glu Leu Asp Gly Asn Thr Ala Glu Gln 210 215 Pro Ser Gln Leu Asp Glu Ser Val Ser Glu Val Asp Met Trp Met Leu

240

MBI15 Sequence Listing.ST25

Asp Asp Val Ile Ala Ser Tyr Glu

225

<210> <211> 1857 <212> DNA Arabidopsis thaliana <221> CDS <222> (458) .. (1663) G261 <400> 7 gtttaggttc gagaagcaga gagggttcga gaagctaata agggtttctt ctttttgatt 60 120 ttaatgetaa aagggtteta gattegttga attttacaag ggttttaggg gttettagaa gettttgett gattgtettt tatttagaaa cagtggtgag tttttagtet tteaetttgt 180 tcaagttcga agctttttt ggagggaatt ttgggcttct gattttgatc gaaacttact 240 gatagtaagt tetttgagte eteettaaet gtagtttetg tgtaetgaag ttattgaatt 300 gaaagttttt atcttttttg gttattgaaa ctttcatagt ttgatcaaaa gagtctcttg 360 ctctgttttt ggctctgttt ttgtgagtgt gattgtaagc tttgttgtga gtagattgaa 420 tcaaggagtg tgagagttgt taaaagtgtt ttcagag atg gat gag aat aat cat Met Asp Glu Asn Asn His 475 gga gtt tca tca agc tca ctt cca cct ttc ctc acc aaa aca tat gag Gly Val Ser Ser Ser Leu Pro Pro Phe Leu Thr Lys Thr Tyr Glu 523 atg gtt gat gat tct tca tcc gat tct atc gtc tct tgg agt cag agc Met Val Asp Asp Ser Ser Ser Asp Ser Ile Val Ser Trp Ser Gln Ser 571 aat aag agt ttc atc gtt tgg aat ccg ccg gag ttt tct aga gat ctt Asn Lys Ser Phe Ile Val Trp Asn Pro Pro Glu Phe Ser Arg Asp Leu 619 ctt ccg aga ttc ttc aag cac aat aac ttc tct agc ttt atc cgc cag 667 Leu Pro Arg Phe Phe Lys His Asn Asn Phe Ser Ser Phe Ile Arg Gln ctt aac aca tat ggt ttt aga aaa gct gat cct gag caa tgg gaa ttt Leu Asn Thr Tyr Gly Phe Arg Lys Ala Asp Pro Glu Gln Trp Glu Phe 715 gcg aat gat gat ttt gtg aga ggt caa cct cat ctt atg aag aac att Ala Asn Asp Asp Phe Val Arg Gly Gln Pro His Leu Met Lys Asn Ile 763 cat aga cgc aaa cca gtt cat agc cac tct tta ccg aat ctt caa gct His Arg Arg Lys Pro Val His Ser His Ser Leu Pro Asn Leu Gln Ala 811 cag tta aac ccg ttg acg gat tca gaa cga gtg aga atg aat aat cag Gln Leu Asn Pro Leu Thr Asp Ser Glu Arg Val Arg Met Asn Asn Gln 859 att gag aga ttg aca aaa gag aaa gaa gga ttg ctt gaa gag tta cat Ile Glu Arg Leu Thr Lys Glu Lys Glu Gly Leu Leu Glu Glu Leu His 907 aaa caa gac gag gaa cga gaa gtg ttt gag atg caa gtg aaa gaa ctt Lys Gln Asp Glu Glu Arg Glu Val Phe Glu Met Gln Val Lys Glu Leu 955

				155			MBII		quer 160	ice I	isti	ing.S	T25	165		
aaa Lys	gaa Glu	cga Arg	tta Leu 170	caa Gln	cac His	atg Met	gag Glu	aag Lys 175	cgt Arg	cag Gln	aaa Lys	aca Thr	atg Met 180	gtt Val	tcg Ser	1003
ttt Phe	gtt Val	tct Ser 185	caa Gln	gta Val	ttg Leu	gaa Glu	aag Lys 190	cca Pro	999 999	ctt Leu	gct Ala	ttg Leu 195	aac Asn	cta Leu	tcg Ser	1051
ccg Pro	tgt Cys 200	gtt Val	ccc Pro	gaa Glu	aca Thr	aac Asn 205	gag Glu	agg Arg	aaa Lys	aga Arg	agg Arg 210	ttc Phe	cct Pro	agg Arg	atc Ile	1099
gag Glu 215	Phe	ttt Phe	ccc Pro	gat Asp	gaa Glu 220	ccg Pro	atg Met	ttg Leu	gaa Glu	gag Glu 225	aac Asn	aaa Lys	act Thr	tgt Cys	gtt Val 230	1147
gtt Val	gtg Val	aga Arg	gag Glu	gaa Glu 235	ggt Gly	tct Ser	aca Thr	agc Ser	cct Pro 240	tct Ser	tca Ser	cac His	aca Thr	aga Arg 245	gag Glu	1195
cat His	caa Gln	gtg Val	gaa Glu 250	cag Gln	tta Leu	gag Glu	tca Ser	tcg Ser 255	ata Ile	gcg Ala	att Ile	tgg Trp	gag Glu 260	aat Asn	ctt Leu	1243
gta Val	tcg Ser	gat Asp 265	tct Ser	tgt Cys	gag Glu	agt Ser	atg Met 270	tta Leu	caa Gln	tca Ser	aga Arg	agt Ser 275	atg Met	atg Met	aca Thr	1291
Leu	Asp 280	Val	Asp	Glu	Ser	Ser 285		Pne	Pro	GIU	290	PIO	110	neu	<b>J</b> C1	1339
Cys 295	Ile	Gln	Leu	Ser	Va1 300	Asp	tca Ser	Arg	ьeu	305	261	PIO	rio	501	310	1387
Arg	Ile	Ile	qeA :	Met 315	Asn	Сув	gag Glu	Pro	320	GIY	Ser	. Буз	. 610	325	71011	1435
Thr	Val	Ala	Ala 330	Pro	Pro	Pro		335	vaı	Ala	GIY	MIC	340	, woh	, or	1483
Phe	Trp	345	Glr	Phe	Phe	: Sex	350	ASD	Pro	GIA	, ser	359	5	. G11	cgg Arg	1531
Glu	1 Val	l Glr	ı Lei	ı GI	Arg	365	a ASP	ASL	, па	, waf	370	)	. 01)	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	cgt Arg	1579
Th:	r Glu 5	ı Lys	s Cys	3 Trj	380	)	ı ser	. ALC	, Abi	385	5				gaa Glu 390	1627
Gl	n Lei	ı Gly	y His	3 Let	i Thi	c Se	t tca r Sei	GIU	400	)	•					1673
															tgttt	
															ttcccag	
tt	catt	gtag	cag	actt	caa	tggt	aatg	at.aa	agct	agag	c tt	atgg	atag	tat	tcataaa	
aa	aa															1857

<sup>&</sup>lt;210> 8 <211> 401 <212> PRT <213> Arabidopsis thaliana

#### MBI15 Sequence Listing.ST25

<400> 1

Met Asp Glu Asn Asn His Gly Val Ser Ser Ser Leu Pro Pro Phe

Leu Thr Lys Thr Tyr Glu Met Val Asp Asp Ser Ser Ser Asp Ser Ile 20 25 30

Val Ser Trp Ser Gln Ser Asn Lys Ser Phe Ile Val Trp Asn Pro Pro 35 40 45

Glu Phe Ser Arg Asp Leu Leu Pro Arg Phe Phe Lys His Asn Asn Phe 50 55 60

Ser Ser Phe Ile Arg Gln Leu Asn Thr Tyr Gly Phe Arg Lys Ala Asp 65 70 75 80

Pro Glu Gln Trp Glu Phe Ala Asn Asp Asp Phe Val Arg Gly Gln Pro

His Leu Met Lys Asn Ile His Arg Arg Lys Pro Val His Ser His Ser 100 105 110

Leu Pro Asn Leu Gln Ala Gln Leu Asn Pro Leu Thr Asp Ser Glu Arg 115 120 125

Val Arg Met Asn Asn Gln Ile Glu Arg Leu Thr Lys Glu Lys Glu Gly 130 135 140

Leu Leu Glu Glu Leu His Lys Gln Asp Glu Glu Arg Glu Val Phe Glu 145 150 155 160

Met Gln Val Lys Glu Leu Lys Glu Arg Leu Gln His Met Glu Lys Arg 165 170 175

Gln Lys Thr Met Val Ser Phe Val Ser Gln Val Leu Glu Lys Pro Gly 180 185 190

Leu Ala Leu Asn Leu Ser Pro Cys Val Pro Glu Thr Asn Glu Arg Lys

Arg Arg Phe Pro Arg Ile Glu Phe Phe Pro Asp Glu Pro Met Leu Glu 210 215 220

Glu Asn Lys Thr Cys Val Val Val Arg Glu Glu Gly Ser Thr Ser Pro 225 230 235 240

Ser Ser His Thr Arg Glu His Gln Val Glu Gln Leu Glu Ser Ser Ile 245 250 255

Ala Ile Trp Glu Asn Leu Val Ser Asp Ser Cys Glu Ser Met Leu Gln 260 270

Ser Arg Ser Met Met Thr Leu Asp Val Asp Glu Ser Ser Thr Phe Pro 275 280 285

Glu	Ser 290	Pro	Pro	Leu	Ser	Cys 295	MBI: Ile	15 Se Gln	Leu Leu	nce 1 Ser	List: Val 300	ing.: Asp	ST25 Ser	Arg	Leu	l		
Lys 305	Ser	Pro	Pro	Ser	Pro 310	Arg	Ile	Ile	Asp	Met 315	Asn	Cys	Glu	Pro	Asp 320			
Gly	Ser	Lys	Glu	Gln 325	Asn	Thr	Val	Ala	Ala 330	Pro	Pro	Pro	Pro	Pro 335	Val	L		
Ala	Gly	Ala	Asn 340	Asp	Gly	Phe	Trp	Gln 345	Gln	Phe	Phe	Ser	Glu 350	Asn	Pro	•		
Gly	Ser	Thr 355	Glu	Gĺn	Arg	Glu	Val 360	Gln	Leu	Glu	Arg	Lys 365	Asp	Asp	Lys	3		
Asp	Lys 370		Gly	Val	Arg	Thr 375	Glu	Lys	Cys	Trp	Trp 380	Asn	Ser	Arg	Ası	n		
Val 385	Asn	Ala	Ile	Thr	Glu 390	Gln	Leu	Gly	His	Leu 395	Thr	Ser	Ser	Glu	Arg 40	9		
Ser																		
<21 <21 <21 <21	1> 2>	9 964 DNA Arab	oidop	sis	thal:	iana												
<22 <22 <22 <22	1> 2>	CDS (63) G28	(8	69)														
<40	0>	9	caag	2200	aa a	ccaa	acaa	ıc aa	aaaa	acat	. tct	taat	aat	tato	ett	ctg		60
_	250	tca	atg Met	aco	aca	oat.	tct	caa	tct	qat	tat	gct	ttt	ctt	gag	l	1	.07
t co Sei		a cga e Arg	a cga g Arg	cac His	tta Leu	cta Leu	gga	a gaa / Glu	tcg Ser 25	gag Glu	ccg Pro	ata Ile	a cto e Leu	ag( 1 Se: 30	t ga r Gl	g u	1	.55
t co	g aca	a gcg	g agt a Ser 35	tcg Ser	gtt Val	act Thr	caa Gl:	tct Ser 40	tgt Cys	gta Val	acc l Thi	gg(	caq y Gli 45	g age	c at r Il	t .e	2	203
aaa Lys	a cc	g gte o Va 50	g tac l Tyr	gga Gly	a cga / Arg	aac Asn	cci Pro	t ago o Sei	tti Phe	ago e Ser	aaa Lys	a cte s Le 60	g tai	r Pr	t te o Cy	JC 78	2	251
t to Ph	ace Th:	c ga r Gl	g ago u Ser	tgg Tr	g gga o Gly	gat Asp 70	tte	g ccg	tte Lei	g aaa u Lym	a gaa s Glu 75	a aa u As:	c ga n As	t tc p Se	t ga r Gl	ag lu	2	299
ga As 80	р Ме	g tt t Le	a gti u Vai	t tac L Ty:	c ggt r Gly 85	ato / Ile	cte Le	c aad u Asi	gae n As	p Ala 90	c tt a Ph	t ca e Hi	c gg s Gl	c gg y Gl	t to y Ti 9!		;	347
ga Gl	g cc u Pr	g to o Se	t to r Se	t to r Se 10	r Sei	t too	ga r As	c gaa p Gl	a ga u As 10	p Ar	t ag g Se	c tc r Se	t tt r Ph	c cc e Pr 11	0 3	gt er	;	395
gt	t aa	g at	c ga	g ac	t cc	g ga	g ag	t tt		g gc		g ga	t tc	t gt	t c	cg		443

Val	Lys	Ile	Glu 115	Thr	Pro	Glu		15 S Phe 120						Val	Pro	
gtc Val	aag Lys	aag Lys 130	gag Glu	aag Lys	acg Thr	agt Ser	cct Pro 135	gtt Val	tcg Ser	gcg Ala	gcg Ala	gtg Val 140	acg Thr	gcg Ala	gcg Ala	491
	gga Gly 145															539
	gcg Ala															587
	acg Thr															635
	ttc Phe															683
	aat Asn															731
	ttt Phe 225															779
	gcc Ala															827
gtt Val	gtt Val	gaa Glu	gtg Val	gca Ala 260	cgt Arg	ggc Gly	gat Asp	cgt Arg	tta Leu 265	ttg Leu	gtt Val	tta Leu	taa			869
ttt	gatt	tt t	cttt	gttg	g at	gatt	atat	: gat	tctt	caa	aaaa	agaaç	gaa d	gtta	ataaa	929
aaaa	atte	jtt t	atta	ttaa	a aa	aaaa	aaaa	a aaa	aa		•					964
<210 <211 <212 <213	l> 2 2> E	0 268 PRT Arabi	dops	is t	:hali	ana					-					
<400	)> 1	.0														
Met 1	Ser	Met	Thr	Ala 5	Asp	Ser	Gln	Ser	Asp 10	Tyr	Ala	Phe	Leu	Glu 15	Ser	
Ile	Arg	Arg	His 20	Leu	Leu	Gly	Glu	Ser 25	Glu	Pro	Ile	Leu	Ser 30	Glu	Ser	
Thr	Ala	Ser 35	Ser	Val	Thr	Gln	Ser 40	Cys	Val	Thr	Gly	Gln 45	Ser	Ile	Lys	
Pro	Val. 50	Tyr	Gly	Arg	Asn	Pro 55	Ser	Phe	Ser	Lys	Leu 60	Tyr	Pro	Суѕ	Phe	

Page 13

Thr Glu Ser Trp Gly Asp Leu Pro Leu Lys Glu Asn Asp Ser Glu Asp 65 70 75 80

Met Leu Val Tyr Gly Ile Leu Asn Asp Ala Phe His Gly Gly Trp Glu 85 90 95

							MBI	15 S	eque	nce 1	List	ing.	ST25	_		
Pro	Ser	Ser	Ser 100	Ser	Ser	Asp	Glu	Asp 105	Arg	Ser	Ser	Phe	Pro 110	Ser	Val	
Lys	Ile	Glu 115	Thr	Pro	Glu	Ser	Phe 120	Ala	Ala	Val	Asp	Ser 125	Val	Pro	Val	
Lys	Lys 130	Glu	Lys	Thr	Ser	Pro 135	Val	Ser	Ala	Ala	Val 140	Thr	Ala	Ala	Lys	
Gly 145	rys	His	Tyr	Arg	Gly 150	Val	Arg	Gln	Arg	Pro 155	Trp	Gly	Lys	Phe	Ala 160	
Ala	Glu	Ile	Arg	Asp 165	Pro	Ala	Lys	Asn	Gly 170	Ala	Arg	Val	Trp	Leu 175	Gly	
Thr	Phe	Glu	Thr 180	Ala	Glu	Asp	Ala	Ala 185	Leu	Ala	Tyr	Asp	Arg 190	Ala	Ala	
Phe	Arg	Met 195		Gly	Ser	Arg	Ala 200	Leu	Leu	Asn	Phe	Pro 205	Leu	Arg	Val	
Asn	Ser 210	Gly	Glu	Pro	двр	Pro 215	Val	Arg	Ile	Lys	Ser 220	Lys	Arg	Ser	Ser	
Phe 225		Ser	Ser	Asn	Glu 230	Asn	Gly	Ala	Pro	Lys 235	Ьув	Arg	Arg	Thr	Val 240	
Ala	Ala	Gly	Gly	Gly 245	Met	Asp	Lys	Gly	Leu 250	Thr	Val	Lys	Cys	Glu 255	Val	
Val	. Glu	Val	Ala 260		Gly	Asp	Arg	Leu 265	Leu	Val	Leu	l				
<21 <21 <21 <21	.1> .2>	11 1571 DNA Arab		sis	thal	iana										
<22 <22 <22 <22	21> 22>	CDS (428 G869	))(	1402	!)											
<40 agg	00> gaaca	11 agtg	aaag	gtto	egg t	tttt	tggg	gt tt	.cgat	ctga	a taa	itcaa	ıcaa	gaaa	aaaggg	60
tt	gati	tat	gtc	gctg	gg t	ttga	atc	ga ct	gtga	tttt	gto	ttt	gatt	cata	tctctt	120
cto	cga	ttc	atca	tcat	ct t	ccc	atca	at co	jtcgt	cttt	t gaa	atc	tgt	ctt	ctcaacg	180
ct	cttca	actt	ctg	tgta	aat a	agca	gagg	gc tt	gtto	tgga	a gad	ctcci	tct	ctti	ccatgc	240
gc	ttaa	gacc	caaa	aagga	act t	gtto	tagi	g tt	gaag	gteti	t tgg	1999 <sup>1</sup>	ttt	caca	ataaagc	300
ag	caaa	agtt	ttc	ttt	ttc a	atagt	tcg	ct ga	agagt	ttt	g agt	ttt	gata	cca	aaaagt	360
tt	tgac	cttt	taga	agtga	att (	ttt	gttc	tt to	etgti	ttc	t gg	gtat	ttt	gag	gagtggg	420
tt	taac	a ato Med	g gti	t gc	a Ile	aga Arg	a aag	g gaa s Gl	a cag u Gl	tci n Se:	t tte r Le	g ag u Se	t gg r Gl	t gt y Va	t agt l Ser	469
ag	c ga	g at	t aa	g aa	g ag	a gc	t aa	g aga		c ac		a tc	g tc	c ct	t cct	517

Ser 15	Glu	Ile	Lys	Lys	Arg 20	Ala					List Leu				Pro 30	
			caa Gln													565
			gat Asp 50													613
			aaa Lys													661
			tct Ser													709
			ggc Gly													757
			gtt Val													805
			gat Asp 130													853
			gaa Glu													901
			att Ile													949
			gag Glu													997
gtt Val	gag Glu	caa Gln	gat Asp	gac Asp 195	act Thr	tct Ser	gca Ala	tca Ser	gct Ala 200	ctc Leu	act Thr	tgt Cys	gtc Val	aac Asn 205	aac Asn	1045
cct Pro	gat Asp	gac Asp	gtc Val 210	tcg Ser	acc Thr	gtt Val	gct Ala	cca Pro 215	act Thr	gct Ala	cca Pro	act Thr	cca Pro 220	aat Asn	gtt Val	1093
			gga Gly													1141
cta Leu	cag Gln 240	atc Ile	cct Pro	gat Asp	ttt Phe	ggt Gly 245	ttc Phe	ttg Leu	gca Ala	gag Glu	gag Glu 250	caa Gln	caa Gln	gac Asp	cta Leu	1189
			tgt Cys													1237
			att Ile													1285
			ttt Phe 290													1333
			ctt Leu													1381

Page 15

W	J U1/	33/2	O													-
Lys S	igt ( Ser )	tt g	gca q Ala i	gct Ala	tca Ser	tag (	MBI1 gatc	.5 Se ttgc	quen tt aç	ce L gtaai	isti tgtta	ng.S a ag	T25 tgaga	aaga		
		tt t	tttc	gttt	a tg	cttt	agta	att	taaga	aca 1	taca	aaag	tg t	gtgti	tccgg	
															taatg	
_			tatg													
<210: <211 <212	> 3 > P	24 RT														
<213			dops	is t	hali	ana										
<400				_	_		<b>~</b> 1			C	C3	v-1	Cor	Car :	G) 11	
Met 1	Val	Ala	Ile	Arg 5	Lys	GIU	GIn	Ser	10	Ser	GIŸ	val	361	15	GIU	
Ile	Lys	Lys	Arg 20	Ala	Lys	Arg	Asn	Thr 25	Leu	Ser	Ser	Leu	Pro 30	Gln	Glu	
Thr	Gln	Pro 35	Leu	Arg	Lys	Val	Arg 40	Ile	Ile	Val	Asn	Asp 45	Pro	Tyr	Ala	
Thr	Авр 50	Asp	Ser	Ser	Ser	Asp 55	Glu	Glu	Glu	Leu	Lys 60	Val	Pro	Lys	Pro	
Arg 65	Lys	Met	Lys	Arg	Ile 70	Val	Arg	Glu	Ile	Asn 75	Phe	Pro	Ser	Met	Glu 80	
<b>Val</b>	Ser	Glu	Gln	Pro 85	Ser	Glu	Ser	Ser	Ser 90	Gln	Asp	Ser	Thr	Lys 95	Thr	
Asp	Gly	Lys	Ile 100	Ala	Val	Ser	Ala	Ser 105	Pro	Ala	Val	Pro	Arg 110	Lys	Lys	
Pro	Val	Gly 115	Val	Arg	Gln	Arg	Lys 120	Trp	Gly	Lys	Trp	Ala 125	Ala	Glu	Ile	
Arg	Asp 130	Pro	Ile	Lys	Lys	Thr 135	Arg	Thr	Trp	Leu	Gly 140	Thr	Phe	Asp	Thr	
Leu 145	Glu	Glu	Ala	Ala	Lys 150	Ala	Tyr	Asp	Ala	Lув 155	Lys	Leu	Glu	Phe	Авр 160	
Ala	Ile	Val	Ala	Gly 165	Asn	Val	Ser	Thr	Thr 170	Lys	Arg	Asp	Val	Ser 175	Ser	
Ser	Glu	Thr	Ser 180	Gln	Cys	Ser	Arg	Ser 185	Ser	Pro	Val	Val	Pro 190	Val	Glu	
Gln	Asp	Авр 195		Ser	Ala	Ser	Ala 200	Leu	Thr	Сув	Val	Asn 205	Asn	Pro	Asp	
Asp	Val 210		Thr	Val	Ala	Pro 215	Thr	: Ala	Pro	Thr	Pro 220	Asn	Val	Pro	Ala	
Gly	Gly	Asn	Lys	Glu	Thr	Leu	Phe	e Asp		Asp age		Thr	Asn	Leu	Gln	

WO 01/35726				PCT/US
225	230	MBI15 Sequence 235	Listing.ST25	240
Ile Pro Asp Phe	Gly Phe Leu 245	Ala Glu Glu Gln 250	Gln Asp Leu Asp 255	Phe
Asp Cys Phe Leu 260	Ala Asp Asp	Gln Phe Asp Asp 265	Phe Gly Leu Leu 270	Asp
Asp Ile Gln Gly 275	Phe Glu Asp	Asn Gly Pro Ser 280	Ala Leu Pro Asp 285	Phe
Asp Phe Ala Asp 290	Val Glu Asp 295		Asp Ser Ser Phe	Gly
Phe Leu Asp Gln 305	Leu Ala Pro 310	Ile Asn Ile Ser 315	Cys Pro Leu Lys	Ser 320
Phe Ala Ala Ser				
<210> 13 <211> 920 <212> DNA <213> Arabidops	sis thaliana			
<220> <221> CDS <222> (1)(85) <223> G237	2)			
<400> 13 atg gcg aag acg Met Ala Lys Thr 1	aaa tat gga Lys Tyr Gly 5	gag aga cat agg Glu Arg His Arg 10	aaa ggg tta tgg Lys Gly Leu Trp 15	tca 48 Ser
cct gaa gaa gac Pro Glu Glu Asp 20	gag aag cta Glu Lys Leu	agg agc ttc atc Arg Ser Phe Ile . 25	ctc tct tat ggc Leu Ser Tyr Gly 30	cat 96 His
tct tgc tgg acc Ser Cys Trp Thr 35	act gtt ccc Thr Val Pro	atc aaa gct ggg Ile Lys Ala Gly 40	tta caa agg aat Leu Gln Arg Asn 45	ggg 144 Gly
_	tta aga tgg	att aat tac cta	aga cca ggg tta	aag 192
aag agc tgc aga Lys Ser Cys Arg 50	Leu Arg Trp	Ile Asn Tyr Leu	Arg Pro Gly Leu 60	гув
Lys Ser Cys Arg 50 agg gat atg att	agt gca gaa	gaa gaa gag act	Arg Pro Gly Leu	cat 240
Lys Ser Cys Arg 50 agg gat atg att Arg Asp Met Ile 65 tct ccc ttg ggt	agt gca gaa Ser Ala Glu 70 aac aag tgg	gaa gaa gag act Glu Glu Glu Thr 75 tog caa ata gct	Arg Pro Gly Leu 60 atc ttg acg ttt	cat 240 His 80 gga 288

Page 17

384

432

aaa tgg ctc aag tct cag agc tta caa gat gca aaa tct att tcc cct Lys Trp Leu Lys Ser Gln Ser Leu Gln Asp Ala Lys Ser Ile Ser Pro 115 120 125

cct tcg tct tca tca tca tca ctt gtt gct tgt gga gaa aga aat ccg Pro Ser Ser Ser Ser Ser Ser Leu Val Ala Cys Gly Glu Arg Asn Pro 130 135 140

gaa Glu 145	acc Thr	ttg Leu	atc Ile	tcg Ser	aat Asn 150	cac	ata	ttc	Ser	ctc	cag	aga	ctt	cta Leu	gag Glu 160	480
aac Asn	aaa Lys	tct Ser	tca Ser	tct Ser 165	ccc Pro	tca Ser	caa Gln	gaa Glu	agc Ser 170	aac Asn	gga Gly	aat Asn	aac Asn	agc Ser 175	cat His	528
caa Gln	tgt Cys	tct Ser	tct Ser 180	gct Ala	cct Pro	gag Glu	att Ile	cca Pro 185	agg Arg	ctt Leu	ttc Phe	ttc Phe	tct Ser 190	gaa Glu	tgg Trp	576
ctt Leu	tct Ser	tct Ser 195	tca Ser	tat Tyr	ccc Pro	cac His	acc Thr 200	gat Asp	tat Tyr	tcc Ser	tct Ser	gag Glu 205	ttt Phe	acc Thr	gac Asp	624
Ser	Lys 210	His	Ser	Gln	gct Ala	Pro 215	Asn	Val	Glu	GIu	220	Leu	ser	ΑΙd	IYI	672
Glu 225	Glu	Met	Gly	Asp	gtt Val 230	Asp	Gln	Phe	HIS	1yr 235	ASN	GIU	met	Met	240	720
Asn	Asn	Ser	Asn	Trp 245	act Thr	Leu	Asn	Asp	250	vai	Pne	GIY	Ser	255	Cys	768
aag Lys	aag Lys	cag Gln	gag Glu 260	cat His	cat His	att Ile	tat Tyr	aga Arg 265	gag Glu	gct Ala	tca Ser	gat Asp	tgt Cys 270	Mail	tct Ser	816
tct Ser	gct Ala	gaa Glu 275	Phe	ttt Phe	tct Ser	cca Pro	cca Pro 280	Thr	acg Thr	acg Thr	taa	att	gcgt	tta		862
ttg	taat	gta	aatc	aaat	tt c	taaq	acaa	a ac	caga	aaaa	aaa	aaaa	aaa	aaaa	aaaa	920
						5			-55-							
<21 <21 <21 <21	l1> l2>	14 283 PRT Arab			thal				~33~							
<21 <21 <21	l1> l2>	283 PRT														
<21 <21 <21	11> 12> 13>	283 PRT Arab	oidop	sis	thal	iana									) Ser	
<21 <21 <21 <40 Met 1	11> 12> 13> 00> = Ala	283 PRT Arab 14	oidop Thr	sis Lys 5	thal Tyr	iana Gly	Glu	ı Arg	His 10	Arg	Lys	Gly	· Leu	Trr 15		
<21 <21 <21 <40 Met 1	11> 12> 13> 00> = Ala	283 PRT Arab 14 Lys	oidop Thr Asp 20	sis Lys 5	thal Tyr Lys	iana Gly Leu	Glu Arg	Arg Ser 25	His 10	Arg	Lys	Gly Ser	Leu Tyr 30	Trr 15	) Ser	
<21 <21 <40 Met 1 Pro	11> 12> 13> 00> = Ala	283 PRT Arab 14 Lys 1 Glu 35	oidop Thr Asp 20	sis Lys 5 Glu	thal Tyr Lys	iana Gly Leu Pro	Glu Arg	Arg Ser 25	His 10 Phe	Arg Ile	Lys Leu	Gly Ser Glr 45	Leu Tyr 30	Trr 15 Gly	Ser	
<21 <21 <21 <4() Met 1 Pro	11> 12> 13> 1000 100	283 PRT Arab 14 1 Lys 1 Glu 5 Trp 35	Thr Asp 20 Thr	Lys 5 Glu Thr	Tyr Lys Val	Gly Leu Pro	Glu Arg	Arg Ser 25 Lys	His 10 Phe Ala	Arg	Leu Leu Arc	Gly Ser 1 Glr 45	· Leu · Tyr 30 · Arc	Trr 15 Gly Ass	o Ser , His	
<21 < 21 < 21 < 40 Met 1 Pro	11> 12> 13> 00> 1 Ala 1 Cys 1 See 50 2 Asy	283 PRT Arab 14 1 Lyss 1 Glu 35 Try 35 Try 98 Met	Thr Asp 20 Thr Arg	Lys 5 Glu Thr	Tyr Lys Val	Gly Leu Pro	Glu Arg	Arg Ser 25 Lys Asr	His 10 Phe Ala Tyr	Arg	Leu Leu Arc 60	Gly Ser 1 Ser 45 Pro	· Leu · Tyr 30 · Arc	Trp 15 Gly Ass	o Ser y His n Gly n Lys	
<21 <21 <21 <41 Metal 1 Pro	11> 12> 13> 13> 100> E Ala  Gluer Cys  S Ser  50  G As  T Pr	283 PRT Arab 14 14 1 Lyss Trp 35 Trp 35 Trp 00 Let	Thr Asp 20 Thr Arg	Lys 5 Glu Thr Thr Lev Ser 85	Tyr Lys Val Arg	Gly Leu Pro Trr 55	Glu Arg	Arg Ser 25 Lys Asr Glu	His 10 Phe Ala Tyr 11 Glv 90	Arg	Lys Leu Leu Arc 60	Gly Seri Glr 45	Leu Tyr 30 Arc	Trrp 15 Gly Ass / Let r Pho 95	o Ser y His n Gly Lys e His 80	

WO 01/35726

#### PCT/US00/31418

MBI15 Sequence Listing.ST25 115 Pro Ser Ser Ser Ser Ser Leu Val Ala Cys Gly Glu Arg Asn Pro Glu Thr Leu Ile Ser Asn His Val Phe Ser Leu Gln Arg Leu Leu Glu Asn Lys Ser Ser Ser Pro Ser Gln Glu Ser Asn Gly Asn Asn Ser His Gln Cys Ser Ser Ala Pro Glu Ile Pro Arg Leu Phe Phe Ser Glu Trp Leu Ser Ser Ser Tyr Pro His Thr Asp Tyr Ser Ser Glu Phe Thr Asp Ser Lys His Ser Gln Ala Pro Asn Val Glu Glu Thr Leu Ser Ala Tyr 210 215 220 Glu Glu Met Gly Asp Val Asp Gln Phe His Tyr Asn Glu Met Met Ile 225 Asn Asn Ser Asn Trp Thr Leu Asn Asp Ile Val Phe Gly Ser Lys Cys Lys Lys Gln Glu His His Ile Tyr Arg Glu Ala Ser Asp Cys Asn Ser Ser Ala Glu Phe Phe Ser Pro Pro Thr Thr Thr <210> 15 <211> 1302 <212> DNA <213> Arabidopsis thaliana <220> CDS <221> <222> (331)..(1149) <223> G409 <400> 15 60 tgtctctctc tctggctctc tttctcttaa cgtgatcata acgtgattcg aaaattggat atagataggt ttcttgttgg atcttgatcc ctctggaaaa ggaggggaga atagcagttc 120 180 atgatgggat titgtatetg ceegitggag teacetgega gattactatg gagtacaage ttcttccgcc ataagatcat gatcttctaa tccttcctac ttcttcccat ctttttaatc 240 atcttctcgc tatctctgct tcctctttct ctctgtttcc tctttctcag aactcagaag 300 tagttgttgt tttatttctg ttgatcaaaa atg gaa tcc aat tcg ttt ttc ttc Met Glu Ser Asn Ser Phe Phe Phe 354 gat cca tct gct tca cac ggc aac agc atg ttc ttc ctt ggg aat ctc Asp Pro Ser Ala Ser His Gly Asn Ser Met Phe Phe Leu Gly Asn Leu 10 15 20 402 aat ccc gtc gtc caa gga gga gga gca aga tcg atg atg aac atg gag Asn Pro Val Val Gln Gly Gly Gly Ala Arg Ser Met Met Asn Met Glu 450

					20		MBII	.5 Se	equer	ice I 35	ist	ing.	ST25		40	
25					30								<b>_</b>			498
gaa Glu	act Thr	tcg Ser	aag Lys	cga Arg 45	agg Arg	ccc Pro	ttc Phe	ttt Phe	agc Ser 50	tcc Ser	Pro	gag Glu	gat Asp	Leu 55	Tyr	450
gac Asp	gat Asp	gac Asp	ttt Phe 60	tac Tyr	gac Asp	gac Asp	cag Gln	ttg Leu 65	cct Pro	gaa Glu	aag Lys	aag Lys	cgt Arg 70	cgc Arg	ctc Leu	546
act Thr	acc Thr	gaa Glu 75	caa Gln	gtg Val	cat His	ctg Leu	ctg Leu 80	gag Glu	aaa Lys	agc Ser	ttc Phe	gag Glu 85	aca Thr	gag Glu	aac Asn	594
aag Lys	cta Leu 90	gag Glu `	cct Pro	gaa Glu	cgc Arg	aag Lys 95	act Thr	cag Gln	ctt Leu	gcc Ala	aag Lys 100	пλя	ctt Leu	ggt Gly	cta Leu	642
cag Gln 105	cca Pro	agg Arg	caa Gln	gtg Val	gct Ala 110	gtc Val	tgg Trp	ttt Phe	cag Gln	aat Asn 115	cgc	cga Arg	gct Ala	cgt Arg	tgg Trp 120	690
aaa Lys	aca Thr	aaa Lys	cag Gln	ctt Leu 125	gag Glu	aga Arg	gac Asp	tac Tyr	gat Asp 130	ctt Leu	ctc Leu	aag Lys	tcc Ser	act Thr 135	ıyı	738
gac Asp	caa Gln	ctt Leu	ctt Leu 140	tct Ser	aac Asn	tac Tyr	gac Asp	tcc Ser 145	116	gtc Val	atg Met	gac Asp	aac Asn 150	voh	aag Lys	786
ctc Leu	aga Arg	tcc Ser 155	gag Glu	gtt Val	act Thr	tcc Ser	ctg Leu 160	Thr	gaa Glu	aag Lys	ctt Leu	cag Gln 165	GIY	aaa Lys	caa Gln	834
gag Glu	aca Thr 170	Ala	aat Asn	gaa Glu	cca Pro	cct Pro 175	GLY	caa Gln	gtg Val	ccc Pro	gaa Glu 180	PIU	aac Asn	caa Glm	ctt Leu	882
gat Asp 185	ccg Pro	gtt Val	tac Tyr	att Ile	aat Asn 190	ATa	gca Ala	gca Ala	atc Ile	aaa Lys 195	1111	gag Glu	gac Asp	cgg Arg	tta Leu 200	930
agt Ser	tca Ser	999 999	ago Ser	gtt Val 205	. GIY	ago Ser	gcg	gta Val	cta Leu 210	Mar	gac Asp	gac Asp	gca Ala	cct Pro 215	caa Gln	. 978
cta Leu	cta Leu	gac	ago Ser 220	: Cys	gac B Asp	tct Ser	tac	Phe 225	PIC	ago Ser	ato	gta Val	e ccc l Pro 230	,	c caa e Gln	1026
gac Asp	aac Asr	ago Ser 235	Asr	gco Ala	agt Ser	gat Ası	cat His	. Asp	aat Asr	gao Asp	c cgg	g ago g Ser 24!	L Cy	t tto s Pho	gcc a Ala	1074
gac	gto Val	Phe	gte Val	g ccc	aco Thi	act Thi	Sei	cce Pro	tco Sei	g cad	gat B Asj 26		t cad	ggt GC	t gaa y Glu	1122
tca Ser 265	Le	g gct i Ala	t tto	tgg Tr	g gga o Gly 270	Tr	g cct p Pro	taq	g aaa	acca	actc	tga	taat	aaa		1169
tgt	gtgl	tta	ttta	agti	tca a	agag	tcate	ct to	cttg	ttgt	t tc	catg	ttga	cga	taattgt	1229
															tgctttt	1289
			aaa													1302
	L0>	16 272														

<211> 272 <212> PRT <213> Arabidopsis thaliana

<400> 16

### MBI15 Sequence Listing.ST25

Met Glu Ser Asn Ser Phe Phe Phe Asp Pro Ser Ala Ser His Gly Asn 1 5 10 15

Ser Met Phe Phe Leu Gly Asn Leu Asn Pro Val Val Gln Gly Gly 25 30

Ala Arg Ser Met Met Asn Met Glu Glu Thr Ser Lys Arg Arg Pro Phe 35 40 45

Phe Ser Ser Pro Glu Asp Leu Tyr Asp Asp Asp Phe Tyr Asp Asp Gln 50 55

Leu Pro Glu Lys Lys Arg Arg Leu Thr Thr Glu Gln Val His Leu Leu 65 70 75 80

Glu Lys Ser Phe Glu Thr Glu Asn Lys Leu Glu Pro Glu Arg Lys Thr 85 90 95

Gln Leu Ala Lys Lys Leu Gly Leu Gln Pro Arg Gln Val Ala Val Trp 100 105 110

Phe Gln Asn Arg Arg Ala Arg Trp Lys Thr Lys Gln Leu Glu Arg Asp 115 120 125

Tyr Asp Leu Leu Lys Ser Thr Tyr Asp Gln Leu Leu Ser Asn Tyr Asp 130 135 140

Ser Ile Val Met Asp Asn Asp Lys Leu Arg Ser Glu Val Thr Ser Leu 145 150 160

Thr Glu Lys Leu Gln Gly Lys Gln Glu Thr Ala Asn Glu Pro Pro Gly 165 170 175

Gln Val Pro Glu Pro Asn Gln Leu Asp Pro Val Tyr Ile Asn Ala Ala 180 185 190

Ala Ile Lys Thr Glu Asp Arg Leu Ser Ser Gly Ser Val Gly Ser Ala 195 200 205

Val Leu Asp Asp Asp Ala Pro Gln Leu Leu Asp Ser Cys Asp Ser Tyr 210 215 220

Phe Pro Ser Ile Val Pro Ile Gln Asp Asn Ser Asn Ala Ser Asp His 225 230 235 240

Asp Asn Asp Arg Ser Cys Phe Ala Asp Val Phe Val Pro Thr Thr Ser 245 250 255

Pro Ser His Asp His His Gly Glu Ser Leu Ala Phe Trp Gly Trp Pro 260 265 270

<210> 17

<211> 2545

<212> DNA

<213> Arabidopsis thaliana

<220>

							,	MBI1	5 Se	quen	ce L	isti	ng.s	125			
	<221>	(103)(2322)															
•	<223:																
			_														
	<400: acata	> 1 atgt	tt t	aaat	tctt	t gt	ctgaa	atct	taca	agga	tcc (	gaga	gagag	ga g	ctct	ggaac	60
	gatai	ttaa	ca t	atat	catg	a ag	aaaa	agat	tga	agta	ttg a	at a	tg g	ga a	ta a	ct	114
	<b>J</b>											M-	et G	ıy ı	le T	nr	
	aaa a				<del>-</del>	act	aca :	att	ctc	tta .	aag :	act	ttt (	cac	aat	aat	162
	aaa i	Thr	Ser	Pro	Asn	Thr	Thr	Ile	Leu	Leu	Lys 15	Thr	Phe	His	Wall	Asn 20	
	5					10											210
	tct : Ser	atg	tcc	caa Gln	gat Asp	tat Tvr	cat His	cat His	cat His	cat His	cat His	cat His	aat Asn	caa Gln	His	Gln	210
	SEL !	Mec	561	<b>J</b>	25	-1-				30					35		
	gga	ggt	atc	ttc	aac	ttc	tct	aat	gga	ttc	gac	cga	tca	gat	tct	CCC	258
	Gly	ĞĪy	Ile	Phe 40	Asn	Phe	Ser	Asn	Gly 45	Phe	Asp	arg	Ser	ASP 50	ser	PIO	
	4.				cag		220	caa	gag	cat	caa	agg	qta	qaq	atq	gac	306
	aat Asn	Leu	Thr	Thr	Gln	Gln	Lys	GIn	Glu	His	Gln	Arg	Val	Ğlű	Met	Asp	
			55					60					65				254
	gag	gaa	tct	tca	gtc Val	gcc	gga	ggt	agg	att Ile	ccg Pro	gtc Val	tac Tyr	gaa Glu	Ser	gcc Ala	354
	GIU	70	SET	Ser	Val	ALU	75	<b></b> ,	5			80	•				
	gat	ato	tta	tcc	gaa	atg	ttt	aat	ttc	ccc	gga	agc	agc	ggt	gga	gga	402
	Gly	Met	Leu	Ser	Glu	Met 90	Phe	Asn	Phe	Pro	Gly 95	Ser	Ser	Gly	GIA	100	
	85											22 <b>+</b>	200	cao	tta	ctt	450
	aga Arg	gat Asp	ctc Leu	gac Asp	ctc Leu	ggc Gly	Gln	Ser	Phe	Arg	Ser	Asn	Arg	Gln	neu	Leu	
	_				105					110					113		
	gag	gag	caa	cat	cag	aat	att	ccg	gct	atg	aat	gct	acg	gat	tca	gcc Ala	498
	Glu	Glu	Gln	H1S	Gln	ASD	me	PIO	125	Met	Abii	n.a	****	130			
	200	acc	acc	aca	gcc	acc	ato	caq	tta	ttc	ttg	atg	aat	cca	ccg	cca	546
	Thr	Ala	Thr	Ala	Ala	Ala	Met	Gln 140	Leu	Phe	Leu	Met	Asn 145	Pro	Pro	Pro	
			135												200	020	594
	ccg	caa Gln	Caa Gln	cca	ccg Pro	tct Ser	ccg	tca Ser	Ser	aca Thr	Thr	Ser	Pro	Arg	Ser	His	22.
	110	150					155					160					
	cac	aat	tct	tca	act	ctt	cac	atg	tta	ctt	cca	agt	cca	tcc	acc	aac Agn	642
	His 165		Ser	Ser	Thr	Leu 170	His	Met	Leu	ren,	175	Ser	PIO	261	1111	180	
					cag	220	tac	act	aat	cat	atα	tct	atq	cat	cag	ctt	690
	aca Thr	Thr	His	His	Gln	Asn	Tyr	Thr	Asn	HIS	met	Ser	Met	His	Gln 195	Бец	
					185					190							730
	cca	cat	cag	cat	cac	caa	cag	ata	tcg	acg Thr	tgg	cag Gln	tct Ser	Ser	Pro	Asp	738
	PIO	HIE	, GII.	200		0			205					210	)		
	cat	cat	: cat	: cat	: cat	cac	aac	ago	caa	acg	gag	att	999	acc	gto	cac	786
	His	His	His 219	3 His	His	His	Asn	Ser 220	GIU	Thr	Glu	Ile	225	IIII	· vaı	His	
			-									. ++0	tcc	tta	tet	ctc	834
	gtg Val	gaa Gl	a aac a Asi	ago 1 Sei	gga Gly	, gga , Gly	, His	Gly	, Gla	Glr	Gly	- BCC		Lev	Ser	ctc Leu	
		230	0				235	•				240	,				
	tca	tc	g tci	t tta	a gag	gct	gca	gca	a aaa	gcg	gaa	gag Glu	tat Tvr	aga Arc	a aac	att	882
	Ser 245		. 56	r nei	י פדו	250	, 410	· Mac	. ~,c		255	5	-,-		-	260	
										1	Page	22					

							MBI	15 S	eque	nce	List	ing.	ST25			
						tct Ser										930
						gct Ala										978
						tct Ser										1026
					Arg	aac Asn 315										1074
ttg Leu 325	ttg Leu	gaa Glu	gag Glu	ttt Phe	tgt Cys 330	agt Ser	gtt Val	gga Gly	aga Arg	gga Gly 335	ttt Phe	ttg Leu	aag Lys	aag Lys	aac Asn 340	1122
						aac Asn										1170
						gcc Ala										1218
						gag Glu										1266
acc Thr	atg Met 390	ctt Leu	gaa Glu	gag Glu	gtg Val	gac Asp 395	cga Arg	cgg Arg	tac Tyr	aac Asn	cat His 400	tac Tyr	tgc Cys	gag Glu	caa Gln	1314
						tct Ser										1362
						ttg Leu										1410
						gtt Val										1458
ctt Leu	ctt Leu	999 Gly 455	gac Asp	aaa Lys	gat Asp	gca Ala	gcg Ala 460	gga Gly	atc Ile	tct Ser	tct Ser	tcc Ser 465	ggg Gly	tta Leu	aca Thr	1506
aaa Lys	ggt Gly 470	gaa Glu	act Thr	ccg Pro	cgt Arg	ttg Leu 475	cgt Arg	ttg Leu	cta Leu	gag Glu	caa Gln 480	agt Ser	ttg Leu	cgt Arg	cag Gln	1554
caa Gln 485	cgt Arg	gcg Ala	ttt Phe	cat His	caa Gln 490	atg Met	ggt Gly	atg Met	atg Met	gaa Glu 495	caa Gln	gaa Glu	gct Ala	tgg Trp	cgg Arg 500	1602
						gaa Glu										1650
						cac His										1698
						ggt Gly										1746
						cgt Arg			ГЛа		Met					1794

	550					555	MBI:	15 Se	equer	nce 1	List: 560	ing.	ST25			
tac Tyr 565	caa Gln	caa Gln	gaa Glu	tca Ser	aaa Lys 570	gaa Glu	aga Arg	gaa Glu	aga Arg	gaa Glu 575	gag Glu	gaa Glu	tta Leu	gaa Glu	gag Glu 580	1842
aac Asn	gaa Glu	gaa Glu	gat Asp	caa Gln 585	gaa Glu	aca Thr	aaa Lys	aac Asn	agc Ser 590	aac Asn	gac Asp	gac Asp	aag Lys	agc Ser 595	aca Thr	1890
aaa Lys	tcc Ser	aac Asn	aac Asn 600	aat Asn	gaa Glu	agc Ser	aac Asn	ttc Phe 605	act Thr	gcc Ala	gtt Val	cgg Arg	acc Thr 610	act Thr	tca Ser	1938
caa Gln	act Thr	cca Pro 615	acg Thr	aca Thr	acc Thr	gca Ala	cca Pro 620	gac Asp	gca Ala	tca Ser	gac Asp	gca Ala 625	gac Asp	gca Ala	gca Ala	1986
gta Val	gcg Ala 630	aca Thr	ggc Gly	cac His	cgt Arg	cta Leu 635	aga Arg	tcc Ser	aac Asn	att Ile	aat Asn 640	gct Ala	tac Tyr	gaa Glu	aac Asn	2034
gac Asp 645	gct Ala	tca Ser	tca Ser	ctt Leu	cta Leu 650	ctc Leu	cct Pro	tcc Ser	tct Ser	tat Tyr 655	tcc Ser	aac Asn	gcc Ala	gcc Ala	gct Ala 660	2082
cct Pro	gcc Ala	gct Ala	gtt Val	tct Ser 665	gac Asp	gac Asp	ttg Leu	aat Asn	tct Ser 670	cgt Arg	tac Tyr	ggt Gly	ggc Gly	tca Ser 675	gac Asp	2130
gcg Ala	ttt Phe	tcc Ser	gcc Ala 680	Val	gcc Ala	acg Thr	tgt Cys	caa Gln 685	caa Gln	agt Ser	gta Val	ggt Gly	999 690	ttc Phe	gat Asp	2178
gat Asp	gct Ala	gac Asp 695		gat Asp	ggt Gly	gtt Val	aac Asn 700	vai	ata Ile	agg Arg	ttt Phe	999 Gly 705	aca Thr	aac Asn	cct Pro	2226
act Thr	ggt Gly 710	Asp	gtg Val	tct Ser	ctc Leu	acg Thr 715	ctt Leu	ggt Gly	tta Leu	cgc	cac His 720	Ala	gga Gly	aac Asn	atg Met	2274
ect Pro 725	Asp	aaa Lys	gac Asp	gct Ala	tct Ser 730	Phe	tgc Cys	gtt Val	aga Arg	gag Glu 735	Phe	ggg Gly	ggt Gly	ttt Phe	tag	2322
ttt	gctt	ttg	tcac	tcca	tt t	aatt	aatt	a at	tata	gttt	tcc	attc	tta	ctta	ttttaa	2382
ttg	aaaa	tct	attt	ttgt	ct c	ttaa	aagt	с са	aaca	atac	att	agtc	tag	ccct	cctctg	2442
ctt	ttt	ttt	tcta	tctc	gt g	aaga	gaag	a aa	acga	tacg	taa	atco	ctt	cgaa	aactaa	2502
tgt	acgt	tgt	acga	ctta	tt g	tttt	cata	a aa	aaaa	aaaa	aaa	ı				2545
<21 <21	10> 11>	18 739														

<211> 739 <212> PRT <213> Arabidopsis thaliana

Met Gly Ile Thr Lys Thr Ser Pro Asn Thr Thr Ile Leu Leu Lys Thr 1 5 15

Phe His Asn Asn Ser Met Ser Gln Asp Tyr His His His His His 20 25 30

Asn Gln His Gln Gly Gly Ile Phe Asn Phe Ser Asn Gly Phe Asp Arg 35

Ser Asp Ser Pro Asn Leu Thr Thr Gln Gln Lys Gln Glu His Gln Arg Page 24

50

# MBI15 Sequence Listing.ST25

Val Glu Met Asp Glu Glu Ser Ser Val Ala Gly Gly Arg Ile Pro Val 65 70 75 80

Tyr Glu Ser Ala Gly Met Leu Ser Glu Met Phe Asn Phe Pro Gly Ser 85 90 95

Ser Gly Gly Arg Asp Leu Asp Leu Gly Gln Ser Phe Arg Ser Asn 100 105 110

Arg Gln Leu Leu Glu Glu Gln His Gln Asn Ile Pro Ala Met Asn Ala 115 120 125

Thr Asp Ser Ala Thr Ala Thr Ala Ala Ala Met Gln Leu Phe Leu Met 130 135 140

Asn Pro Pro Pro Pro Gln Gln Pro Pro Ser Pro Ser Ser Thr Thr Ser 145 150 155 160

Pro Arg Ser His His Asn Ser Ser Thr Leu His Met Leu Leu Pro Ser 165 170 175

Pro Ser Thr Asn Thr Thr His His Gln Asn Tyr Thr Asn His Met Ser 180 185 190

Met His Gln Leu Pro His Gln His His Gln Gln Ile Ser Thr Trp Gln 195 200 205

Ser Ser Pro Asp His His His His His Asn Ser Gln Thr Glu Ile 210 215 220

Gly Thr Val His Val Glu Asn Ser Gly Gly His Gly Gln Gly Leu 225 230 240

Ser Leu Ser Leu Ser Ser Leu Glu Ala Ala Ala Lys Ala Glu Glu 245 250 255

Tyr Arg Asn Ile Tyr Tyr Gly Ala Asn Ser Ser Asn Ala Ser Pro His 260 265 270

His Gln Tyr Asn Gln Phe Lys Thr Leu Leu Ala Asn Ser Ser Gln His 275 280 285

His His Gln Val Leu Asn Gln Phe Arg Ser Ser Pro Ala Ala Ser Ser 290 295 300

Ser Ser Met Ala Ala Val Asn Ile Leu Arg Asn Ser Arg Tyr Thr Thr 305 310 315 320

Ala Ala Gln Glu Leu Leu Glu Glu Phe Cys Ser Val Gly Arg Gly Phe 325 330 335

Leu Lys Lys Asn Lys Leu Gly Asn Ser Ser Asn Pro Asn Thr Cys Gly 340 345 350

- MBI15 Sequence Listing.ST25
  Gly Asp Gly Gly Ser Ser Pro Ser Ser Ala Gly Ala Asn Lys Glu
  355 360 365
- His Pro Pro Leu Ser Ala Ser Asp Arg Ile Glu His Gln Arg Arg Lys 370 375 380
- Val Lys Leu Leu Thr Met Leu Glu Glu Val Asp Arg Arg Tyr Asn His 385 390 395 400
- Tyr Cys Glu Gln Met Gln Met Val Val Asn Ser Phe Asp Ile Val Met 405 410 415
- Gly His Gly Ala Ala Leu Pro Tyr Thr Ala Leu Ala Gln Lys Ala Met 420 425 430
- Ser Arg His Phe Arg Cys Leu Lys Asp Ala Val Ala Ala Gln Leu Lys 435 440 445
- Gln Ser Cys Glu Leu Leu Gly Asp Lys Asp Ala Ala Gly Ile Ser Ser 450 455 460
- Ser Gly Leu Thr Lys Gly Glu Thr Pro Arg Leu Arg Leu Leu Glu Gln 465 470 475 480
- Ser Leu Arg Gln Gln Arg Ala Phe His Gln Met Gly Met Met Glu Gln 485 490 495
- Glu Ala Trp Arg Pro Gln Arg Gly Leu Pro Glu Arg Ser Val Asn Ile 500 505 510
- Leu Arg Ala Trp Leu Phe Glu His Phe Leu His Pro Tyr Pro Ser Asp 515 520 525
- Ala Asp Lys His Leu Leu Ala Arg Gln Thr Gly Leu Ser Arg Asn Gln 530 540
- Val Ser Asn Trp Phe Ile Asn Ala Arg Val Arg Leu Trp Lys Pro Met 545 550 560
- Val Glu Glu Met Tyr Gln Gln Glu Ser Lys Glu Arg Glu Arg Glu Glu 565 570 575
- Glu Leu Glu Glu Asn Glu Glu Asp Gln Glu Thr Lys Asn Ser Asn Asp 580 585 590
- Asp Lys Ser Thr Lys Ser Asn Asn Glu Ser Asn Phe Thr Ala Val
- Arg Thr Thr Ser Gln Thr Pro Thr Thr Thr Ala Pro Asp Ala Ser Asp 610 615 620
- Ala Asp Ala Ala Val Ala Thr Gly His Arg Leu Arg Ser Asn Ile Asn 625 630 635 640
- Ala Tyr Glu Asn Asp Ala Ser Ser Leu Leu Leu Pro Ser Ser Tyr Ser 645 650 655

#### MBI15 Sequence Listing.ST25

Asn Ala Ala Pro Ala Ala Val Ser Asp Asp Leu Asn Ser Arg Tyr
660 665 670

Gly Gly Ser Asp Ala Phe Ser Ala Val Ala Thr Cys Gln Gln Ser Val 675 680 685

Gly Gly Phe Asp Asp Ala Asp Met Asp Gly Val Asn Val Ile Arg Phe 690 695 700

Gly Thr Asn Pro Thr Gly Asp Val Ser Leu Thr Leu Gly Leu Arg His 705 710 715 720

Ala Gly Asn Met Pro Asp Lys Asp Ala Ser Phe Cys Val Arg Glu Phe
725 730 735

Gly Gly Phe

<210> 19 <211> 1240 <212> DNA <213> Arabidopsis thaliana <220> <221> CDS <222> (88)..(1020) <223> G591

gtaaatctct ctttgaaggt tcctaactcg ttaatcgtaa ctcacagtga ctcgttcgag tcaaagtctc tgtctttagc tcaaacc atg gct agt aac aac cct cac gac aac Met  $\tt Ala$  Ser  $\tt Asn$   $\tt Asn$   $\tt Pro$   $\tt His$   $\tt Asp$   $\tt Asn$ ctt tot gad daa act oot tot gat gat the the gag daa ate ote ggo 162 Leu Ser Asp Gln Thr Pro Ser Asp Asp Phe Phe Glu Gln Ile Leu Gly ctt cct aac ttc tca gcc tct tct gcc gcc ggt tta tct gga gtt gac Leu Pro Asn Phe Ser Ala Ser Ser Ala Ala Gly Leu Ser Gly Val Asp 210 gga gga tta ggt gga gga ccg cct atg atg ctg cag ttg ggt tcc Gly Gly Leu Gly Gly Gly Ala Pro Pro Met Met Leu Gln Leu Gly Ser 258 gga gaa gaa gga agt cac atg ggt ggc tta gga gga agt gga cca act Gly Glu Glu Gly Ser His Met Gly Gly Leu Gly Gly Ser Gly Pro Thr 60 65 70 306 ggg ttt cac aat cag atg ttt cct ttg ggg tta agt ctt gat caa ggg Gly Phe His Asn Gln Met Phe Pro Leu Gly Leu Ser Leu Asp Gln Gly 354 aaa gga cct ggg ttt ctt aga cct gaa gga gga cat gga agt ggg aaa Lys Gly Pro Gly Phe Leu Arg Pro Glu Gly Gly His Gly Ser Gly Lys 90 95 100 105 402 aga ttc tca gat gat gtt gtt gat aat cga tgt tct tct atg aaa cct Arg Phe Ser Asp Asp Val Val Asp Asn Arg Cys Ser Ser Met Lys Pro 450 gtt ttc cac ggg cag cct atg caa cag cca cct cca tcg gcc cca cat Val Phe His Gly Gln Pro Met Gln Gln Pro Pro Pro Ser Ala Pro His 498 130

#### MBI15 Sequence Listing.ST25

Gly Gly Leu Gly Gly Ser Gly Pro Thr Gly Phe His Asn Gln Met Phe

Pro Leu Gly Leu Ser Leu Asp Gln Gly Lys Gly Pro Gly Phe Leu Arg

Pro Glu Gly Gly His Gly Ser Gly Lys Arg Phe Ser Asp Asp Val Val 100 105 110

Asp Asn Arg Cys Ser Ser Met Lys Pro Val Phe His Gly Gln Pro Met

Gln Gln Pro Pro Pro Ser Ala Pro His Gln Pro Thr Ser Ile Arg Pro

Arg Val Arg Ala Arg Gly Gln Ala Thr Asp Pro His Ser Ile Ala 145 150 155 160

Glu Arg Leu Arg Glu Arg Ile Ala Glu Arg Ile Arg Ala Leu Glu 165 170 175

Glu Leu Val Pro Thr Val Asn Lys Thr Asp Arg Ala Ala Met Ile Asp 180 185 190

Glu Ile Val Asp Tyr Val Lys Phe Leu Arg Leu Gln Val Lys Val Leu

Ser Met Asn Arg Leu Gly Gly Ala Gly Ala Val Ala Pro Leu Val Thr 210 215 220

Asp Met Pro Leu Ser Ser Ser Val Glu Asp Glu Thr Gly Glu Gly Gly

Arg Thr Pro Gln Pro Ala Trp Glu Lys Trp Ser Asn Asp Gly Thr Glu 245 250 255

Arg Gln Val Ala Lys Leu Met Glu Glu Asn Val Gly Ala Ala Met Gln

Leu Leu Gln Ser Lys Ala Leu Cys Met Met Pro Ile Ser Leu Ala Met 275 280 285

Ala Ile Tyr His Ser Gln Pro Pro Asp Thr Ser Ser Val Val Lys Pro 295

Glu Asn Asn Pro Pro Gln 305

<210>

<211> 1179 <212> DNA

<213> Arabidopsis thaliana

<220>

<221> CDS

<222> (109)..(966)

G525

<400 cttc	> 2	1 tt c	tcaa	aaac	c ct	tccc	tctt	cgt	ctcc	aaa .	caac	aaca	aa c	acaa	caaca	60
acaa	aaat	ct t	acaa	gaag	a tc	attt	ttag	aaa	ccct	att	agga	taaa	atg Met 1	gat Asp	tac Tyr	117
gag Glu	gca Ala 5	tca Ser	aga Arg	atc Ile	gtc Val	gaa Glu 10	atg Met	gta Val	gaa Glu	gat Asp	gaa Glu 15	gaa Glu	cat His	ata Ile	gat Asp	165
cta Leu 20	cca Pro	cca Pro	gga Gly	ttc Phe	aga Arg 25	ttt Phe	cac His	cct Pro	act Thr	gat Asp 30	gaa Glu	gaa Glu	ctc Leu	ata Ile	act Thr 35	213
cac His	tac Tyr	ctc Leu	aaa Lys	cca Pro 40	aag Lys	gtt Val	ttc Phe	aac Asn	act Thr 45	ttc Phe	ttc Phe	tct Ser	gct Ala	act Thr 50	gcc Ala	261
att Ile	ggt Gly	gaa Glu	gtt Val 55	gat Asp	ctc Leu	aac Asn	aag Lys	att Ile 60	gag Glu	cct Pro	tgg Trp	gac Asp	tta Leu 65	cca Pro	tgg Trp	309
aag Lys	gct Ala	aag Lys 70	atg Met	gga Gly	gaa Glu	aaa Lys	gaa Glu 75	tgg Trp	tat Tyr	ttc Phe	ttc Phe	tgt Cys 80	gtg Val	aga Arg	gac Asp	357
cgg Arg	aaa Lys 85	tac Tyr	ccg Pro	acc Thr	ggt Gly	tta Leu 90	agg Arg	aca Thr	aac Asn	cgg Arg	gcg Ala 95	aca Thr	gaa Glu	gcc Ala	ggt Gly	405
tat Tyr 100	tgg Trp	aaa Lys	gcc Ala	aca Thr	gga Gly 105	aaa Lys	gac Asp	aaa Lys	gag Glu	ata Ile 110	ttc Phe	aag Lys	gga Gly	aaa Lys	tca Ser 115	<b>453</b>
ctt Leu	gtg Val	ggt Gly	atg Met	aag Lys 120	aaa Lys	act Thr	ttg Leu	gtt Val	ttc Phe 125	tat Tyr	aaa Lys	gga Gly	aga Arg	gct Ala 130	cct Pro	501
aaa Lys	gga Gly	gtt Val	aaa Lys 135	Thr	aat Asn	tgg Trp	gtt Val	atg Met 140	cat His	gaa Glu	tat Tyr	cgt Arg	tta Leu 145	gaa Glu	gly	549
aaa Lys	tat Tyr	tgt Cys 150	att Ile	gaa Glu	aat Asn	ctt Leu	ccc Pro 155	Gln	aca Thr	gct Ala	aag Lys	aac Asn 160	gaa Glu	tgg Trp	gtt Val	597
ata Ile	tgt Cys 165	cgt Arg	gtt Val	ttc Phe	caa Gln	aaa Lys 170	cgt Arg	gcc Ala	gat Asp	ggt Gly	aca Thr 175	aag Lys	gtt Val	cca Pro	atg Met	645
tca Ser 180	Met	ctt Leu	gat Asp	cca Pro	cac His 185	att Ile	aac Asn	cga Arg	atg Met	gaa Glu 190	cca Pro	gcc Ala	ggt Gly	tta Leu	cct Pro 195	693
tcg Ser	tta Leu	atg Met	gat Asp	tgt Cys 200	Ser	caa Gln	cga Arg	gac Asp	ser 205	ttc Phe	acc Thr	ggt Gly	tcg Ser	tcg Ser 210	tct Ser	741
His	Val	Thr	tgc Cys 215	Phe	Ser	Asp	Gln	220	Inr	GIU	Авр	гÀя	225	neu	vai	789
cac His	gag Glu	Ser 230	aaa Lys	gac Asp	ggt Gly	ttt Phe	ggt Gly 235	ser	ctg Leu	ttt Phe	tac Tyr	Ser 240	wah	cct Pro	ctg Leu	837
Ph∈	245	Glr		) Asn	Туг	250	Leu	n Met	: гув	ren	255	Leu	, wab	GLY	GIN	885
gaa Gl: 260	ı Thi	Caa Gli	a tto n Phe	tco Sex	ggc Gly 265	Lys	Pro	tto Phe	. Asp	ggt Gly 270	Arg	gat Asp	tcg Ser	Ser	ggt Gly 275	933

#### MBI15 Sequence Listing.ST25

		gc gtt tgg ys Val Trp	aat ttc tga Asn Phe 285	gttgtataag	ttatgttgta	986
gacttgtagt	agtcatgtgt	tcgtgtgtgt	gaatgaatat	tcttgttaca	tttttttgta	1046
aaaaaggaga	aaaaaatatg	ctagaaagtc	aattgctttt	gttatgtagc	attagtgttt	1106
tttatgtact	caatagactt	cctaattaaa	taaaaatctt	aatttatttg	ccaaaaaaaa	1166
aaaaaaaaa	aaa					1179

<210> 22

<211> 285

<212> PRT

<213> Arabidopsis thaliana

<400> 22

Met Asp Tyr Glu Ala Ser Arg Ile Val Glu Met Val Glu Asp Glu Glu 1 5 15

His Ile Asp Leu Pro Pro Gly Phe Arg Phe His Pro Thr Asp Glu Glu 25 30

Leu Ile Thr His Tyr Leu Lys Pro Lys Val Phe Asn Thr Phe Phe Ser 35 40 45

Ala Thr Ala Ile Gly Glu Val Asp Leu Asn Lys Ile Glu Pro Trp Asp 50 55 60

Leu Pro Trp Lys Ala Lys Met Gly Glu Lys Glu Trp Tyr Phe Phe Cys 65 70 75 80

Val Arg Asp Arg Lys Tyr Pro Thr Gly Leu Arg Thr Asn Arg Ala Thr 85 90 95

Glu Ala Gly Tyr Trp Lys Ala Thr Gly Lys Asp Lys Glu Ile Phe Lys 100 105 110

Gly Lys Ser Leu Val Gly Met Lys Lys Thr Leu Val Phe Tyr Lys Gly 115 120 125

Arg Ala Pro Lys Gly Val Lys Thr Asn Trp Val Met His Glu Tyr Arg 130 135 140

Leu Glu Gly Lys Tyr Cys Ile Glu Asn Leu Pro Gln Thr Ala Lys Asn 145 150 150 160

Glu Trp Val Ile Cys Arg Val Phe Gln Lys Arg Ala Asp Gly Thr Lys

Val Pro Met Ser Met Leu Asp Pro His Ile Asn Arg Met Glu Pro Ala 180 185 190

Gly Leu Pro Ser Leu Met Asp Cys Ser Gln Arg Asp Ser Phe Thr Gly 195 200 205

Ser Ser Ser His Val Thr Cys Phe Ser Asp Gln Glu Thr Glu Asp Lys 210 215 220

Arg Leu Val Hi	s Glu Ser Lys 2 230	Asp Gly Phe Gl 23	y Ser Leu Phe Tyr	Ser 240
Asp Pro Leu Ph	e Leu Gln Asp . 245	Asn Tyr Ser Le 250	eu Met Lys Leu Leu 255	Leu
Asp Gly Gln Gl 26		Ser Gly Lys Pr 265	o Phe Asp Gly Arg 270	Asp
Ser Ser Gly Th 275		Asp Cys Val Ti 280	rp Asn Phe 285	
<210> 23 <211> 890 <212> DNA <213> Arabido	opsis thaliana			
<220> <221> CDS <222> (55)( <223> G545	(738)			
<400> 23 gcaaccttca aac	ctaaaact cgagag	gacaa gaaatcct	ca gaatctttaa ctta	atg 57 Met 1
gcg ctc gag gc Ala Leu Glu Al 5	ct ctt aca tca La Leu Thr Ser	cca aga tta g Pro Arg Leu A 10	ct tct ccg att cct la Ser Pro Ile Pro 15	cct 105 Pro
ttg ttc gaa ga Leu Phe Glu As 20	at tct tca gtc sp Ser Ser Val	ttc cat gga g Phe His Gly V 25	tc gag cac tgg aca al Glu His Trp Thr 30	aag 153 Lys
ggt aag cga to Gly Lys Arg Se 35	ct aag aga tca er Lys Arg Ser 40	aga tcc gat t Arg Ser Asp P	tc cac cac caa aac he His His Gln Asn 45	ctc 201 Leu
act gag gaa ga Thr Glu Glu Gl 50	ag tat cta gct lu Tyr Leu Ala 55	ttt tgc ctc a Phe Cys Leu M 6	tg ctt ctc gct cgc et Leu Leu Ala Arg 0	gac 249 Asp 65
aac cgt cag co Amn Arg Gln Pr	ct cct cct cct ro Pro Pro Pro 70	ccg gcg gtg g Pro Ala Val G 75	ag aag ttg agc tac lu Lys Leu Ser Tyr 80	aag 297 Lys
tgt agc gtc tg Cys Ser Val Cy 85	ys Asp Lys Thr	ttc tct tct t Phe Ser Ser T 90	ac caa gct ctc ggt yr Gln Ala Leu Gl <sub>y</sub> 95	ggt 345 Gly
cac aag gca ag His Lys Ala Se 100	gc cac cgt aag er His Arg Lys	aac tta tca c Asn Leu Ser G 105	ag act ctc tcc ggo In Thr Leu Ser Gly 110	gga 393 Gly
gga gat gat ca Gly Asp Asp H: 115	at tca acc tcg is Ser Thr Ser 120	Ser Ala Thr T	cc aca tcc gcc gtg hr Thr Ser Ala Val 125	act 441 Thr
act gga agt gg Thr Gly Ser G 130	gg aaa tca cac ly Lys Ser His 135	Val Cys Thr I	tc tgt aac aag tct le Cys Asn Lys Sei 40	ttt 489 Phe 145
cct tcc ggt c Pro Ser Gly G	aa gct ctc ggc ln Ala Leu Gly 150	gga cac aag c Gly His Lys A 155	egg tge cac tac gaa Arg Cys His Tyr Glu 160	GIA
aac aac aac a	tc aac act agt		ac tcc gaa ggt gc ge 32	g ggg 585

MBI15 Sequence Listing.ST25 Asn Asn Asn Ile Asn Thr Ser Ser Val Ser Asn Ser Glu Gly Ala Gly 165 170 175	
tcc act agc cac gtt agc agt agc cac cgt ggg ttt gac ctc aac atc Ser Thr Ser His Val Ser Ser Ser His Arg Gly Phe Asp Leu Asn Ile 180 185 190	633
cct ccg atc cct gaa ttc tcg atg gtc aac gga gac gac gaa gtc atg Pro Pro Ile Pro Glu Phe Ser Met Val Asn Gly Asp Asp Glu Val Met 195 200 205	681
agc cct atg ccg gcg aag aag cct cgg ttt gac ttt ccg gtc aaa ctt Ser Pro Met Pro Ala Lys Lys Pro Arg Phe Asp Phe Pro Val Lys Leu 210 225 225	729
caa ctt taa ggaaatttac ttagacgata agatttcgtt tgtatactgt Gln Leu	778
tgagagttgt gtaggaattt gttgactgta cataccaaat tggactttga ctgattccaa	838
ttcttcttgt tctttcattt taaaaattat taaaccgatt ctttaccaca aa	890
<210> 24 <211> 227 <212> PRT <213> Arabidopsis thaliana	
<400> 24	
Met Ala Leu Glu Ala Leu Thr Ser Pro Arg Leu Ala Ser Pro Ile Pro 1 5 10 15	
Pro Leu Phe Glu Asp Ser Ser Val Phe His Gly Val Glu His Trp Thr 20 25 30	
Lys Gly Lys Arg Ser Lys Arg Ser Arg Ser Asp Phe His His Gln Asn 35 40 45	
Leu Thr Glu Glu Glu Tyr Leu Ala Phe Cys Leu Met Leu Leu Ala Arg 50 55 60	٠
Asp Asn Arg Gln Pro Pro Pro Pro Pro Ala Val Glu Lys Leu Ser Tyr 65 70 75 80	
Lys Cys Ser Val Cys Asp Lys Thr Phe Ser Ser Tyr Gln Ala Leu Gly 95	
Gly His Lys Ala Ser His Arg Lys Asn Leu Ser Gln Thr Leu Ser Gly 100 105 110	
Gly Gly Asp Asp His Ser Thr Ser Ser Ala Thr Thr Thr Ser Ala Val	
Thr Thr Gly Ser Gly Lys Ser His Val Cys Thr Ile Cys Asn Lys Ser	
Phe Pro Ser Gly Gln Ala Leu Gly Gly His Lys Arg Cys His Tyr Glu 145 150 155 160	
Gly Asn Asn Ile Asn Thr Ser Ser Val Ser Asn Ser Glu Gly Ala 165 170 175	

MBI15 Sequence Listing.ST25 Gly Ser Thr Ser His Val Ser Ser Ser His Arg Gly Phe Asp Leu Asn 185 Ile Pro Pro Ile Pro Glu Phe Ser Met Val Asn Gly Asp Asp Glu Val Met Ser Pro Met Pro Ala Lys Lys Pro Arg Phe Asp Phe Pro Val Lys Leu Gln Leu 225 25 <210> <211> 1126 <212> DNA <213> Arabidopsis thaliana <220> <221> CDS (282) . . (920) <222> G865 <223> <400> 25 60 atccccactt gttgttcatc accaagccaa gctccatgtc ctagtcactc cacagattcc ctatcatcat caattegttt caaacttagt teettteaaa gtettgtaca tatatacaca 120 cacacctatt attotottgg tgtgtttgtg tgttacatat acgtgtgagt acatactttg 180 ttgtaaaagt ggatcggagg tatggaaagg gaccggttcc accggaaaca tcggcggcgg 240 cggatgataa ttcgtcttgg aacgagactg atgtcaccgc c atg gtc tcc gct ctc Met Val Ser Ala Leu 296 age cgt gtc ata gag aat ccg aca gac ccg ccg gtc aaa caa gag ctt Ser Arg Val Ile Glu Asn Pro Thr Asp Pro Pro Val Lys Gln Glu Leu 344 gat aaa tcg gat caa cat caa cca gac caa gat caa cca aga aga aga Asp Lys Ser Asp Gln His Gln Pro Asp Gln Asp Gln Pro Arg Arg 392 cac tat aga ggc gta agg cag aga cca tgg ggt aaa tgg gcg gca gaa His Tyr Arg Gly Val Arg Gln Arg Pro Trp Gly Lys Trp Ala Ala Glu 440 atc cgc gat cca aag aaa gca gcc cgt gtc tgg ctc ggg act ttc gag Ile Arg Asp Pro Lys Lys Ala Ala Arg Val Trp Leu Gly Thr Phe Glu 488 acg gca gag gaa gct gct tta gcc tat gac cga gct gcc ctc aaa ttc Thr Ala Glu Glu Ala Ala Leu Ala Tyr Asp Arg Ala Ala Leu Lys Phe 536 aaa ggc acc aag gct aaa ctg aac ttc cct gaa cgg gtc caa ggc cct Lys Gly Thr Lys Ala Lys Leu Asn Phe Pro Glu Arg Val Gln Gly Pro 584 act acc acc aca acc att tct cat gca cca aga gga gtt agt gaa tcc Thr Thr Thr Thr Thr Ile Ser His Ala Pro Arg Gly Val Ser Glu Ser 632

Page 34

145

680

728

atg aac tca cct cct cct cga cct ggt cca cct tca act act act act Met Asn Ser Pro Pro Pro Arg Pro Gly Pro Pro Ser Thr Thr Thr

tcg tgg cca atg act tat aac cag gac ata ctt caa tac gct cag ttg Ser Trp Pro Met Thr Tyr Asn Gln Asp Ile Leu Gln Tyr Ala Gln Leu

140

MRT15	Sequence	Ligting	CT25
LIDITIO	seduence	DISCING.	. 5125

ctt acg Leu Thr 150								776
ttc agt Phe Ser								824
cag acg Gln Thr								872
gaa gag Glu Glu								920
tctaatta	tt attgt	tggtc g	aatcagtt	t tataaa	tagc tate	catagtt	tcatttttgg	980
tttccgta	ac ctttg	gttgca t	ggaaaata	t gaatga	acga ggg	acatgtg	taacaatttg	1040
tttgtgtt	tc gtaaa	atgtta g	ttgtattt	g gatttg	ctga agt	ttgattt	tctgagcata	1100
aatcattt	ga cggto	aaaaa a	aaaaa					1126

<210> 26

<211> 212

<212> PRT

<213> Arabidopsis thaliana

<400> 26

Met Val Ser Ala Leu Ser Arg Val Ile Glu Asn Pro Thr Asp Pro Pro 1 5 10 15

Val Lys Gln Glu Leu Asp Lys Ser Asp Gln His Gln Pro Asp Gln Asp 20 25 30

Gln Pro Arg Arg Arg His Tyr Arg Gly Val Arg Gln Arg Pro Trp Gly 35 40 45

Lys Trp Ala Ala Glu Ile Arg Asp Pro Lys Lys Ala Ala Arg Val Trp 50 55 60

Leu Gly Thr Phe Glu Thr Ala Glu Glu Ala Ala Leu Ala Tyr Asp Arg 65 70 75 80

Ala Ala Leu Lys Phe Lys Gly Thr Lys Ala Lys Leu Asn Phe Pro Glu 85 90 95

Arg Val Gln Gly Pro Thr Thr Thr Thr Thr Ile Ser His Ala Pro Arg

Gly Val Ser Glu Ser Met Asn Ser Pro Pro Pro Arg Pro Gly Pro Pro 115 120 125

Ser Thr Thr Thr Ser Trp Pro Met Thr Tyr Asn Gln Asp Ile Leu

Gln Tyr Ala Gln Leu Leu Thr Ser Asn Asn Glu Val Asp Leu Ser Tyr

Tyr Thr Ser Thr Leu Phe Ser Gln Pro Phe Ser Thr Pro Ser Ser Ser 165 170 175

Ser Ser Ser Gln Gln Thr Gln Gln Gln Gln Leu Gln Gln Gln Gln Gln 180 185 190

Gln Gln Arg Glu Glu Glu Lys Asn Tyr Gly Tyr Asn Tyr Tyr Asn 195 200 205

Tyr Pro Arg Glu 210

<210> 27 <211> 1152 <212> DNA <213> Arabidopsis thaliana <220> <221> CDS <222> (76)..(1008) <223> G881

<400> 27 gtgaccgaag aaagcaaatt gagactacgc accaactagt cctttggttt gtatcttaag 60 ataaaggttt ctttt atg gac ggt tct tcg ttt ctc gac atc tct ctc gat
Met Asp Gly Ser Ser Phe Leu Asp Ile Ser Leu Asp 111 ctc aac acc aat cct ttc tcc gca aaa ctt ccg aag aag gag gtc tca Leu Asn Thr Asn Pro Phe Ser Ala Lys Leu Pro Lys Lys Glu Val Ser 159 20 gtt ttg gct tct act cac tta aag agg aaa tgg ttg gag caa gac gag Val Leu Ala Ser Thr His Leu Lys Arg Lys Trp Leu Glu Gln Asp Glu 207 35 agc gca agt gag tta cga gag gag cta aac aga gtt aat tca gag aac Ser Ala Ser Glu Leu Arg Glu Glu Leu Asn Arg Val Asn Ser Glu Asn 255 aag aag cta aca gag atg tta gct aga gtc tgt gag agc tac aac gaa Lys Lys Leu Thr Glu Met Leu Ala Arg Val Cys Glu Ser Tyr Asn Glu 65 70 75 303 cta cat aat cat ttg gag aag ctt cag agt cgc cag agc cct gaa atc Leu His Asn His Leu Glu Lys Leu Gln Ser Arg Gln Ser Pro Glu Ile 351 gag cag acc gat ata ccg ata aag aaa aga aaa caa gac ccg gat gag Glu Gln Thr Asp Ile Pro Ile Lys Lys Arg Lys Gln Asp Pro Asp Glu ttc tta ggc ttt cct att gga ctc agt agt gga aaa act gag aac agc Phe Leu Gly Phe Pro Ile Gly Leu Ser Ser Gly Lys Thr Glu Asn Ser 110 115 120 tcc agc aac gaa gat cat cat cat cat cat cag caa cat gag cag aaa Ser Ser Asn Glu Asp His His His His Gln Gln His Glu Gln Lys 495 aat cag ctt ctt tca tgt aaa aga cca gtc act gat agc ttc aac aaa Asn Gln Leu Ser Cys Lys Arg Pro Val Thr Asp Ser Phe Asn Lys 543 gca aaa gtt tcg act gtc tac gtg cct act gaa aca tcg gac aca agc Ala Lys Val Ser Thr Val Tyr Val Pro Thr Glu Thr Ser Asp Thr Ser 591 ttg aca gtt aaa gat gga ttt caa tgg agg aaa tac gga caa aag gtt Leu Thr Val Lys Asp Gly Phe Gln Trp Arg Lys Tyr Gly Gln Lys Val 175 180 185 639

aca aga gac aac ccg tca cct aga gct tac ttt aga tgc tcg ttt gca Thr Arg Asp Asn Pro Ser Pro Arg Ala Tyr Phe Arg Cys Ser Phe Ala 190 195 200	687
ccgtcttgtccagtaaaaaagaaggtacaacgcagcgcagaggatccaProSerCysProValLysLysLysValGlnArgSerAlaGluAspPro205210215220	735
Ser Leu Val Ala Thr Tyr Glu Gly Thr His Asn His Leu Gly Pro 225 230 235	783
aat gct tct gaa ggg gat gct aca agc cag ggt ggg tca agc aca gtg Asn Ala Ser Glu Gly Asp Ala Thr Ser Gln Gly Gly Ser Ser Thr Val 240 245 250	831
act ttg gat ctg gtt aat ggc tgt cat aga cta gcg ttg gag aaa aac Thr Leu Asp Leu Val Asn Gly Cys His Arg Leu Ala Leu Glu Lys Asn 255 260 265	879
gaa agg gat aat acg atg caa gag gtt ctg att caa caa atg gcg tca Glu Arg Asp Asn Thr Met Gln Glu Val Leu Ile Gln Gln Met Ala Ser 270 275 280	927
tcg tta aca aaa gat tcg aaa ttt aca gct gct ctt gct gct gct ata Ser Leu Thr Lys Asp Ser Lys Phe Thr Ala Ala Leu Ala Ala Ala Ile 285 290 295 300	975
tct ggg agg tta atg gag caa tct aga aca tga acgtttttag tgaatgtatt Ser Gly Arg Leu Met Glu Gln Ser Arg Thr 305 310	1028
gtttttgttt gtttagaatg attcttcgtt ttcgaattgt gtctttcgat taggagataa	1088
aagatgtata taaatattat aagtagatga agaaatcgta taagtaaaaa aaaaaaaaaa	1148
aaaa	1152

<210> 28

<211> 310

<213> Arabidopsis thaliana

<400> 28

Met Asp Gly Ser Ser Phe Leu Asp Ile Ser Leu Asp Leu Asn Thr Asn 1 5 10 15

Pro Phe Ser Ala Lys Leu Pro Lys Lys Glu Val Ser Val Leu Ala Ser 20 25 30

Thr His Leu Lys Arg Lys Trp Leu Glu Gln Asp Glu Ser Ala Ser Glu 35 40 45

Leu Arg Glu Glu Leu Asn Arg Val Asn Ser Glu Asn Lys Lys Leu Thr 50 55 60

Glu Met Leu Ala Arg Val Cys Glu Ser Tyr Asn Glu Leu His Asn His 65 70 75 80

Leu Glu Lys Leu Gln Ser Arg Gln Ser Pro Glu Ile Glu Gln Thr Asp 85 90 95

Ile Pro Ile Lys Lys Arg Lys Gln Asp Pro Asp Glu Phe Leu Gly Phe 100 105 110

Pro	Ile	Gly 115	Leu	Ser	Ser	Gly	MBI: Lys 120	15 Se Thr	equer Glu	nce l Asn	List: Ser	ing.S Ser 125	ST25 Ser	Asn	Glu		
Asp	His 130	His	нія	His	His	Gln 135	Gln	His	Glu	Gln	Lys 140	Asn	Gln	Leu	Leu		
Ser 145	Сув	Lys	Arg	Pro	Val 150	Thr	ĄsĄ	Ser	Phe	Asn 155	Lys	Ala	Lys	Val	Ser 160		
Thr	Val	Tyr	Val	Pro 165	Thr	Glu	Thr	Ser	Asp 170	Thr	Ser	Leu	Thr	Val 175	Lys		
Asp	Gly	Phe	Gln 180	Trp	Arg	Lys	Tyr	Gly 185	Gln	Lys	Val	Thr	Arg 190	Asp	Asn		
Pro	Ser	Pro 195		Ala	Tyr	Phe	Arg 200	Суз	Ser	Phe	Ala	Pro 205	Ser	Сув	Pro		
Val	Lys 210		Lys	Val	Gln	Arg 215	Ser	Ala	Glu	Asp	Pro 220	Ser	Leu	Leu	Val		
Ala 225		Tyr	Glu	Gly	Thr 230	His	Asn	His	Leu	Gly 235	Pro	Asn	Ala	Ser	Glu 240		
				245					250					255			
			260	•				265	į				270		Asn		
		275	5				280	)				285	)		. FÀ8		
Ası	290		3 Phe	Thr	Ala	Ala 295	Lev	ı Ala	a Ala	Ala	300	e Ser	Gly	Arg	, Leu		
Me(		ı Glı	n Sei	Arg	310												
<2 <2	10> 11> 12> 13>	29 127 DNA Aral		psis	thal	liana	ı										
<2 <2	20> 21> 22> 23>		) (	1150	)		,										
<4 ta	00> atcc	29 gatt	cgt	cttc	atc (	tgati	ccc	tc c	cttc	cgag	a at	aata	atg Met 1	tac Tyr	ccg Pro		55
CC Pr	a cc o Pr 5	t cc o Pr	c tc o Se	a ag r Se	c ato	c ta e Ty: 10	c gc r Al	t cc a Pr	t cc o Pr	g at o Me	g ct t Le 15	u va	g aa l As	t tg n Cy	c tcc s Ser		103
99 G1 20	у Су	s Ar	g ac g Th	g cc r Pr	t ct o Le 25	n GI	g ct n Le	c cc u Pr	a tc o Se	30	y AI	c cg .a Ar	a to g Se	t at r Il	t cgc e Arg 35	: !	151
										Page	≥ 38						

									-4			9.				
					gct Ala											199
					tcc Ser											247
					ctg Leu											295
					tat Tyr											343
					tgc Cys 105											391
					att Ile											439
					aag Lys											487
gta Val	cag Gln	gga Gly 150	tgc Cys	aca Thr	gca Ala	ggc Gly	gac Asp 155	tca Ser	ctt Leu	gtc Val	ttc Phe	cac His 160	tac Tyr	tct Ser	ggt Gly	535
					aga Arg											583
					cct Pro 185											631
					gca Ala											679
aag Lys	ctc Leu	cat His	tca Ser 215	att Ile	atc Ile	gat Asp	gct Ala	tgc Cys 220	cat His	agt Ser	ggt Gly	acc Thr	gtt Val 225	ctg Leu	gat. Asp	727
					aga Arg											775
					tca Ser											823
gcc Ala 260	att Ile	tca Ser	att Ile	agt Ser	gga Gly 265	tgt Cys	gat Asp	gat Asp	gat Asp	cag Gln 270	act Thr	tcg Ser	gcc Ala	gac Asp	aca Thr 275	871
tca Ser	gcg Ala	ctg Leu	tcg Ser	aag Lys 280	atc Ile	acg Thr	tct Ser	acg Thr	ggt Gly 285	gct Ala	atg Met	act Thr	ttc Phe	tgt Cys 290	ttt Phe	919
att Ile	caa Gln	gca Ala	att Ile 295	gaa Glu	cgc Arg	agc Ser	gca Ala	caa Gln 300	ggc Gly	aca Thr	acc Thr	tat Tyr	99a Gly 305	agc Ser	ctt Leu	967
					acc Thr											1015
					gtg Val				Leu		Met				999 Gly	1063

	325					330	MBII	.5 Se	quen		isti 335	ng . S	T25		
gga Gly 340	agt Ser	gcg Ala	att Ile	Gly (	gga Gly 345	tta Leu .	aga Arg	cag ( Gln (	GIU .	cct ( Pro ( 350	caa ( Gln 1	ctg Leu	act o	#1 a /	gc Cys 355
caa Gln	aca Thr	ttc Phe	gat Asp	gtc Val 360	tat Tyr	gca Ala	aag Lys	cct Pro	ttc Phe 365	act Thr	ctc Leu	tag	taaa	ggaca	aa
gtca	cttt	tt a	ıtgta	tage	g ag	tgtg	attt	gag	aatc	cgt	ccat	ataa	сс а	cctt	ttgtt
								aag							
<210 <211 <212 <213	l> : 2> 1	30 367 PRT Arabi	idops	is t	hali	lana									
<400	)> :	30													
Met 1	Tyr	Pro	Pro	Pro 5	Pro	Ser	Ser	Ile	Tyr 10	Ala	Pro	Pro	Met	Leu 15	Val
Asn	Cys	Ser	Gly 20	Сув	Arg	Thr	Pro	Leu 25	Gln	Leu	Pro	Ser	Gly 30	Ala	Arg
Ser	Ile	Arg 35	Суз	Ala	Leu	Сув	Gln 40	Ala	Val	Thr	His	Ile 45	Ala	Asp	Pro
Arg	Thr 50	Ala	Pro	Pro	Pro	Gln 55	Pro	Ser	Ser	Ala	Pro 60	Ser	Pro	Pro	Pro
Gln 65	Ile	His	Ala	Pro	Pro 70	Gly	Gln	Leu	Pro	His 75	Pro	His	Gly	Arg	Lys 80
Arg	Ala	Val	Ile	Cys 85	Gly	Ile	Ser	Tyr	Arg 90	Phe	Ser	Arg	His	Glu 95	Leu
ГЛа	Gly	. Cys	Ile 100		Asp	Ala	Lys	Суs 105	Met	Arg	Нів	Leu	Leu 110	Ile	Asn
Lys	Phe	Lys 115		Ser	Pro	Asp	Ser 120	Ile	Leu	Met	Leu	Thr 125	Glu	Glu	Glu
Thr	Asp 130		Tyr	Arg	Ile	Pro 135	Thr	Lys	Gln	Asn	Met 140	Arg	Met	Ala	Leu
Tyr 145		) Lev	ı Val	Gln	Gly 150	Cys	The	Ala	Gly	Asp 155	Ser	Leu	Val	Phe	His 160
Туг	Se	c Gly	/ His	Gly 165		Arg	Glr	a Arg	Asn 170	Tyr	Asn	Gly	Asp	Glu 175	Val
Ası	Gl <sub>y</sub>	у Туз	Asr 180		Thr	Leu	Суя	Pro 185	Leu	Asp	Phe	Glu	Thr 190	Gln	Gly
Me	t Il	e Va:		gaA c	Glı	ı Ile	200	n Ala	Thr	Ile	. Val	Arg 205	Pro	Leu	Pro
Hi	в Gl	y, Va	l Lys	s Lev	Hi:	s Ser	: 11	e Ile		Ala Page	_	His	Ser	Gly	Thr

210

96

192

240

MBI15 Sequence Listing.ST25

Val Leu Asp Leu Pro Phe Leu Cys Arg Met Asn Arg Ala Gly Gln Tyr 230 235

Val Trp Glu Asp His Arg Pro Arg Ser Gly Leu Trp Lys Gly Thr Ala

Gly Gly Glu Ala Ile Ser Ile Ser Gly Cys Asp Asp Asp Gln Thr Ser 260 265 270

Ala Asp Thr Ser Ala Leu Ser Lys Ile Thr Ser Thr Gly Ala Met Thr

Phe Cys Phe Ile Gln Ala Ile Glu Arg Ser Ala Gln Gly Thr Thr Tyr

Gly Ser Leu Leu Asn Ser Met Arg Thr Thr Ile Arg Asn Thr Gly Asn

Asp Gly Gly Ser Gly Gly Val Val Thr Thr Val Leu Ser Met Leu

Leu Thr Gly Gly Ser Ala Ile Gly Gly Leu Arg Gln Glu Pro Gln Leu

Thr Ala Cys Gln Thr Phe Asp Val Tyr Ala Lys Pro Phe Thr Leu

<210> 31 <211> 726

<212> DNA

<213> Arabidopsis thaliana

<220>

<221>

<222> (1)..(726)

<400> 31

atg gcc tcg tca tca tca tca tct tat aga ttc caa tct ggg tct tac Met Ala Ser Ser Ser Ser Ser Tyr Arg Phe Gln Ser Gly Ser Tyr

cct ctt tcg tca agt cct tct ctt ggg aat ttc gtc gaa cgc att aaa Pro Leu Ser Ser Ser Pro Ser Leu Gly Asn Phe Val Glu Arg Ile Lys 20 25 30

gac gct tgt cat ttc ctt gtc tct gct gtt ttg ggt acc att atc tcc Asp Ala Cys His Phe Leu Val Ser Ala Val Leu Gly Thr Ile Ile Ser 144

gcg atc ttg acc ttc ttc ttc gca cta gtg ggc aca ttg cta ggg gca Ala Ile Leu Thr Phe Phe Phe Ala Leu Val Gly Thr Leu Leu Gly Ala 55

ctt aca gga gct ttg ata ggt caa gaa act gag agt ggt ttc att aga Leu Thr Gly Ala Leu Ile Gly Gln Glu Thr Glu Ser Gly Phe Ile Arg

gga gca gca att gga gcc att tcg gga gct gtt ttc tct atc gag gtc Gly Ala Ala Ile Gly Ala Ile Ser Gly Ala Val Phe Ser Ile Glu Val 288

ttt Phe	gaa Glu	tca Ser	tct Ser 100	ctg Leu	gat Asp	ctc Leu	tgg	15 Se aaa Lys 105	tcc	gat	gag	tcg	ggt	ttc Phe	gga Gly	336
tgt Cys	ttt Phe	ctc Leu 115	tac Tyr	ttg Leu	att Ile	gat Asp	gtc Val 120	att Ile	gtt Val	agt Ser	ctt Leu	cta Leu 125	agc Ser	999 999	aga Arg	384
ctt Leu	gta Val 130	cga Arg	gag Glu	cgc Arg	att Ile	ggt Gly 135	cct Pro	gca Ala	atg Met	cta Leu	agt Ser 140	gca Ala	gtg Val	caa Gln	agt Ser	432
caa Gln 145	atg Met	gga Gly	gct Ala	gtg Val	gat Asp 150	aca Thr	gct Ala	ttt Phe	gat Asp	gat Asp 155	cac His	aca Thr	agc Ser	ctt Leu	ttt Phe 160	480
gat Asp	aca Thr	gga Gly	ggc Gly	tca Ser 165	aaa Lys	gga Gly	ttg Leu	aca Thr	gga Gly 170	gac Asp	ctt Leu	gtt Val	gag Glu	aaa Lys 175	atc Ile	528
cca Pro	aag Lys	atg Met	aca Thr 180	atc Ile	act Thr	ggc Gly	aac Asn	aat Asn 185	aac Asn	act Thr	gat Asp	gct Ala	tct Ser 190	gag Glu	aac Asn	576
aca Thr	gac Asp	tca Ser 195	tgt Cys	tct Ser	gtt Val	tgt Cys	ctt Leu 200	cag Gln	gat Asp	ttc Phe	cag Gln	ctc Leu 205	ggt Gly	gaa Glu	aca Thr	624
gtt Val	aga Arg 210	agc Ser	ttg Leu	cct Pro	cat His	tgt Cys 215	cat His	cac His	atg Met	ttt Phe	cac His 220	tta Leu	cct Pro	tgc Cys	ata Ile	672
gac Asp 225	aat Asn	tgg Trp	ctc Leu	ctt Leu	aga Arg 230	cac His	ggt Gly	tct Ser	tgc Cys	ccg Pro 235	atg Met	tgt Cys	aga Arg	cgt Arg	gat Asp 240	720
att Ile	taa		ſ													726
<21 <21 <21	1 > 2 >	32 241 PRT	i don	ai a	+hal	iana										
<21 <40		Arab 32	rdop	818	CHAI	14114				•						
			Ser	Ser 5	Ser	Ser	Ser	Tyr	Arg 10	Phe	Gln	Ser	Gly	Ser 15	Tyr	
Pro	Leu	Ser	Ser 20	Ser	Pro	Ser	Leu	Gly 25	Asn	Phe	Val	Glu	Arg 30	Ile	Lys	
Asp	Ala	Cys 35	His	Phe	Leu	Val	Ser 40	Ala	Val	Leu	Gly	Thr 45	Ile	Ile	Ser	
Ala	11e 50	. Leu	Thr	Phe	Phe	Phe 55	Ala	Leu	val	Gly	Thr 60	Leu	Leu	Gly	Ala	
Leu 65	Thr	Gly	Ala	Lev	Ile 70	Gly	Gln	Glu	Thr	Glu 75	Ser	Gly	Phe	: Ile	Arg 80	

Gly Ala Ala Ile Gly Ala Ile Ser Gly Ala Val Phe Ser Ile Glu Val 85 90 95

Phe Glu Ser Ser Leu Asp Leu Trp Lys Ser Asp Glu Ser Gly Phe Gly 100 105 110

#### MBI15 Sequence Listing.ST25

Cys Phe Leu Tyr Leu Ile Asp Val Ile Val Ser Leu Leu Ser Gly Arg

Leu Val Arg Glu Arg Ile Gly Pro Ala Met Leu Ser Ala Val Gln Ser 130 135 140

Gln Met Gly Ala Val Asp Thr Ala Phe Asp Asp His Thr Ser Leu Phe 145 150 155 160

Asp Thr Gly Gly Ser Lys Gly Leu Thr Gly Asp Leu Val Glu Lys Ile 165 170 175

Pro Lys Met Thr Ile Thr Gly Asn Asn Asn Thr Asp Ala Ser Glu Asn 180 185 190

Thr Asp Ser Cys Ser Val Cys Leu Gln Asp Phe Gln Leu Gly Glu Thr
195 200 205

Val Arg Ser Leu Pro His Cys His His Met Phe His Leu Pro Cys Ile 210 215 220

Asp Asn Trp Leu Leu Arg His Gly Ser Cys Pro Met Cys Arg Arg Asp 225 230 235 240

Ile

<210> 33

<211> 1370 <212> DNA

<213> Arabidopsis thaliana

<220>

<221> CDS

<400> 33

<222> (184)..(969)

<223> G569

gtcgacccac gcgtccgggt ttttctttta tcctcttatc gctaatctgg agctctatat 60 agactataaa gggtttttga ttgattcggg agctcgagat ttgacttctt ttagctgatt 120 cggcaagttt gtatctagaa aggatcgatt ggtgaggtca atagtggttg gtgggtttta 180 gta atg gaa gac ggt gag ctt gat ttc tcc aat cag gaa gtg ttt tcg Met Glu Asp Gly Glu Leu Asp Phe Ser Asn Gln Glu Val Phe Ser 228 agt tcg gag atg ggt gaa tta cca cct agc aat tgt tcg atg gat agt Ser Ser Glu Met Gly Glu Leu Pro Pro Ser Asn Cys Ser Met Asp Ser 276 ttc ttt gat ggg ctt tta atg gat act aat gct gct tgt acc cac act Phe Phe Asp Gly Leu Leu Met Asp Thr Asn Ala Ala Cys Thr His Thr 324 cac acc tgt aac ccc act gga cca gag aac act cat act cac acg tgc His Thr Cys Asn Pro Thr Gly Pro Glu Asn Thr His Thr His Thr Cys 372 ttc cat gtc cac acc aag att ctc ccg gat gag agc gat gaa aaa gtt Phe His Val His Thr Lys Ile Leu Pro Asp Glu Ser Asp Glu Lys Val 420 70

tct act gat gat aca gct gag tct tgt ggg aag aag ggt gaa aag aga Ser Thr Asp Asp Thr Ala Glu Ser Cys Gly Lys Lys Gly Glu Lys Arg 80 85 90 95	468
cct ttg gga aac cgg gaa gcg gtt aga aag tat aga gag aag aag aag Pro Leu Gly Asn Arg Glu Ala Val Arg Lys Tyr Arg Glu Lys Lys Lys 100 105 110	516
gct aaa gct gct tct ttg gag gat gag gtt gca agg ctt agg gcg gtg Ala Lys Ala Ala Ser Leu Glu Asp Glu Val Ala Arg Leu Arg Ala Val 115 120 125	564
aat cag cag ctg gtg aag agg ttg caa aat cag gct acc ttg gaa gct Asn Gln Gln Leu Val Lys Arg Leu Gln Asn Gln Ala Thr Leu Glu Ala 130 135 140	612
gag gtt tcg agg ctt aag tgt ttg ctt gtg gat ttg aga gga aga ata Glu Val Ser Arg Leu Lys Cys Leu Leu Val Asp Leu Arg Gly Arg Ile 145 150 155	660
gat gga gag att gga tct ttt cct tat cag aaa cct atg gct gca aat Asp Gly Glu Ile Gly Ser Phe Pro Tyr Gln Lys Pro Met Ala Ala Asn 160 165 170 175	708
att cct tct tcc tcg cac atg atg aat cct tgt aat gta caa tgt gat Ile Pro Ser Phe Ser His Met Met Asn Pro Cys Asn Val Gln Cys Asp 180 185 190	756
gat gaa gtt tat tgc cct cag aat gtg ttt gga gtg aat agc caa gaa Asp Glu Val Tyr Cys Pro Gln Asn Val Phe Gly Val Asn Ser Gln Glu 195 200 205	804
ggt gcc tcg atc aat gac caa ggg tta agt ggt tgt gat ttt gat cag Gly Ala Ser Ile Asn Asp Gln Gly Leu Ser Gly Cys Asp Phe Asp Gln 210 215 220	852
cta caa tgc atg gct aat cag aac tta aat gga aat gga aac gga tca Leu Gln Cys Met Ala Asn Gln Asn Leu Asn Gly Asn Gly Asn Gly Ser 225 230 235	900
ttc agc aac gtc aat aca tct gtc tcg aat aag aga aaa ggt ggg cat Phe Ser Asn Val Asn Thr Ser Val Ser Asn Lys Arg Lys Gly Gly His 240 245 250 255	948
cgt gca tca aga gca gtt tga agcatcatca agcttgtact atctatttcc Arg Ala Ser Arg Ala Val 260	999
accagcatag atattgtatt ccaaataagt tgtagagttc agctgcagga tcagcttcgc	1059
tcagctttga ggggttggtg gtgtggtctt tctttgtggc acgagtgaga tctatggaca	1119
gaacccagat ttagtagtag tagaggcagg atttcgactt ccactaacca tcatgttgct	1179
tggtgaagaa caaggtatgc ccatgaagca cactgttttg tacattgagc ttgaggggct	1239
gtctctgatc tagccttact gtaacattgc aacgttctca caattgtgat cccaagttgc	1299
tttgttgact taaatgtgat aatatagctt aacttttact tgaaaaaaaa aaaaaaaaaa	1359
aaaaaaaaa a	1370
<210> 34	

<210> 34 <211> 261 <212> PRT <213> Arabidopsis thaliana

<400> 34

Met Glu Asp Gly Glu Leu Asp Phe Ser Asn Gln Glu Val Phe Ser Ser 1 10 15

Ser Glu Met Gly Glu Leu Pro Pro Ser Asn Cys Ser Met Asp Ser Phe Page 44

20

MBI15 Sequence Listing.ST25

Phe Asp Gly Leu Leu Met Asp Thr Asn Ala Ala Cys Thr His Thr His 35 40 45

Thr Cys Asn Pro Thr Gly Pro Glu Asn Thr His Thr His Thr Cys Phe 50 60

His Val His Thr Lys Ile Leu Pro Asp Glu Ser Asp Glu Lys Val Ser 65 70 75 80

Thr Asp Asp Thr Ala Glu Ser Cys Gly Lys Lys Gly Glu Lys Arg Pro

Leu Gly Asn Arg Glu Ala Val Arg Lys Tyr Arg Glu Lys Lys Lys Ala

Lys Ala Ala Ser Leu Glu Asp Glu Val Ala Arg Leu Arg Ala Val Asn 115 120 125

Gln Gln Leu Val Lys Arg Leu Gln Asn Gln Ala Thr Leu Glu Ala Glu 130 135 140

Val Ser Arg Leu Lys Cys Leu Leu Val Asp Leu Arg Gly Arg Ile Asp 145 150 150 160

Gly Glu Ile Gly Ser Phe Pro Tyr Gln Lys Pro Met Ala Ala Asn Ile 165 170 175

Pro Ser Phe Ser His Met Met Asn Pro Cys Asn Val Gln Cys Asp Asp 180 185 190

Glu Val Tyr Cys Pro Gln Asn Val Phe Gly Val Asn Ser Gln Glu Gly

Ala Ser Ile Asn Asp Gln Gly Leu Ser Gly Cys Asp Phe Asp Gln Leu 210 215 220

Gln Cys Met Ala Asn Gln Asn Leu Asn Gly Asn Gly Asn Gly Ser Phe 225 230 235 240

Ser Asn Val Asn Thr Ser Val Ser Asn Lys Arg Lys Gly Gly His Arg 245 250 255

Ala Ser Arg Ala Val

<210> 35

<211> 1638

<212> DNA <213> Arabidopsis thaliana

<220>

<221> CDS

<222> (267)..(1259)

<223> G558

<400> 35

MBI15 Sequence Listing.ST25	
ggaatttcgg atcgtgtctc tctctgtttc tttgtttcaa tccgatttcg aatcaagccc	60
tttacttgtg caccttcaag atttcgtttt ttccagcgcc cagaatgctc cgggtgacca	120
acatttgttc ctgattcatt tcctattggt tcgtattgtc tgtgcacaca agagaaattt	180
caagaagttg ttactaaaag agaggccaca agtggatatt gtctttgtta tcaagtgtta	240
gtacagaaaa gtggtgagaa agtaat atg gct gat acc agt ccg aga act gat Met Ala Asp Thr Ser Pro Arg Thr Asp 1 5	293
gtc tca aca gat gac gac aca gat cat cct gat ctt ggg tcg gag gga Val Ser Thr Asp Asp Asp Thr Asp His Pro Asp Leu Gly Ser Glu Gly 10 15 20 25	341
gca cta gtg aat act gct gct tct gat tcg agt gac cga tcg aag gga Ala Leu Val Asn Thr Ala Ala Ser Asp Ser Ser Asp Arg Ser Lys Gly 30 35 40	389
aag atg gat caa aag act ctt cgt agg ctt gct caa aac cgt gag gca Lys Met Asp Gln Lys Thr Leu Arg Arg Leu Ala Gln Asn Arg Glu Ala 45 50 55	437
gca agg aaa agc aga ttg agg aag aag gct tat gtt cag cag cta gag Ala Arg Lys Ser Arg Leu Arg Lys Lys Ala Tyr Val Gln Gln Leu Glu 60 65 70	485
aac agc cgc ttg aaa cta acc cag ctt gag cag gag ctg caa aga gca Asn Ser Arg Leu Lys Leu Thr Gln Leu Glu Gln Glu Leu Gln Arg Ala 75 80 85	533
aga cag cag ggc gtc ttc att tca ggc aca gga gac cag gcc cat tct Arg Gln Gln Gly Val Phe Ile Ser Gly Thr Gly Asp Gln Ala His Ser 90 95 100 105	581
act ggt gga aat ggt gct ttg gcg ttt gat gct gaa cat tca cgg tgg Thr Gly Gly Asn Gly Ala Leu Ala Phe Asp Ala Glu His Ser Arg Trp 110 115 120	629
ttg gaa gaa aag aac aag caa atg aac gag ctg agg tct gct ctg aat Leu Glu Glu Lys Asn Lys Gln Met Asn Glu Leu Arg Ser Ala Leu Asn 125 130 135	677
gcg cat gca ggt gat tct gag ctt cga ata ata gtc gat ggt gtg atg Ala His Ala Gly Asp Ser Glu Leu Arg Ile Ile Val Asp Gly Val Met 140 145 150	725
gct cac tat gag gag ctt ttc agg ata aag agc aat gca gct aag aat Ala His Tyr Glu Glu Leu Phe Arg Ile Lys Ser Asn Ala Ala Lys Asn 155 160 165	773
gat gtc ttt cac ttg cta tct ggc atg tgg aaa aca cca gct gag aga Asp Val Phe His Leu Leu Ser Gly Met Trp Lys Thr Pro Ala Glu Arg 170 175 180 185	821
tgt ttc ttg tgg ctc ggt gga ttt cgt tca tcc gaa ctt cta aag ctt Cys Phe Leu Trp Leu Gly Gly Phe Arg Ser Ser Glu Leu Leu Lys Leu 190 195 200	869
ctg gcg aat cag ttg gag cca atg aca gag aga cag ttg atg ggc ata Leu Ala Asn Gln Leu Glu Pro Met Thr Glu Arg Gln Leu Met Gly Ile 205 210 215	917
aat aac ctg caa cag aca tcg cag cag gct gaa gat gct ttg tct caa Asn Asn Leu Gln Gln Thr Ser Gln Gln Ala Glu Asp Ala Leu Ser Gln 220 225 230	965
ggg atg gag agc tta caa cag tca cta gct gat act tta tcg agc ggg Gly Met Glu Ser Leu Gln Gln Ser Leu Ala Asp Thr Leu Ser Ser Gly 235 240 245	1013
act ctt ggt tca agt tca tca ggg aat gtc gca agc tac atg ggt cag Thr Leu Gly Ser Ser Ser Ser Gly Asn Val Ala Ser Tyr Met Gly Gln 250 255 260 265	1061

## MBI15 Sequence Listing.ST25

	ca atg gga aag l la Met Gly Lys l 270		u Glu Gly Phe	
	at ttg aga cta ( sn Leu Arg Leu ( 85			
	ga cag tca gca o rg Gln Ser Ala A			
	ta cga gct cta a eu Arg Ala Leu S 320			
gag tga aactgt Glu 330	tattt tggtcacato	g tcagctgtac a	aaatccata tgga	cacaaa 1309
accaggagag act	tattaatc aacacti	tgtc agattcttc	t taccaaatcc a	tcaacaaat 1369
aagcaaattt ctg	gggaaaca aaagact	tctt tgtatgtag	g tttcttctac a	tggttgtgg 1429
taattcatgt tgt	ttttagtt gtagtca	atca gtttttaat	t tagcatttga a	aagttcaat 1489
gttgtttata tag	gcatcttc gattato	ctta gaaaggtta	t tgaattttgt t	ttttttgt 1549
tacttttgtg tgt	tggtaaag gtgttt	taac cttgcaact	t ctgtactgta a	tcatttaac 1609
aatattaaga tgt	ttctattt gagttt!	tgt		1638

<210> 36

<211> 330

<213> Arabidopsis thaliana

<400> 36

Met Ala Asp Thr Ser Pro Arg Thr Asp Val Ser Thr Asp Asp Asp Thr 1 10 15

Asp His Pro Asp Leu Gly Ser Glu Gly Ala Leu Val Asn Thr Ala Ala 20 30

Ser Asp Ser Ser Asp Arg Ser Lys Gly Lys Met Asp Gln Lys Thr Leu 35 40 45

Lys Lys Ala Tyr Val Gln Gln Leu Glu Asn Ser Arg Leu Lys Leu Thr 65 70 80

Gln Leu Glu Gln Glu Leu Gln Arg Ala Arg Gln Gln Gly Val Phe Ile 90 95

Ser Gly Thr Gly Asp Gln Ala His Ser Thr Gly Gly Asn Gly Ala Leu 100 105 110 .

Ala Phe Asp Ala Glu His Ser Arg Trp Leu Glu Glu Lys Asn Lys Gln 115 120 125

Met Asn Glu Leu Arg Ser Ala Leu Asn Ala His Ala Gly Asp Ser Glu 130 135 140

Leu 145	Arg	Ile	Ile	Val	Asp 150	Gly	Val	Met	Ala	His 155	Tyr	Glu	Glu	Leu	Phe 160	
Arg	Ile	Lys	Ser	Asn 165	Ala	Ala	Lys	Asn	Asp 170	Val	Phe	His	Leu	Leu 175	Ser	
Gly	Met	Trp	Lys 180	Thr	Pro	Ala	Glu	Arg 185	Cys	Phe	Leu	Trp	Leu 190	Gly	Gly	
Phe	Arg	Ser 195	Ser	Glu	Leu	Leu	Lys 200	Leu	Leu	Ala	Asn	Gln 205	Leu	Glu	Pro	
Met	Thr 210	Glu	Arg	Gln	Leu	Met 215	Gly	Ile	Asn	Asn	Leu 220	Gln	Gln	Thr	Ser	
Gln 225	Gln	Ala	Glu	Asp	Ala 230	Leu	Ser	Gln	Gly	Met 235	Glu	Ser	Leu	Gln	Gln 240	
Ser	Leu	Ala	Asp	Thr 245	Leu	Ser	Ser	Gly	Thr 250	Leu	Gly	Ser	Ser	Ser 255	Ser	
Gly	Asn	Val	Ala 260		Tyr	Met	Gly	Gln 265	Met	Ala	Met	Ala	Met 270	Gly	Lys	
Leu	Gly	Thr 275	Leu	Glu	Gly	Phe	Ile 280	Arg	Gln	Ala	Asp	Asn 285	Leu	Arg	Leu	
Gln	Thr 290		Gln	Gln	Met	Ile 295		Val	Leu	Thr	Thr 300	Arg	Gln	Ser	Ala	
Arg 305		Leu	Leu	Ala	Ile 310	His	Asp	Tyr	Phe	Ser 315	.Arg	Leu	Arg	Ala	Leu 320	
Ser	Ser	Leu	Trp	Leu 325		Arg	Pro	Arg	Glu 330			•			. *	
<21 <21 <21 <21	1> 2>	37 436 DNA Arab	oidop	sis	thal	iana										
<22 <22 <22 <22	!1> !2>	CDS (83) G139	(3 6	13)												
tc															gatete	60
acq	gtata	ttt	tgga	tcgt	aa t	c at Me 1	g ga et As	ac gg sp Gl	gc ga ly Gl	a ga lu As 5	t ti sp Pl	t go ne Al	c gg a Gl	ga aa Ly Ly	ng gcg ys Ala 10	112
gct Ala	gct Ala	gaa Glu	a gco ı Ala	aag Lys 15	gga Gly	tto Lei	g aad ı Ası	e ccg	g gga 5 Gly 20	tta / Lei	a ato	gtg Val	cto Lei	ctt Lev 25	gtt val	160
gt! Va:	t gga l Gly	a ggt 7 Gly	r ccg	g cti	t ctt 1 Lei	gto u Va	tto 1 Phe	c cta e Lei 35	a ato	gce Ala	a aa	tao n Ty	gtq Va 40	g cti Lei	tac Tyr	208

0/31418

, <b>V</b>	V <b>O</b> 0:	1/357	26													PCT/US00
							MBI	15 S	eque	nce :	List	ing.	ST25			
		gct Ala 45														256
		aag Lys														304
gga Gly 75		taa	aago	cago	ett a	aagct	tcct	t ca	acttg	gtgc	c tco	ettea	aaag			353
cggt	ttt	tgt 1	cggt	taco	ca aa	attto	acco	tte	cggg	gttt	tttt	ctto	ct t	tact	tctgt	413
cato	agg	att a	atctt	tgac	מם כנ	٠,		_		-					_	436
cuc	יכפטי			. cguş	,9 -				•							450
<210 <211 <212 <213	l> ' !> !	38 76 PRT Arabi	idops	sis t	hali	iana										
<400	)> :	38														
		Gly	Glu	Asp 5	Phe	Ala	Gly	Lys	Ala 10	Ala	Ala	Glu	Ala	Lув 15	Gly	
Leu	Asn	Pro	Gly 20	Leu	Ile	Val	Leu	Leu 25	Val	Val	Gly	Gly	Pro 30	Leu	Leu	
Val	Phe	Leu 35	Ile	Ala	Asn	Tyr	Val 40	Leu	Tyr	Val	туг	Ala 45	Gln	Lys	Asn	
	Pro 50	Pro	Arg	Lys	Lys	<b>L</b> ув 55	Pro	Val	Ser	Lys	Lys 60	Lys	Leu	Lys	Arg	
Glu 65	Lys	Leu	Lys	Gln	Gly 70	Val	Pro	Val	Pro	Gly 75	Glu					
<210 <211 <212 <213	>    >	39 1470 DNA Arabi	idops	sis t	hali	lana				-						
<220 <221 <222 <223	l> ( !>	CDS (280) 3265	) (1	(317)												

ctttggtctt ggaagccaaa tcaaaccttt ccttcaatcc tcaaattttc gaaaattttc tcttttgctt tacgttctct caattcttat ttgtaagaaa gtttgttcct ttaatcaatc 120 180 aaatcaaaga gacttttgaa gattgtttcc caatttgcgt caatcgggat cgagtcaaat ctgaaatctt ctccactcat catctgacta taagacttaa tcaagggact ttttgttcgg 240 gtttggtttt aaacgtcttg gattcgaagt ggttaaggt atg gaa aat aat Met Asp Glu Asn Asn 1 5 294 342 gtt gat gat tet tet tet gae teg gte g<br/>t get teg age gaa aac aac Val Asp Asp Ser Ser Ser Asp Ser Val Val A<br/>la Trp Ser Glu Asn Asn 390

			25				MBII	15 Se 30	quer	ice I	Listi		T25 35			
aaa Lys	agc Ser	ttc Phe 40	atc Ile	gtc Val	aag Lys	aat Asn	cca Pro 45	gca Ala	gag Glu	ttt Phe	tca Ser	aga Arg 50	gac Asp	ctt Leu	ctt Leu	438
ccg Pro	aga Arg 55	ttc Phe	ttc Phe	aag Lys	cat His	aag Lys 60	aat Asn	ttc Phe	tca Ser	agt Ser	ttc Phe 65	atc Ile	cgt Arg	cag Gln	ctt Leu	486
aat Asn 70	aca Thr	tat Tyr	ggt Gly	ttt Phe	cga Arg 75	aaa Lys	gta Val	gat Asp	cct Pro	gag Glu 80	aaa Lys	tgg Trp	gaa Glu	ttc Phe	ttg Leu 85	534
aat Asn	gat Asp	gat Asp	ttt Phe	gtt Val 90	aga Arg	ggt Gly	cga Arg	cct Pro	tac Tyr 95	ctt Leu	atg Met	aag Lys	aac Asn	att Ile 100	cat His	582
aga Arg	cga Arg	aaa Lys	ccg Pro 105	gtt Val	cat His	agc Ser	cac His	tcg Ser 110	tta Leu	gtg Val	aat Asn	cta Leu	caa Gln 115	gcg Ala	caa Gln	630
aat Asn	cct Pro	ttg Leu 120	acg Thr	gaa Glu	tca Ser	gaa Glu	aga Arg 125	cgg Arg	agc Ser	atg Met	gag Glu	gat Asp 130	cag Gln	ata Ile	gaa Glu	678
aga Arg	ctg Leu 135	aaa Lys	aat Asn	gag Glu	aaa Lys	gaa Glu 140	ggc Gly	ctt Leu	ctt Leu	gcg Ala	gag Glu 145	tta Leu	cag Gln	aac Asn	caa Gln	726
gag Glu 150	caa Gln	gaa Glu	cgg Arg	aaa Lys	gag Glu 155	ttt Phe	gag Glu	ctg Leu	caa Gln	gta Val 160	acg Thr	aca Thr	ttg Leu	aaa Lys	gat Asp 165	774
cgg	tta Leu	caa Gln	cat His	atg Met 170	gaa Glu	caa Gln	cat His	cag Gln	aaa Lys 175	tca Ser	ata Ile	gtg Val	gca Ala	tat Tyr 180	Val	822
tca Ser	cag Gln	gtt Val	ttg Leu 185	gga Gly	aaa Lys	cca Pro	gga Gly	ctt Leu 190	ser	cta Leu	aac Asn	ctc Leu	gaa Glu 195	aac Asn	cat His	870
gag Glu	aga Arg	aga Arg 200	Lys	aga Arg	aga Arg	ttt Phe	caa Gln 205	Glu	aac Asn	tct Ser	ctt Leu	cct Pro 210	PLO	ago Ser	agt Ser	918
tca Ser	cac His	Ile	gaa Glu	cag Gln	gtc Val	gaa Glu 220	Lys	tta Leu	gaa Glu	tct Ser	Ser 225	ьeu	acg Thr	ttt Phe	tgg Trp	966
gag Glu 230	a Asn	ctt Leu	gta Val	tcg Ser	gaa Glu 235	Ser	tgc Cys	gag Glu	aag Lys	ago Ser 240	GIY	ttg Leu	cag Gln	tca Ser	tca Ser 245	1014
ago Sei	atg r Met	gat Asp	cat His	gat Asp 250	) Ala	gct	gag Glu	tca Ser	agt Ser 255	ner	agt Ser	att Ile	ggc Gly	gat Asp 260	aca Thr	1062
cga	a cco	aaa Lys	tca Ser 265	Ser	aag Lys	att Ile	gat Asp	atg Met 270	ASI	tca Sei	gag Glu	ccg Pro	Pro 275	, val	acc Thr	1110
gt! Va:	t act l Thi	gcg Ala 280	a Pro	gct Ala	cca Pro	aaa Lys	aca Thi 285	c GT	gtt Val	aad L Asi	gat n Ası	gac Asr 290	Pile	tgg Tr	g gaa p Glu	1158
ca: Gl:	a tgi n Cys 29!	s Le	g aca	gag Glu	g aac 1 Ast	cct Pro 300	Gly	a tca y Sei	a acc	gaç Gl	g caa u Gli 30	GII	a gaa n Glu	a gti ı Val	t cag l Gln	1206
tc Se 31	r Gl	g ag	a aga g Arg	a gal	t gto p Val	Gl	aa Y Asi	t gat n Asj	t aat	t aa n As: 32	u GT	t aat y Asi	t aag n Lys	g at	t gga e Gly 325	1254
aa	t ca	a ag	gac	g ta	t tg	g tg	g aa	t tc	a gg	g aa Page		a aa	t aa	c at	t aca	1302

	MBI:	15 8	Seque	nce	List.	ing.:	ST25		
ጥተጥ	Aen	Ser	Clv	Aen	Val.	Aen	Ban	Tla	ч

As Gln Arg Thr Tyr Trp Trp As Ser Gly As Val As As Ile 330 335

gag aaa gct tct tga catgaatgag gtttttgtaa aatagttttc ttttggttcc 1357 Glu Lys Ala Ser

actgagatta ttgtatgtgt tcattattta ttactctgtt tctgtaaaaa caaatctctc 1417 tattgtttga ggcaggagtg acataaatgc atatgcagaa ttggtttcaa aaa

1470

<210> 40

<211> 345

<212> PRT

<213> Arabidopsis thaliana

Met Asp Glu Asn Asn Gly Gly Ser Ser Ser Leu Pro Pro Phe Leu Thr 1 10 15

Lys Thr Tyr Glu Met Val Asp Asp Ser Ser Ser Asp Ser Val Val Ala

Trp Ser Glu Asn Asn Lys Ser Phe Ile Val Lys Asn Pro Ala Glu Phe

Ser Arg Asp Leu Leu Pro Arg Phe Phe Lys His Lys Asn Phe Ser Ser 50 60

Phe Ile Arg Gln Leu Asn Thr Tyr Gly Phe Arg Lys Val Asp Pro Glu 65 70 75 80

Lys Trp Glu Phe Leu Asn Asp Asp Phe Val Arg Gly Arg Pro Tyr Leu 85 90 95

Met Lys Asn Ile His Arg Arg Lys Pro Val His Ser His Ser Leu Val 100 110

Asn Leu Gln Ala Gln Asn Pro Leu Thr Glu Ser Glu Arg Arg Ser Met 115 120 125  $_{-2}$ 

Glu Asp Gln Ile Glu Arg Leu Lys Asn Glu Lys Glu Gly Leu Leu Ala

Glu Leu Gln Asn Gln Glu Gln Glu Arg Lys Glu Phe Glu Leu Gln Val

Thr Thr Leu Lys Asp Arg Leu Gln His Met Glu Gln His Gln Lys Ser

Ile Val Ala Tyr Val Ser Gln Val Leu Gly Lys Pro Gly Leu Ser Leu 180 185 190

Asn Leu Glu Asn His Glu Arg Arg Lys Arg Arg Phe Gln Glu Asn Ser 195 200 205

Leu Pro Pro Ser Ser Ser His Ile Glu Gln Val Glu Lys Leu Glu Ser 210 215 220

Ser	Leu	Thr	Phe	Trp	Glu	Asn	MBI: Leu	l5 Se Val	equer Ser	Glu	ist: Ser	ing.S Cys	T25 Glu	Lys	Ser	
225				_	230					235					240	
Gly	Leu	Gln		Ser 245	Ser	Met	Asp	His	Asp 250	Ala	Ala	Glu	Ser	Ser 255	Leu	
Ser	Ile	Gly	Asp 260	Thr	Arg	Pro	Lys	Ser 265	Ser	Lys	Ile	Asp	Met 270	Asn	Ser	
Glu	Pro	Pro 275	Val	Thr	Val	Thr	Ala 280	Pro	Ala	Pro	Lys	Thr 285	Gly	Val	Asn	
Asp	Asp 290	Phe	Trp	Glu	Gln	Cys 295	Leu	Thr	Glu	Asn	Pro 300	Gly	Ser	Thr	Glu	
Gln 305	Gln	Glu	Val	Gln	Ser 310	Glu	Arg	Arg	Asp	Val 315	Gly	Asn	Asp	Asn	Asn 320	
Gly	Asn	Lys	Ile	Gly 325	Asn	Gln	Arg	Thr	Tyr 330	Trp	Trp	Asn	Ser	Gly 335	Asn	
Val	Asn	Asn	Ile 340	Thr	Glu	Lys	Ala	Ser 345								
<21 <21 <21 <21	1> 2>	41 913 DNA Arab	idopa	sis :	thal	iana										
(21	•			_												
<22 <22 <22 <22 <22	0> 1> 2>	CDS (52) G100	(7													
<22 <22 <22 <22	0> 1> 2> 3>	CDS (52) G100	(7! 6	83)			aaac	t ct	atag	ttag	ttt	ctct	gaa	a at Me 1	g tac t Tyr	57
<22 <22 <22 <22 <40 gat	0> 1>	CDS (52) G100 41 caa	(7)	83) caaa	ac a	aaaa tcc	gac	tac	act	tta	ttq	qaq	tcg	1 ata	g tac t Tyr aca Thr	57 105
<22 <22 <22 <22 <40 gat	0> 1> 2> 3> 0> aaat	CDS (52) G100 41 caa tgc Cys 5	(7)	caaa ata Ile	ac a gaa Glu	aaaa tcc Ser	gac Asp 10	tac Tyr	gct Ala	ttg Leu gag Glu	ttg Leu	gag Glu 15 cga Arg	tcg Ser	ata Ile	aca	
<22 <22 <22 <22 <40 gat gga Gly cgt	0> 1> 2> 3> 0> aaat cag Gln cac His	CDS (52) G100 41 caa tgc Cys 5 ttg	(7) 6 tcaa aat Asn cta Leu	ata Ile gga Gly	gaa Glu gga Gly	tcc Ser gga Gly 25	gac Asp 10 gga Gly	tac Tyr gag Glu	gct Ala aac Asn	ttg Leu gag Glu	ttg Leu ctg Leu 30	gag Glu 15 cga Arg	tcg Ser ctc Leu	ata Ile aat Asn	aca Thr	105
<222 <222 <222 <40 gat ggaggly cgt Arg	0> 1> 2> 3> 0> aaaat cag Gln cac His 20	CDS (52) G100 41 caa tgc Cys 5 ttgc From From From From From From From From	aat Asn cta agt Ser	caaaa ata Ile gga Gly tcg Ser	gaa Glu gga Gly tgt Cys	tcc Ser gga Gly 25	gac Asp 10 gga Gly aca Thr	tac Tyr gag Glu gag	gct Ala aac Asn agt	ttg Leu gag Glu tgg Trp 45	ttg Leu ctg Leu 30 gga	gag Glu 15 cga Arg	tcg Ser ctc Leu ttg	ata ata Ile aat Asn cca Pro	aca Thr gag Glu	105 153
<222 <222 <222 <222 <400 gat gga gga gga gga tcar 35 aaa Lys	0> 1> 2> 3> 0> aaaat caggGln caceHis 20 acac Thr	CDS (52) G100 41 caa tgc 5 5 ttgg From 1 cat 1 ccg 1 c	aat Asn cta Agr	ata Ile gga Gly tcg Ser tca Ser	gaa Glu	tcc Ser gga gGly 25 ttc Phe	gac Asp 10 gga Gly aca Thr	gag Glu gag Glu ttg	gct Ala aac Asn agt Ser Val 60	ttg Leu gag Glu tgg Trp 45 tac	ctg Leu 30 gga Gly	gag Glu 15 cga Arg Gly	tcg Ser ctc Lev	ata Ile aat Asn cca Pro	aca Thr gag Glu ttg Leu 50	105 153 201
<222 <222 <222 <222 <400 gat gga Gly cgt Arg tca Ser 35 aaa Lys	0> 1> 2> 3> 0> aaaat caggGln cacathis 20 acathric gagg cttc	CDS (52) G100 41 caa tgc Cys 5 ttgc Cys 1 cat 1 ccg Pro	aat Asn cta Asp ser gat ttte	ata ata Ile gga Gly tcg Ser tca Ser 55	gaa Glu ggag Glu gag Glu gag Glu	tcc Ser gga Gly 25 ttc Phe	gac Asp 10 gga Gly aca Thr	tac Tyr gag Glu gag Glu ttg Leu tcg 75	gct Ala aac Asn agt Ser Val 60	ttgg Glu tgg Trp 45 tac Tyr	ttg Leu ctg Leu 30 gga Gly	gag Glu 15 cga Arg ggt Gly ctc	tcg Ser ctc Leu ttg Leu ctc Leu	ata Ile	aca Thr gag Glu ttg Leu 50	105 153 201 249

							MBI	15 S	edre	nce	List	ing.	ST25			
														gcg Ala		441
														999 Gly 145		489
														gct Ala		537
														gtt Val		585
														tct Ser		633
tcg Ser 195	tcg Ser	tcg Ser	tcg Ser	tcg Ser	tcc Ser 200	tct Ser	tct Ser	acg Thr	tcg Ser	tcg Ser 205	tct Ser	gaa Glu	aac Asn	Gly ggg	aag Lys 210	681
														gtg Val 225		729
gtg Val	aag Lys	tgt Cys	gag Glu 230	gtt Val	ggt Gly	gat Asp	gag Glu	aca Thr 235	cgt Arg	gtt Val	gat Asp	gag Glu	tta Leu 240	ttg Leu	gtt Val	777
tca Ser	taa	gtt	gato	ett g	gtgtg	gttt	g ta	agtt	gaata	a gtt	ttg	ctat	aaat	gttg	gag	833
gcad	ccaaç	gta a	aagt	gtto	ec co	gtgat	gtaa	a att	agtt	act	aaac	cagag	gcc a	atata	atcttc	893
aato	caaaa	aaa a	aaaa	aaaa	aa											913
<210 <211 <212 <213	L> 2 2> I	12 243 PRT Arabi	dops	sis t	hali	iana				;						
<400	)> 4	2							•						•	
Met 1	Tyr	Gly	Gln	Cys 5	Asn	Ile	Glu	Ser	Asp 10	Tyr	Ala	Leu	Leu	Glu 15	Ser	
Ile	Thr	Arg	His 20	Leu	Leu	Gly	Gly	Gly 25	Gly	Glu	Asn	Glu	Leu 30	Arg	Leu	
Asn	Glu	Ser	Thr	Pro	Ser	Ser	Сув	Phe	Thr	Glu	Ser	Trp	Gly	Gly	Leu	

35

Pro Leu Lys Glu Asn Asp Ser Glu Asp Met Leu Val Tyr Gly Leu Leu 50 60

Lys Asp Ala Phe His Phe Asp Thr Ser Ser Ser Asp Leu Ser Cys Leu 65 70 75 80 80

Phe Asp Phe Pro Ala Val Lys Val Glu Pro Thr Glu Asn Phe Thr Ala 85 90 95

Met Glu Glu Lys Pro Lys Lys Ala Ile Pro Val Thr Glu Thr Ala Val

Lys Ala Ly	ys His 1 15	Tyr Arg		al Arg 20	g Gln	Arg	Pro	Trp 125	Gly	Lys	Phe	
Ala Ala Gl 130	lu Ile i	Arg Asp	Pro A 135	la Lys	Asn	Gly	Ala 140	Arg	Val	Trp	Leu	
Gly Thr Ph 145	he Glu 1	Thr Ala 150	Glu A	sp Ala	a Ala	Leu 155	Ala	Tyr	qaA	Ile	Ala 160	
Ala Phe A	rg Met	Arg Gly 165	Ser A	rg Ala	170	Leu	Asn	Phe	Pro	Leu 175	Arg	
Val Asn Se	er Gly (	Glu Pro	Asp P	ro Val	l Arg	Ile	Thr	Ser	Lys 190	Arg	Ser	
Ser Ser Se	er Ser 95	Ser Ser		Ser Ser 100	r Ser	Thr	Ser	Ser 205	Ser	Glu	Asn	
Gly Lys Lo	eu Lys .	Arg Arg	Arg L 215	ys Ala	a Glu	Asn	Leu 220	Thr	Ser	Glu	Val	
Val Gln Va 225	al Lys	Cys Glu 230	Val G	Sly As <sub>l</sub>	p Glu	Thr 235	Arg	Val	Asp	Glu	Leu 240	
Leu Val S	er											
<210> 43 <211> 91 <212> DN <213> Ar	2 A	is thal:	iana									
	S 3)(85 309	9)										
<400> 43 cgtcgacctc ttaattaaga cgacttgaga gagaaagaaa gatacgtgga ag atg acc 58 Met Thr 1												
aaa tct g Lys Ser G 5	ga gag ly Glu	aga cca Arg Pro	aaa c Lys (	3ln Ar	g Gln	agg Arg	Lys	Gly	tta Leu	tgg Trp	tca Ser	106
cct gaa g Pro Glu G 20	aa gac lu Asp	cag aag Gln Lys	ctc a Leu l 25	aag ag Lys Se	t ttc r Phe	atc Ile	ctc Leu 30	tct Ser	cgt Arg	ggc Gly	cat His	154
gct tgc t Ala Cys T 35	gg acc rp Thr	act gtt Thr Val 40	ecc a	atc ct Ile Le	a gct u Ala	gga Gly 45	ttg Leu	caa Gln	agg Arg	aat Asn	999 Gly 50	202
aaa agc t Lys Ser C	gc aga Ys Arg	tta agg Leu Arg 55	tgg a	att aa Ile As	t tac n Tyr 60	cta Leu	aga Arg	cca Pro	gga Gly	cta Leu 65	aag Lys	250
agg ggg t Arg Gly S	cg ttt Ser Phe 70	agt gaa Ser Glu	gaa (	gaa ga Glu Gl 75	u Glu	acc Thr	atc Ile	ttg Leu	act Thr 80	tta Leu	cat His	298
tet tee t	tg ggt	aac aag	tgg	tct cg	_	gca Page		tat	tta	ccg	gga	346

Ser	Ser	Leu 85	Gly	Asn	Lys	Trp		15 S Arg							Gly	
						aag Lys 105										394
						cca Pro										442
						cta Leu										490
						gtg Val										538
						aaa Lys										586
						aaa Lys 185										634
						tac Tyr										682
						caa Gln										730
						tca Ser										778
						gaa Glu										826
		Ile				caa Gln 265				taa	gaaq	gagto	gaa (	tatga	atcgta	879
agag	ggaad	cat a	agct	agtt	a ct	tgtg	jttad	e ago	2							912
<210 <211 <212 <213	l> 2 2> I	14 268 PRT Arabi	idops	sis t	:hali	lana										
<400	)> 4	14														
Met 1	Thr	Lys	Ser	Gly 5	Glu	Arg	Pro	Lys	Gln 10	Arg	Gln	Arg	Lys	Gly 15	Leu	
Trp	Ser	Pro	Glu 20	Glu	Asp	Gln	Lys	Leu 25	Lys	Ser	Phe	Ile	Leu 30	Ser	Arg	
Gly	His	Ala 35	Сув	Trp	Thr	Thr	Val 40	Pro	Ile	Leu	Ala	Gly 45	Leu	Gln	Arg	
Asn	Gly 50	Lys	Ser	Сув	Arg	Leu 55	Arg	Trp	Ile	Asn	Tyr 60	Leu	Arg	Pro	Gly	
Leu 65	Lys	Arg	Gly	Ser	Phe 70	Ser	Glu	Glu	Glu	Glu 75	Glu	Thr	Ile	Leu	Thr 80	

							MBI1	.5 Se	equer	nce I	isti	ing.S	T25					
Leu	His	Ser	Ser	Leu 85	Gly	Asn	Lys	Trp	Ser 90	Arg	Ile	Ala	Lys	Tyr 95	Leu			
Pro	Gly	Arg	Thr 100	Asp	Asn	Glu	Ile	Lys 105	Asn	Tyr	Trp	His	Ser 110	Tyr	Leu			
Lys	Lys	Arg 115	Trp	Leu	Lys	Ser	Gln 120	Pro	Gln	Leu	Lys	Ser 125	Gln	Ile	Ser			
Asp	Leu 130	Thr	Glu	Ser	Pro	Ser 135	Ser	Leu	Leu	Ser	Cys 140	Gly	Lys	Arg	Asn			
Leu 145		Thr	Glu	Thr	Leu 150	Asp	His	Val	Ile	Ser 155	Phe	Gln	Lys	Phe	Ser 160			
Glu	Asn	Pro	Thr	Ser 165	Ser	Pro	Ser	Lys	Glu 170	Ser	Asn	Asn	Asn	Met 175	Ile			
Met	Asn	Asn	Ser 180	Asn	Asn	Leu	Pro	Lys 185	Leu	Phe	Phe	Ser	Glu 190	Trp	Ile			
Ser	Ser	Ser 195		Pro	His	Ile	Asp 200	Tyr	Ser	Ser	Ala	Phe 205	Thr	Asp	Ser			
Lys	His 210		Asn	Glu	Thr	Gln 215	Asp	Gln	Ile	Asn	Glu 220	Glu	Glu	Val	Met			
Met 225		Asn	Asn	Asn	Asn 230	Tyr	Ser	Ser	Leu	Glu 235	Asp	Val	Met	Leu	Arg 240			
Thr	Asp	Phe	Leu	Gln 245		Азр	His	Glu	Tyr 250	Ala	Asn	Tyr	Туг	Ser 255	Ser			
Gly	Asp	Phe	Phe 260	Ile	Asn	Ser	Asp	Gln 265	Asn	Tyr	Val							
<23 <23	12>	45 1575 DNA Arab		sis	thal	iana												
<2: <2:	20> 21> 22> 23>		. (15 60	75)														
200	00> g gct t Ala		tat Tyr	tac Tyr 5	cct Pro	aat Asn	agt Ser	gtc Val	ggc Gly	atg Met	caa Glr	tct Ser	ctt Leu	tac Tyr 15	caa Gln		48	•
ga G1	a tco u Sei	att Ile	tac Tyr 20	cto Leu	aac Asn	gaa Glu	caa Gln	caa Glr 25	caa Gln	caa Glr	caa Glr	caa Gln	caa Gln 30	gct Ala	tct Ser		96	
tc Se	t tco	tct Sei 35	gct Ala	gca Ala	tct Ser	tto Phe	tcc Ser 40	gag Glu	att i Ile	gtt Val	tco Ser	ggt Gly 45	gat Asp	gtt Val	cga Arg	1	.44	
aa	c aa	gag	gate	ggta	ttt	ato	cca	CC	a aca	a ago	gad	gta	gcc	gto	aac	1	.92	

Asn	Asn	Glu	Met	Val	Phe	Ile							ST25 Ala		Asn	
gga	50	ota	acc	ata	t ca	55 agt		cat	cta	acc	60	Cac	aat	<b>772</b>	002	240
						Ser										240
						aat Asn										288
						cag Gln										336
aat Asn	ctt Leu	aat Asn 115	cct Pro	tct Ser	act Thr	atg Met	tct Ser 120	gat Asp	gag Glu	aat Asn	G1y 999	aag Lys 125	agc Ser	ttg Leu	agt Ser	384
						gat Asp 135										432
						gtt Val										480
						agt Ser										528
						gaa Glu										576
						aag Lys										624
						aca Thr 215										. 672
						cag Gln										720
tta Leu	aca Thr	atg Met	gtg Val	gat Asp 245	gag Glu	gta Val	gat Asp	aaa Lys	agg Arg 250	tat Tyr	aac Asn	caa Gln	tac Tyr	cat His 255	cat His	768
					Àla	tcg Ser	Ser	Phe								816
						tcc Ser										864
						gcg Ala 295										912
						gag Glu										960
						gat Asp										1008
						gtt Val										1056

tta Leu	cct Pro	gaa Glu 355	aac Asn	tct Ser	gtc Val	tct Ser	ata	ctt	equer cga Arg	gct	tgg	ctc	ttt	gag Glu	cat His	1104
ttc Phe	ctt Leu 370	cat His	cca Pro	tat Tyr	cct Pro	aaa Lys 375	gaa Glu	tca Ser	gag Glu	aaa Lys	atc Ile 380	atg Met	ctt Leu	tca Ser	aag Lys	1152
cag Gln 385	aca Thr	gga Gly	cta Leu	tcg Ser	aaa Lys 390	aac Asn	cag Gln	gtt Val	gca Ala	aat Asn 395	tgg Trp	ttt Phe	att Ile	aac Asn	gcg Ala 400	1200
aga Arg	gtt Val	cga Arg	cta Leu	tgg Trp 405	aaa Lys	cca Pro	atg Met	att Ile	gaa Glu 410	gag Glu	atg Met	tat Tyr	aaa Lys	gaa Glu 415	gag Glu	1248
ttt Phe	gga Gly	gaa Glu	tca Ser 420	gca Ala	gag Glu	tta Leu	ctc Leu	tct Ser 425	aac Asn	tct Ser	aat Asn	caa Gln	gac Asp 430	acc Thr	aaa Lys	1296
aaa Lys	atg Met	cag Gln 435	gaa Glu	aca Thr	tct Ser	cag Gln	ctc Leu 440	aaa Lys	cac His	gaa Glu	gac Asp	tct Ser 445	tcg Ser	tct Ser	tcg Ser	1344
caa Gln	caa Gln 450	Gln	aat Asn	cag Gln	gga Gly	aac Asn 455	aac Asn	aac Asn	aac Asn	aac Asn	atc Ile 460	cca Pro	tat Tyr	aca Thr	tct Ser	1392
gat Asp 465	gca Ala	gaa Glu	caa Gln	aac Asn	cta Leu 470	gtc Val	ttt Phe	gca Ala	gat Asp	cct Pro 475	aaa Lys	cca Pro	gac Asp	cgt Arg	gct Ala 480	1440
act Thr	act Thr	gga Gly	gat Asp	tac Tyr 485	Asp	agc Ser	ttg Leu	atg Met	aac Asn 490	tat Tyr	cat His	G1y 999	ttt Phe	ggt Gly 495	att Ile	1488
gat Asp	gat Asp	tac Tyr	aat Asn 500	Arg	tac Tyr	gtt Val	ggc	ctt Leu 505	gga Gly	aac Asn	caa Gln	caa Gln	gat Asp 510	ggc Gly	aga Arg	1536
tat Tyr	tct Ser	aat Asn 515	Pro	cat Kis	caa Gln	tta Leu	cac His 520	Asp	ttt Phe	gtt Val	gtc Val	taa				1575
<21 <21 <21 <21	.1> .2>	46 524 PRT Arab	oidop	sis	thal	iana									-	
<40	0>	46														
Met 1	: Ala	l Val	Туг	Tyr 5	Pro	Asn	Ser	· Val	. Gly 10	Met	Gln	Ser	Leu	Tyr 15	Gln	
Glu	ı Sei	: Ile	Tyr 20	Leu	Asn	Glu	Glr	Glr 25	Gln	Gln	Gln	Gln	Gln 30	Ala	Ser	
Ser	: Sei	35	Ala	Ala	Ser	Phe	Ser 40	: Glu	ıIle	· Val	. Ser	Gly 45	Asp	Val	Arg	
Ası	1 Ası 50	n Glu	ı Met	: Val	Phe	11e 55	Pro	Pro	Thr	Ser	Asp 60	Val	Ala	. Val	. Asn	
G1 <sub>3</sub>	y Ası	n Val	l Thi	c Val	Ser 70	Sei	: Ası	n Ası	) Lev	Sez 75	Phe	His	Gly	Gly	Gly 80	

Leu Ser Leu Ser Leu Gly Asn Gln Ile Gln Ser Ala Val Ser Val Ser 85 90 95

#### MBI15 Sequence Listing.ST25

Pro Phe Gln Tyr His Tyr Gln Asn Leu Ser Asn Gln Leu Ser Tyr Asn 100 105 110

Asn Leu Asn Pro Ser Thr Met Ser Asp Glu Asn Gly Lys Ser Leu Ser 115 120 125

Val His Gln His His Ser Asp Gln Ile Leu Pro Ser Ser Val Tyr Asn 130 135 140

Asn Asn Gly Asn Asn Gly Val Gly Phe Tyr Asn Asn Tyr Arg Tyr Glu 145 150 155 160

Thr Ser Gly Phe Val Ser Ser Val Leu Arg Ser Arg Tyr Leu Lys Pro 165 170 175

Thr Gln Gln Leu Leu Asp Glu Val Val Ser Val Arg Lys Asp Leu Lys 180 185 190

Leu Gly Asn Lys Lys Met Lys Asn Asp Lys Gly Gln Asp Phe His Asn 195 200 205

Gly Ser Ser Asp Asn Ile Thr Glu Asp Asp Lys Ser Gln Ser Gln Glu 210 215 220

Leu Ser Pro Ser Glu Arg Gln Glu Leu Gln Ser Lys Lys Ser Lys Leu 225 230 235 240

Leu Thr Met Val Asp Glu Val Asp Lys Arg Tyr Asn Gln Tyr His His 245 250 255

Gln Met Glu Ala Leu Ala Ser Ser Phe Glu Met Val Thr Gly Leu Gly 260 265 270

Ala Ala Lys Pro Tyr Thr Ser Val Ala Leu Asn Arg Ile Ser Arg His 275 280 285

Phe Arg Cys Leu Arg Asp Ala Ile Lys Glu Gln Ile Gln Val Ile Arg 290 295 300

Gly Lys Leu Gly Glu Arg Glu Thr Ser Asp Glu Gln Gly Glu Arg Ile 305 310 315 320

Pro Arg Leu Arg Tyr Leu Asp Gln Arg Leu Arg Gln Gln Arg Ala Leu 325 330 335

His Gln Gln Leu Gly Met Val Arg Pro Ala Trp Arg Pro Gln Arg Gly 340 345 350

Leu Pro Glu Asn Ser Val Ser Ile Leu Arg Ala Trp Leu Phe Glu His 355 360 365

Phe Leu His Pro Tyr Pro Lys Glu Ser Glu Lys Ile Met Leu Ser Lys 370 375 380

Gln Thr Gly Leu Ser Lys Asn Gln Val Ala Asn Trp Phe Ile Asn Ala 385 390 395 400

### MBI15 Sequence Listing.ST25

A	rg	Val	Arg	Leu	Trp 405	Lys	Pro	Met	Ile	Glu 410	Glu	Met	Tyr	Lya	Glu 415	Glu	
P	he	Gly	Glu	Ser 420	Ala	Glu	Leu	Leu	Ser 425	Asn	Ser	Asn	Gln	Asp 430	Thr	Lys	
I	ys	Met	Gln 435	Glu	Thr	Ser	Gln	Leu 440	Lys	His	Glu	Asp	Ser 445	Ser	Ser	Ser	
G	ln	Gln 450	Gln	Asn	Gln	Gly	Asn 455	Asn	Asn	Asn	Asn	Ile 460	Pro	Tyr	Thr	Ser	
	sp 165	Ala	Glu	Gln	Asn	Leu 470	Val	Phe	Ala	Asp	Pro 475	Lys	Pro	Asp	Arg	Ala 480	
7	hr	Thr	Gly	Asp	Tyr 485	Asp	Ser	Leu	Met	Asn 490	Tyr	His	Gly	Phe	Gly 495	Ile	
1	Asp	Asp	Tyr	Asn 500	Arg	Tyr	Val	Gly	Leu 505	Gly	Asn	Gln	Gln	Asp 510	Gly	Arg	
7	ſyr	Ser	Asn 515	Pro	His	Gln	Leu	His 520		Phe	Val	Val					
•	<210 <211 <211 <211	l > 2 >	47 1983 DNA Arab		sis	thal:	iana										
	<22( <22) <22( <22)	1 > 2 >	CDS (73) G965	(1	956)												
	<40 gat	0> tctc	47 tgt	gtat	gtct	ga a	tcct	taca	g ga	tcca	agag	ctt	tgga	aaa	aaga	tataat	60
4	gaa	taac	aag	at a M	et G	gt t ly L	tag eu A	ct a la T 5	hr T	ca a hr T	ct t hr S	ct t er S	ct a er M 1	et S	ca c er G	aa gat In Asp	111
	tat Tyr	cat His	cat His	cac His	caa Gln	gga Gly	atc Ile 20	ttt Phe	tcc Ser	ttc Phe	tct Ser	aat Asn 25	gga Gly	ttc Phe	cac His	cga Arg	159
	tca Ser 30	t ca Ser	tca Ser	acc Thr	act Thr	cat His 35	cag Gln	gag Glu	gaa Glu	gta Val	gat Asp 40	gaa Glu	tcc Ser	gcc	gto Val	gtc Val 45	207
	tcc Ser	ggt Gly	gct Ala	caa Glr	att Ile 50	ccg Pro	gtt Val	tat Tyr	gaa Glu	acc Thr 55	gcc	gga Gly	atg Met	ttg Leu	tct Ser 60	gaa Glu	255
	atg Met	t t t Phe	gct Ala	tac Tyr 65	cct Pro	ggc Gly	gga Gly	ggt	ggc Gly 70	ggc Gly	ggt	tcc Ser	ggt	99a Gly 75	gag Glu	att lle	303
	ctt Leu	gat	Caç Gli 80	g tot 1 Sei	act Thr	aaa Lys	cag Gln	ttg Lev 85	g cta 1 Lev	gag Glu	caa Gln	caa Gln	aac Asn 90	cgt Arg	cac His	aac Asn	351
	aac Asn	aa Ası 95	aat n Asi	aac n Asi	tca Ser	act Thr	Leu 100	His	ato Met	Lev	. Leu	105	Asr	cat His	cat His	caa Gln	399
										1	Page	60					

### MBI15 Sequence Listing.ST25

					gac Asp 115											447
					tct Ser											495
atg Met	atc Ile	gga Gly	acc Thr 145	gtc Val	cac His	gtg Val	gaa Glu	gga Gly 150	gga Gly	aag Lys	ggt Gly	ttg Leu	tct Ser 155	tta Leu	tct Ser	543
					gcc Ala											591
					gat Asp											639
					aat Asn 195											687
					cac His											735
					gcg Ala											783
					tat Tyr											831
					aga Arg											879
aac Asn 270	aac Asn	tca Ser	aac Asn	Pro	aat Asn 275	act Thr	acc Thr	ggt Gly	gga Gly	gga Gly 280	gga Gly	ggc Gly	gga Gly	gly ggg	tcc Ser 285	927
					aca Thr											975
					caa Gln											1023
gaa Glu	gag Glu	gtg Val 320	gac Asp	cga Arg	cgg Arg	Tyr	aac Asn 325	cac His	tac Tyr	tgc Cys	gaa Glu	caa Gln 330	atg Met	caa Gln	atg Met	1071
					gac Asp											1119
					caa Gln 355											1167
aaa Lys	gac Asp	gcg Ala	gta Val	gcg Ala 370	gtt Val	cag Gln	ctt Leu	aaa Lys	cgc Arg 375	agc Ser	tgt Cys	gag Glu	ctt Leu	cta Leu 380	G1y 999	1215
gat Asp	aaa Lys	gag Glu	gcg Ala 385	gca Ala	<b>61</b> Å 888	gct Ala	gca Ala	tcc Ser 390	tcg Ser	61 y 999	tta Leu	acc Thr	aaa Lys 395	999 Gly	gaa Glu	1263
					ttg Leu											1311

		400					MBI: 405	L5 Se	equer	ice 1	List:	ing.9 410	ST25			
ttt Phe	cat His 415	cat His	atg Met	ggt Gly	Met	atg Met 420	gag Glu	caa Gln	gag Glu	gca Ala	tgg Trp 425	aga Arg	ccg Pro	caa Gln	cgt Arg	1359
ggt Gly 430	ttg Leu	cct Pro	gaa Glu	cgc Arg	tcc Ser 435	gtt Val	aat Asn	atc Ile	ctt Leu	aga Arg 440	gct Ala	tgg Trp	cta Leu	ttc Phe	gag Glu 445	1407
cat His	ttt Phe	ctt Leu	aat Asn	ccg Pro 450	tac Tyr	cca Pro	agc Ser	gat Asp	gct Ala 455	gat Asp	aag Lys	cac His	ctc Leu	tta Leu 460	gca Ala	1455
cga Arg	cag Gln	act Thr	ggt Gly 465	tta Leu	tcc Ser	aga Arg	aat Asn	cag Gln 470	gtg Val	tca Ser	aat Asn	tgg Trp	ttc Phe 475	ata Ile	aat Asn	1503
gct Ala	agg Arg	gtt Val 480	cgc Arg	cta Leu	tgg Trp	aaa Lys	cca Pro 485	atg Met	gtg Val	gaa Glu	gag Glu	atg Met 490	tat Tyr	caa Gln	caa Gln	1551
gaa Glu	gca Ala 495	aaa Lys	gaa Glu	aga Arg	gaa Glu	gaa Glu 500	gca Ala	gaa Glu	gaa Glu	gaa Glu	aat Asn 505	gaa Glu	aat Asn	caa Gln	caa Gln	1599
caa Gln 510	caa Gln	aga Arg	aga Arg	cag Gln	caa Gln 515	caa Gln	aca Thr	aac Asn	aac Asn	aac Asn 520	gac Asp	acg Thr	aaa Lys	ccc Pro	aac Asn 525	1647
aac Asn	aat Asn	gaa Glu	aac Asn	aac Asn 530	ttc Phe	act Thr	gtc Val	ata Ile	acc Thr 535	gca Ala	caa Gln	act Thr	cca Pro	acg Thr 540	acg Thr	1695
atg Met	aca Thr	tcg Ser	aca Thr 545	cat His	cac His	gaa Glu	aac Asn	gac Asp 550	tct Ser	tca Ser	ttc Phe	ctc Leu	tct Ser 555	tcc Ser	gtc Val	1743
gcc Ala	gcc Ala	gct Ala 560	tct Ser	cac His	ggc Gly	ggt Gly	tca Ser 565	gac Asp	gcg Ala	ttc Phe	acc Thr	gtc Val 570	gcc Ala	acg Thr	tgt Cys	1791
cag Gln	caa Gln 575	gac Asp	gtc Val	agt Ser	gac Asp	ttc Phe 580	His	gtc Val	gac Asp	gga Gly	gat Asp 585	GLY	gtg Val	aac Asn	gtc Val	1839
ata Ile 590	Arg	ttc Phe	ggg	acc Thr	aaa Lys 595	cag Gln	act Thr	ggt Gly	gac Asp	gtg Val 600	Ser	ctt Leu	acg Thr	ctt Leu	ggt Gly 605	1887
cta Leu	cgc Arg	cac His	tct Ser	ggc Gly 610	Asn	att Ile	cct	gat Asp	aag Lys 615	aac Asn	act Thr	tct Ser	ttc Phe	tcc Ser 620	gtt Val	1935
aga Arg	gac J Asp	ttt Phe	gga Gly 625	Asp	ttt Phe	tag	tct	tctt	tgt	ttct	caat	tt a	ttca	tc		1983
<21 <21 <21 <21	.1> .2>	48 627 PRT Arab	oidop	sis	thal	iana	ı					•				
<40	)0>	48														
Met 1	: Gly	/ Lev	ı Ala	Thr 5	Thr	Thr	Ser	Ser	Met 10	Ser	Glr	a Asp	Туг	His 15	His	
Hi	s Gl:	ı Gly	7 Ile 20	e Phe	e Ser	Phe	e Sei	25	n Gly	Phe	His	a Arg	Ser 30	Ser	Ser	

Thr Thr His Gln Glu Glu Val Asp Glu Ser Ala Val Val Ser Gly Ala Page 62

35

# MBI15 Sequence Listing.ST25

Gln Ile Pro Val Tyr Glu Thr Ala Gly Met Leu Ser Glu Met Phe Ala 50  $\phantom{000}$  55  $\phantom{000}$  60

Tyr Pro Gly Gly Gly Gly Gly Gly Gly Glu Ile Leu Asp Gln 65 70 75 80

Ser Thr Lys Gln Leu Leu Glu Gln Gln Asn Arg His Asn Asn Asn Asn 90 95

Asn Ser Thr Leu His Met Leu Leu Pro Asn His His Gln Gly Phe Ala

Phe Thr Asp Glu Asn Thr Met Gln Pro Gln Gln Gln His Phe Thr 115 120 125

Trp Pro Ser Ser Ser Asp His His Gln Asn Arg Asp Met Ile Gly 130 135 140

Thr Val His Val Glu Gly Gly Lys Gly Leu Ser Leu Ser Leu Ser Ser 145 150 160

Ser Leu Ala Ala Ala Lys Ala Glu Glu Tyr Arg Ser Ile Tyr Cys Ala 165 170 175

Ala Val Asp Gly Thr Ser Ser Ser Ser Asn Ala Ser Ala His His His 180 185 190

Gln Phe Asn Gln Phe Lys Asn Leu Leu Glu Asn Ser Ser Gln
195 200 205

His His His Gln Val Val Gly His Phe Gly Ser Ser Ser Ser Ser 210 215 220

Pro Met Ala Ala Ser Ser Ser Ile Gly Gly Ile Tyr Thr Leu Arg Asn 225 230 230 240

Ser Lys Tyr Thr Lys Pro Ala Gln Glu Leu Leu Glu Glu Phe Cys Ser 245 250 255

Val Gly Arg Gly His Phe Lys Lys Asn Lys Leu Ser Arg Asn Asn Ser 260 265 270

Asn Pro Asn Thr Thr Gly Gly Gly Gly Gly Gly Ser Ser Ser Ser 275 280 285

Ala Gly Thr Ala Asn Asp Ser Pro Pro Leu Ser Pro Ala Asp Arg Ile 290 295

Glu His Gln Arg Arg Lys Val Lys Leu Leu Ser Met Leu Glu Glu Val 305 310 315 320

Asp Arg Arg Tyr Asn His Tyr Cys Glu Gln Met Gln Met Val Val Asn 325 330 335

- MBI15 Sequence Listing.ST25
  Ser Phe Asp Gln Val Met Gly Tyr Gly Ala Ala Val Pro Tyr Thr Thr
  340 345 350
- Leu Ala Gln Lys Ala Met Ser Arg His Phe Arg Cys Leu Lys Asp Ala 355 360 Sep Ala
- Val Ala Val Gln Leu Lys Arg Ser Cys Glu Leu Leu Gly Asp Lys Glu 370 375 380
- Ala Ala Gly Ala Ala Ser Ser Gly Leu Thr Lys Gly Glu Thr Pro Arg 385 390 395 400
- Leu Arg Leu Leu Glu Gln Ser Leu Arg Gln Gln Arg Ala Phe His His 405 410 415
- Met Gly Met Met Glu Gln Glu Ala Trp Arg Pro Gln Arg Gly Leu Pro 420 430
- Glu Arg Ser Val Asn Ile Leu Arg Ala Trp Leu Phe Glu His Phe Leu 435 440 445
- Asn Pro Tyr Pro Ser Asp Ala Asp Lys His Leu Leu Ala Arg Gln Thr 450 455 460
- Gly Leu Ser Arg Asn Gln Val Ser Asn Trp Phe Ile Asn Ala Arg Val 465 470 475 480
- Arg Leu Trp Lys Pro Met Val Glu Glu Met Tyr Gln Gln Glu Ala Lys 485 490 495
- Glu Arg Glu Glu Ala Glu Glu Glu Asn Glu Asn Gln Gln Gln Gln Arg 500 505 510
- Arg Gln Gln Gln Thr Asn Asn Asn Asp Thr Lys Pro Asn Asn Glu
  515 520 525
- Asn Asn Phe Thr Val Ile Thr Ala Gln Thr Pro Thr Thr Met Thr Ser 530 535 540
- Thr His His Glu Asn Asp Ser Ser Phe Leu Ser Ser Val Ala Ala Ala 545 550 560
- Ser His Gly Gly Ser Asp Ala Phe Thr Val Ala Thr Cys Gln Gln Asp 565 570 575
- Val Ser Asp Phe His Val Asp Gly Asp Gly Val Asn Val Ile Arg Phe 580 585 595
- Gly Thr Lys Gln Thr Gly Asp Val Ser Leu Thr Leu Gly Leu Arg His 595 600 605
- Ser Gly Asn Ile Pro Asp Lys Asn Thr Ser Phe Ser Val Arg Asp Phe 610 620

Gly Asp Phe

### MBI15 Sequence Listing.ST25

<210> 49 <211> 1420 <212> DNA <213> Arabidopsis thaliana	
<220> <221> CDS <222> (138)(1046) <223> G793	
<400> 49 cattetetea cetaacaact ceacacaaqa ttetteqeat qqaaaqttqt tetteqaett	60
ctetteteta actegetate ttttaactea eccageteea etgagtegaa aattteaaac	120
ctttactcgt ttccttc atg gct aat aac aac atc cca cat gat agc Met Ala Asn Asn Asn Asn Ile Pro His Asp Ser 1 5 10	170
atc tcc gat cca tct cct acc gac gat ttc ttc gag cag atc ctc ggg Ile Ser Asp Pro Ser Pro Thr Asp Asp Phe Phe Glu Gln Ile Leu Gly 15 20 25	218
ctt tcc aac ttc tcc ggt tct tca ggt tct ggt ctc tct gga atc ggc Leu Ser Asn Phe Ser Gly Ser Ser Gly Ser Gly Leu Ser Gly Ile Gly 30 35 40	<b>266</b>
ggc gtg ggt cca cct ccg atg atg ctt cag ctt ggt tca ggc aac gaa Gly Val Gly Pro Pro Pro Met Met Leu Gln Leu Gly Ser Gly Asn Glu 45 50 55	314
ggg aat cat aat cat atg ggt gcc att gga gga ggt gga cct gta ggg Gly Asn His Asn His Met Gly Ala Ile Gly Gly Gly Gly Pro Val Gly 60 65 70 75	362
ttt cat aat cag atg ttt ccg ttg gga tta agt ctc gat caa ggg aaa Phe His Asn Gln Met Phe Pro Leu Gly Leu Ser Leu Asp Gln Gly Lys 80 85 90	410
gga cat ggc ttt ctt aaa cct gat gaa act ggt aaa cgt ttc caa gac Gly His Gly Phe Leu Lys Pro Asp Glu Thr Gly Lys Arg Phe Gln Asp 95 100 105	458
gat gtt ctt gat aat cga tgt tcc tct atg aaa cct att ttc cat ggg Asp Val Leu Asp Asn Arg Cys Ser Ser Met Lys Pro Ile Phe His Gly 110 115 120	506
cag cca atg tca cag cca gct cca cca atg ccg cat caa cag tct act Gln Pro Met Ser Gln Pro Ala Pro Pro Met Pro His Gln Gln Ser Thr 125 130 135	554
att cgg cct aga gtt agg gct agg cga ggt caa gct acc gat cca cat Ile Arg Pro Arg Val Arg Ala Arg Arg Gly Gln Ala Thr Asp Pro His 140 145 150 155	602
agc atc gct gag agg ctc cga agg gaa aga ata gca gaa cgg atc agg Ser Ile Ala Glu Arg Leu Arg Arg Glu Arg Ile Ala Glu Arg Ile Arg 160 : 165 170	650
tcg ttg cag gaa ctt gta cct acc gtt aac aag aca gat agg gct gct Ser Leu Gln Glu Leu Val Pro Thr Val Asn Lys Thr Asp Arg Ala Ala 175 180 185	698
atg atc gac gag att gtc gat tat gta aag ttt ctc agg ctc caa gtt Met Ile Asp Glu Ile Val Asp Tyr Val Lys Phe Leu Arg Leu Gln Val 190 195 200	746
aag gtc ctg agc atg agc cgt ctt ggt gga gcc ggt gct gtc gca cca Lys Val Leu Ser Met Ser Arg Leu Gly Gly Ala Gly Ala Val Ala Pro 205 210 215	794
cta gtc act gaa atg cca tta tct tca tca gtt gag gat gag acg cag Leu Val Thr Glu Met Pro Leu Ser Ser Ser Val Glu Asp Glu Thr Gln Page 65	842

					1	MBI1	5 Sec	quen	ce L	isti	ng.S	T25			
220				225					230					235	
gcc g Ala V	tg tg	gg ga rp Gl	g aaa u Lys 240	Trp	tca a Ser i	aac g Asn 1	Asp (	999 8 31y 7 245	ca (	gag Glu	agg Arg	caa Gln	gtg Val 250	gct Ala	890
aag c Lys L	tg a eu M	tg ga et G1 25	u Glu	aac Asn	gtt ( Val (	3ly A	gca q Ala 1 260	gcg a	atg Met	caa Gln	Leu	ttg Leu 265	caa Gln	tca Ser	938
aag g Lys A	la L	tt tg eu Cy 70	c ata s Ile	atg Met	Pro	atc     11e     275	tca ( Ser )	ttg ( Leu i	gca Ala	Met	gcg Ala 280	att Ile	tac Tyr	cat His	986
Ser G		aa cc	a gac	aca Thr	tct Ser 290	tct Ser	tca a	atc (	vaı	aaa Lys 295	cca Pro	gag Glu	atg Met	aat Asn	1034
	ca c		ıg att	tttgt		tcca	acgg	t cc	ccag	ctga	. tga	ttga	cat		1086
tttgc	tctg	t tto	ccact	ac ta	ıgact	tttg	tga	ctca	tga	aagg	taag	ta a	aaaag	gcatt	1146
ggaga	atgga	a tc	aagta	igg at	ttgt	gcag	taa	agaa	gta	aaac	ggga	tc 1	tgtca	aaaaga	1206
aggaa	aaaag	jc tci	cgctt	gc tt	ggct	agta	ttt	atca	ttt	tgat	gaaa	ıgt i	aacto	etttt	1266
tgtto	caaag	ja cti	tagt	tg at	tttc	agga	сса	aggg	ctt	tgaç	ggta	ıgt 🤉	gctag	gctgta	1326
gtaat	tagta	a tga	aaggto	jtg g	gatcg	tgtt	ttt	gaat	tat	gtaa	aaaa	igg i	aagaa	aaaaac	1386
aaatg	gttgg	gt at	tatatt	at gg	gtttt	gcct	gaa	a							1420
<210: <211: <212: <213:	> 30 > Pi	D2 RT	opsis	thal	iana										
<400	> 50	0													
Met 1	Ala A	Asn A	sn Ası 5	n Asn	Ile	Pro	His	Asp 10	Ser	Ile	Ser	Asp	Pro 15	Ser	
Pro '	Thr i		sp Ph	e Phe	Glu								_		
GIV:			0		914	GIII	Ile 25	Leu	Gly	Leu	Ser	Asn 30	Phe	Ser	
<u></u>		Ser G 35	0 ly Se				25					30			
Pro		35		r Gly	Leu	Ser 40	Gly	Ile	Gly	Gly	Val 45	Gly	Pro	Pro	
Pro	Met   50	35 Met I	ly Se	r Gly n Leu	Leu Gly 55	Ser 40 Ser	Gly Gly	Ile Asn	Gly Glu	Gly Gly 60	Val 45 Asn	Gly	Pro	Pro His	
Pro:	Met   50	35 Met I Ala I	ly Se eu Gl	r Gly n Leu y Gly 70 u Ser	Leu Gly 55	Ser 40 Ser Gly	Gly Gly Pro	Ile Asn Val	Gly Glu Gly 75	Gly 60	Val 45 Asn	Gly	Pro Asn	Pro His Met	
Pro	Met 50 Gly	35 Met I Ala I Leu (	ly Se eu Gl	r Gly n Leu y Gly 70 u Ser	Leu Gly 55 Gly	Ser 40 Ser Gly	Gly Gly Pro Gln	Ile Asn Val Gly 90 Gln	Gly Glu Gly 75 Lys	Gly 60 Phe	Val 45 Asn His	Gly His	Pro Asn Gln Phe 95	Pro His Met 80	
Pro Met 65 Phe	Met 50 Gly Pro	Met I Ala I Leu (	ly Se eu Gl le Gl Ely Le 85	r Gly n Leu y Gly 70 u Ser	Gly 55 Gly Leu	Ser 40 Ser Gly Asp	Gly  Gly  Pro  Gln  Phe 105	Ile Asn Val Gly 90 Gln	Gly Glu Gly 75 Lys	Gly 60 Phe Gly	Val 45 Asn His	Gly His Asr	Pro Asn Gln Phe 95	Pro His Met 80	

MBI15 Sequence Listing.ST25

Arg Ala Arg Arg Gly Gln Ala Thr Asp Pro His Ser Ile Ala Glu Arg 145 150 155 160

Leu Arg Arg Glu Arg Ile Ala Glu Arg Ile Arg Ser Leu Gln Glu Leu 165 170 175

Val Pro Thr Val Asn Lys Thr Asp Arg Ala Ala Met Ile Asp Glu Ile 180 185 190

Val Asp Tyr Val Lys Phe Leu Arg Leu Gln Val Lys Val Leu Ser Met 195 200 205

Ser Arg Leu Gly Gly Ala Gly Ala Val Ala Pro Leu Val Thr Glu Met 210 220

Pro Leu Ser Ser Ser Val Glu Asp Glu Thr Gln Ala Val Trp Glu Lys 225 230 235 240

Trp Ser Asn Asp Gly Thr Glu Arg Gln Val Ala Lys Leu Met Glu Glu 245 250 255

Asn Val Gly Ala Ala Met Gln Leu Leu Gln Ser Lys Ala Leu Cys Ile 260 265 270

Met Pro Ile Ser Leu Ala Met Ala Ile Tyr His Ser Gln Pro Pro Asp 275 280 285

Thr Ser Ser Ser Ile Val Lys Pro Glu Met Asn Pro Pro Pro 290 295 300

<210> 51

<211> 1198 <212> DNA

<213> Arabidopsis thaliana

<220>

<221> CDS

<222> (96)..(1052)

<223> G764

55	60	MBI15 Seque	nce Listing.ST25	70
tgg aag gct aag ct Trp Lys Ala Lys Le	u Gly Glu	aaa gag tgg Lys Glu Trp 80	Tyr Phe Phe Cys	gta aga 353 Val Arg 85
gac cga aaa tac co Asp Arg Lys Tyr Pr 90	g act ggt o Thr Gly	tta aga acg Leu Arg Thr 95	aat cgt gct act Asn Arg Ala Thr 100	aaa gcc 401 Lys Ala
ggt tat tgg aaa gg Gly Tyr Trp Lys A 105	t aca ggg a Thr Gly	aaa gat aaa Lys Asp Lys 110	gag atc ttc aaa Glu Ile Phe Lys 115	ggg aaa 449 Gly Lys
tct ctt gtt ggt at Ser Leu Val Gly Mo 120	g aag aaa t Lys Lys 125	aca ttg gtt Thr Leu Val	ttc tac aaa gga Phe Tyr Lys Gly 130	aga gct 497 Arg Ala
cct aaa gga gta a Pro Lys Gly Val L 135	a aca aat s Thr Asn 140	tgg gtc atg Trp Val Met	cat gag tat cga His Glu Tyr Arg 145	tta gaa 545 Leu Glu 150
ggc aaa ttc gct a Gly Lys Phe Ala I 1	c gat aat e Asp Asn 5	ctc tct aaa Leu Ser Lys 160	Thr Ala Lys Asn	gaa tgt 593 Glu Cys 165
gtt att agt cgt g Val Ile Ser Arg V 170	t ttt cat il Phe His	aca cgg act Thr Arg Thr 175	gat ggt acg aag Asp Gly Thr Lys 180	gag cat 641 Glu His
atg tcc gtt ggt t Met Ser Val Gly L 185	a cct ccg eu Pro Pro	ctg atg gat Leu Met Asp 190	tct tct cca tat Ser Ser Pro Tyr 195	cta aag 689 Leu Lys
agt aga gga caa g Ser Arg Gly Gln A 200	ac tct tta ap Ser Leu 205	Ala Gly Thr	acc ctt ggt ggg Thr Leu Gly Gly 210	ttg ttg 737 Leu Leu
tct cac gtt acc t Ser His Val Thr T 215	ac ttc tcc yr Phe Ser 220	gac caa aca Asp Gln Thr	acc gat gac aag Thr Asp Asp Lys 225	agt ctt 785 Ser Leu 230
gtg gcc gat ttt a Val Ala Asp Phe L 2	ys Thr Thr	atg ttt ggt Met Phe Gly 240	Ser Gly Ser Thr	aac ttt 833 Asn Phe 245
tta cca aac ata g Leu Pro Asn Ile G 250	gt tct cta ly Ser Leu	cta gac tto Leu Asp Phe 255	gat cct ctg ttt Asp Pro Leu Phe 260	cta caa 881 Leu Gln
aac aat tot toa g Asn Asn Ser Ser V 265	ta ctg aag al Leu Lys	atg ttg ctt Met Leu Leu 270	gac aat gaa gaa Asp Asn Glu Glu 275	acc caa 929 Thr Gln
ttt aag aag aat o Phe Lys Lys Asn I 280	tt cac aat eu His Asn 285	Ser Gly Ser	tca gag agt gaa Ser Glu Ser Glu 290	cta aca 977 Leu Thr
gcg agt tct tgg c Ala Ser Ser Trp G 295	aa ggt cac ln Gly His 300	aat tot tat Asn Ser Tyi	ggt tcc act ggt Gly Ser Thr Gly 305	cca gtg 1025 Pro Val 310
aat ctt gat tgc g Asn Leu Asp Cys V	tt tgg aaa al Trp Lys 15	ttc tga att Phe	tggaaaa tcgaaaat	tt 1072
ggatgttaac tagggg	gtat atagg	gtttt taaaa	acagt gtatatatgc	gttatgtgtt 1132
agetttagat tetag	atat acaaa	igatga cacta	ataga ttcttataac	attttgtaaa 1192
aaaaaa				1198

<210> 52 <211> 318

MBI15 Sequence Listing.ST25

<212> PRT

<213> Arabidopsis thaliana

<400> 52

Met Asp Tyr Lys Val Ser Arg Ser Gly Glu Ile Val Glu Gly Glu Val 1 5 10 15

Glu Asp Ser Glu Lys Ile Asp Leu Pro Pro Gly Phe Arg Phe His Pro 20 25 30

Thr Asp Glu Glu Leu Ile Thr His Tyr Leu Arg Pro Lys Val Val Asn 35 40 45

Ser Phe Phe Ser Ala Ile Ala Ile Gly Glu Val Asp Leu Asn Lys Val

Glu Pro Trp Asp Leu Pro Trp Lys Ala Lys Leu Gly Glu Lys Glu Trp 65 70 75 80

Tyr Phe Phe Cys Val Arg Asp Arg Lys Tyr Pro Thr Gly Leu Arg Thr 85 90 95

Asn Arg Ala Thr Lys Ala Gly Tyr Trp Lys Ala Thr Gly Lys Asp Lys
100 105 110

Glu Ile Phe Lys Gly Lys Ser Leu Val Gly Met Lys Lys Thr Leu Val

Phe Tyr Lys Gly Arg Ala Pro Lys Gly Val Lys Thr Asn Trp Val Met 130 140

His Glu Tyr Arg Leu Glu Gly Lys Phe Ala Ile Asp Asn Leu Ser Lys 145 150 155 160

Thr Ala Lys Asn Glu Cys Val Ile Ser Arg Val Phe His Thr Arg Thr 165 170 175

Asp Gly Thr Lys Glu His Met Ser Val Gly Leu Pro Pro Leu Met Asp 180 180 190

Ser Ser Pro Tyr Leu Lys Ser Arg Gly Gln Asp Ser Leu Ala Gly Thr 195 200 205

Thr Leu Gly Gly Leu Leu Ser His Val Thr Tyr Phe Ser Asp Gln Thr 210 215 220

Thr Asp Asp Lys Ser Leu Val Ala Asp Phe Lys Thr Thr Met Phe Gly 225 230 240

Ser Gly Ser Thr Asn Phe Leu Pro Asn Ile Gly Ser Leu Leu Asp Phe 245 250 255

Asp Pro Leu Phe Leu Gln Asn Asn Ser Ser Val Leu Lys Met Leu Leu 260 265 270

Asp Asn Glu Glu Thr Gln Phe Lys Lys Asn Leu His Asn Ser Gly Ser 275 280 285

Ser Glu Ser Glu Leu Thr Ala Ser Ser Trp Gln Gly His Asn Ser Tyr 290 295 300

Gly Ser Thr Gly Pro Val Asn Leu Asp Cys Val Trp Lys Phe 305 310

305				•	310											
<210><211><211><212><213>	9: Di	32 NA	dops	is t	hali	ana										
<220: <221: <222: <223:	> C	DS 43). 350	. (75	9)												
<400:	> 5 cttc	3 tc a	attt	agaa	ç tt	agta	gcta	gtc	ttca	aga	ta a M 1	ec A	ca c	tt g eu G	aa lu	54
act of Thr 3	ctt Leu	act Thr	tct Ser	cca Pro	aga Arg 10	tta Leu	tct Ser	tct Ser	ccg Pro	atg Met 15	ccg Pro	act Thr	ctg Leu	ttt Phe	caa Gln 20	102
gat Asp	tca Ser	gca Ala	cta Leu	999 Gly 25	ttt Phe	cat His	gga Gly	agc Ser	aaa Lys 30	ggc Gly	aaa Lys	cga Arg	tct Ser	aag Lys 35	cga Arg	150
tca Ser	aga Arg	tct Ser	gaa Glu 40	ttc Phe	gac Asp	cgt Arg	cag Gln	agt Ser 45	ctc Leu	acg Thr	gag Glu	gat Asp	gaa <sup>.</sup> Glu 50	tat Tyr	atc Ile	198
gct Ala	tta Leu	tgt Cys 55	ctc Leu	atg Met	ctt Leu	ctt Leu	gct Ala 60	cgc Arg	gac Asp	gga Gly	gat Asp	aga Arg 65	aac Asn	cgt Arg	gac Asp	246
ctt Leu	gac Asp 70	ctg Leu	cct Pro	tct Ser	tct Ser	tcg Ser 75	tct Ser	tca Ser	cct Pro	cct Pro	ctg Leu 80	ctt Leu	cct Pro	cct Pro	ctt Leu	294
cct Pro 85	act Thr	ccg Pro	atc Ile	tac Tyr	aag Lys 90	tgt Cys	agc Ser	gtc Val	tgt Cys	gac Asp 95	aag Lys	gcg Ala	ttt Phe	tcg Ser	tct Ser 100	342
tac Tyr	cag Gln	gct Ala	ctt Leu	ggt Gly 105	gga Gly	cac His	aag Lys	gca Ala	agt Ser 110	cac His	cgg Arg	aaa Lys	agc Ser	ttt Phe 115	tcg Ser	390
ctt Leu	act Thr	caa Gln	tct Ser 120	gcc Ala	gga Gly	gga Gly	gat Asp	gag Glu 125	ctg Leu	tcg Ser	aca Thr	tcg Ser	tcg Ser 130	gcg Ala	ata Ile	438
acc Thr	acg Thr	tct Ser 135	Gly	ata Ile	tcc Ser	ggt Gly	ggc Gly 140	GIA	gga Gly	gga Gly	agt Ser	gtg Val 145	aag Lys	tcg Ser	cac His	486
gtt Val	tgc Cys 150	tct Ser	atc Ile	tgt Cys	cat His	aaa Lys 155	tcg Ser	ttc Phe	gcc Ala	acc Thr	ggt Gly 160	caa Gln	gct Ala	ctc Leu	ggc Gly	534
ggc Gly 165	cac His	aaa Lys	cgg Arg	tgc Cys	cac His 170	Tyr	gaa Glu	gga Gly	aag Lys	aac Asn 175	gga Gly	ggc Gly	ggt Gly	gtg Val	agt Ser 180	582
Ser	Ser	Val	Ser	185	Ser	Glu	Asp	vaI	190	ser	aca Thr	Ser	uis	195	261	630
agt	ggo	cac	: cgt	999	ttt	gac	ctc	aac		ccg	70	ata	ccg	gaa	ttc	678

				_		_	MBII	L5 Se	diner	ice I	isti	ing.	T25	<b>a</b> 3	nL.	
			200					Asn 205					210			-
cg Ser	atg Met	gtc Val 215	aac Asn	gga Gly	gac Asp	gaa Glu	gag Glu 220	gtg Val	atg Met	agt Ser	cct Pro	atg Met 225	ccg Pro	gcg Ala	aag Lys	726
ys	ctc Leu 230	cgg Arg	ttt Phe	gac Asp	ttc Phe	ccg Pro 235	gag Glu	aaa Lys	ccc Pro	taa	acat	aaac	ct a	ggaa	aáact	779
	-														gatt	
atgt	tctt	ct t	cact	gaaa	a at	tate	atto	ttt	gttg	jtat	aatt	gato	itt t	ctga	aaaaq	3 899
atat	aact	tt t	tatt	aaaa	a aa	aaaa	aaaa	a aaa	l							932
<210 <211 <212 <213	> 2 > 1	34 238 PRT Arabi	idops	sis t	hali	iana					٠					
<400	> 5	54														
Met 1	Ala	Leu	Glu	Thr 5	Leu	Thr	Ser	Pro	Arg 10	Leu	Ser	Ser	Pro	Met 15	Pro	
Thr	Leu	Phe	Gln 20	Asp	Ser	Ala	Leu	Gly 25	Phe	His	Gly	Ser	Lys 30	Gly	Lys	
Arg	Ser	<b>L</b> ув 35	Arg	Ser	Arg	Ser	Glu 40	Phe	Asp	Arg	Gln	Ser 45	Leu	Thr	Glu	
Asp	Glu 50	Tyr	Ile	Ala	Leu	Сув 55	Leu	Met	Leu	Leu	Ala 60	Arg	Авр	Gly	Авр	
Arg 65	Asn	Arg	Asp	Leu	Asp 70	Leu	Pro	Ser	Ser	Ser 75	Ser	Ser	Pro	Pro	Leu 80	
Leu	Pro	Pro	Leu	Pro 85	Thr	Pro	Ile	Tyr	Lys 90	Суз	Ser	Val	Сув	Авр 95	Lys	
Ala	Phe	Ser	Ser 100	туг	Gln	Ala	Leu	Gly 105	Gly	His	Lys	Ala	Ser 110	His	Arg	
ГÀа		Phe 115		Leu		Gln		Ala	Gly	Gly	Asp	Glu 125	Leu	Ser	Thr	
Ser	Ser 130		Ile	Thr	Thr	Ser 135		Ile	Ser	Gly	Gly 140	Gly	Gly	Gly	Ser	
Val 145	Lys	Ser	His	Val	Cys 150		Ile	Cys	His	Lys 155	Ser	Phe	Ala	Thr	Gly 160	
Gln	Ala	Leu	Gly	Gly 165		Lys	Arg	Сув	His 170	Tyr	Glu	Gly	Lys	Asn 175	Gly	
Gly	Gly	Val	Ser 180		Ser	Val	Ser	Asn 185	Ser	Glu	Asp	Val	Gly 190	Ser	Thr	
Ser	His	Val 195		Ser	Gly	His	Arg 200	Gly				Asn 205	Ile	Pro	Pro	
										age	11					

Ile E	Pro (	3lu I	Phe S	Ser M		/al / 215	Asn (	Gly A	Asp (	Glu (	Glu ' 220	Val N	let S	er I	Pro	
Met I 225	Pro 1	Ala 1	Lys 1	Lys I	Leu <i>1</i> 230	Arg 1	Phe .	Asp :	Phe	Pro 235	Glu i	Lys I	Pro			
<210: <211: <212: <213:	> 1 > D	022 NA	dops	is t	hali	ana										
<220: <221: <222: <223:	> C > (	DS 31). 986	. (84	6)												
<400 catt	> 5 aaat	5 tg g	ctcc	tgtg	a ac	ctaa	attt	atg Met	gac Asp	tat Tyr	gat Asp	ccc Pro 5	aac Asn	acc Thr	aat Asn	54
Pro	ttc Phe 10	gac Asp	ctt Leu	cat His	Phe	tcc Ser 15	ggt Gly	aaa Lys	ctt Leu	ccg Pro	aaa Lys 20	aga Arg	gaa Glu	gtc Val	tcg Ser	102
gct Ala 25	tca Ser	gct Ala	tct Ser	aaa Lys	gtt Val 30	gta Val	gag Glu	aag Lys	aaa Lys	tgg Trp 35	tta Leu	gtg Val	aaa Lys	gat Asp	gag Glu 40	
aag Lys	aga Arg	aat Asn	atg Met	cta Leu 45	caa Gln	gat Asp	gaa Glu	ata Ile	aac Asn 50	cgg Arg	gtt Val	aat Asn	tcg Ser	gag Glu 55	aac Asn	198
aag Lys	aag Lys	cta Leu	acc Thr 60	gaa Glu	atg Met	tta Leu	gca Ala	aga Arg 65	gtc Val	tgt Cys	gag Glu	aag Lys	tac Tyr 70	tat Tyr	gct Ala	246
ctt Leu	aat Asn	aat Asn 75	ctt Leu	atg Met	gag Glu	gag Glu	ttg Leu 80	cag Gln	agt Ser	cga Arg	aag Lys	agt Ser 85	cct Pro	gaa Glu	agt Ser	294
gtt Val	aac Asn 90	ttt Phe	cag Gln	aac Asn	aaa Lys	cag Gln 95	cta Leu	acg Thr	Gly ggg	aaa Lys	cga Arg 100	aaa Lys	caa Gln	gaa Glu	ctt Leu	342
gat Asp 105	gag Glu	ttt Phe	gtt Val	agc Ser	tcc Ser 110	cca Pro	att Ile	gga Gly	ctc Leu	agt Ser 115	ctc Leu	gga Gly	cca Pro	atc Ile	gag Glu 120	390
aac Asn	atc Ile	acc Thr	aac Asn	gat Asp 125	aaa Lys	gcg Ala	acg Thr	vaı	tca Ser 130	TIII	gct Ala	tac Tyr	ttt Phe	gct Ala 135	gct Ala	438
gag Glu	aag Lys	tct Ser	gac Asp 140	aca Thr	agc Ser	ttg Leu	act Thr	gtg Val 145	гÀг	gat Asp	gga Gly	tat Tyr	caa Gln 150	tgg Trp	agg Arg	486
aaa Lys	tac Tyr	999 Gly 155	Gln	aag Lys	att Ile	acg Thr	aga Arg	Asp	aat Asn	cca Pro	tct Ser	cct Pro 165	aga Arg	gct Ala	tac Tyr	534
ttc Phe	aga Arg 170	Сув	tcg Ser	ttt Phe	tca Ser	ccg Pro 175	Ser	tgt Cys	cta Leu	gto Val	aag Lys 180	aag Lys	aag Lys	gtg Val	caa Gln	582
cga Arg 185	Ser	gca Ala	gaa Glu	gat Asp	cca Pro 190	Ser	tto Phe	ttg Lev	gta Val	gco Ala 199	Tur	tac Tyr	gaa Glu	ggg Gly	aca Thr 200	630
														222	att	678

cat aac cac acc gga cca cat gca agt gtg tcc agg aca gtg aaa ctt

His	Asn	His	Thr	Gl <u>y</u> 205	Pro	His					List Arg				Leu	
											gaa Glu					726
											gct Ala					774
											gct Ala 260					822
		gag Glu					tga	aagi	tete	cta q	gaaca	atgta	at · a	tttcI	tgttt	876
tgtt	ctat	ctt (	gtt	gctca	at to	cctag	gtaaa	a aag	ggtaa	aga	ttt	gttt	gat (	ettga	attagg	936
aggo	atag	gat g	gtcaa	attt	a at	gtgt	gtgt	t ata	ataat	tac	atca	aato	cta a	agtai	tccaaa	996
aagg	gtca	acc o	ccal	ttta	at c	tate	3									1022
<210 <211 <212 <213	.> 2 !> 1	56 271 PRT Arab	idopa	sis t	hal:	iana										
<400	)> 5	56														
Met 1	Asp	Tyr	Asp	Pro 5	Asn	Thr	Asn	Pro	Phe 10	Asp	Leu	His	Phe	Ser 15	Gly	
Lys	Leu	Pro	Lys 20	Arg	Glu	Val	Ser	Ala 25	Ser	Ala	Ser	Lys	Val 30	Val	Glu	
ГÀЗ	ГÀЗ	Trp 35	Leu	Val	Lys	Asp	Glu 40	Lys	Arg	Asn	Met	Leu 45	Gln	Asp	Glu	
Ile	Asn 50	Arg	Val	Asn	Ser	Glu 55	Asn	Lys	Ĺув	Leu	Thr 60	Glu	Met	Leu	Ala	
Arg 65	Val	Суз	Glu	Lys	Tyr 70	Tyr	Ala	Leu	Asn	Asn 75	Leu	Met	Glu	Glu	Leu 80	
Gln	Ser	Arg	Lys	Ser 85	Pro	Glu	Ser	Val	Asn 90	Phe	Gln	Asn	Lys	Gln 95	Leu	
Thr	Gly	Lys	Arg 100	Lys	Gln	Glu	Leu	Asp 105	Glu	Phe	Val	Ser	Ser 110	Pro	Ile	
Gly	Leu	Ser 115	Leu	Gly	Pro	Ile	Glu 120	Asn	Ile	Thr	Asn	Asp 125	Lys	Ala	Thr	
	Ser 130	Thr	Ala	Tyr	Phe	Ala 135	Ala	Glu	Lys	Ser	Asp 140	Thr	Ser	Leu	Thr	
Val 145	Lys	Asp	Gly	Tyr	Gln 150	Trp	Arg	Lys	туг	Gly 155	Gln	Lys	Ile	Thr	Arg 160	
Asp	Asn	Pro	Ser	Pro 165	Arg	Ala	Tyr	Phe	170	_	Ser	Phe	Ser	Pro 175	Ser	
										age						

Cys 1	Leu	Val	Lys 180	Lys	Lys	Val	Gln	Arg 185	Ser	Ala	Glu	Авр	Pro 190	Ser	Phe	
Leu '		Ala 195	Thr	Tyr	Glu	Gly	Thr 200	His	Asn	His	Thr	Gly 205	Pro	His	Ala	
Ser	Val 210	Ser	Arg	Thr	Val	Lув 215	Leu	Asp	Leu	Val	Gln 220	Gly	Gly	Leu	Glu	
Pro 225	Val	Glu	Glu	Lys	Lys 230	Glu	Arg	Gly	Thr	Ile 235	Gln	Glu	Val	Leu	Val 240	
Gln	Gln	Met	Ala	Ser 245	Ser	Leu	Thr	Lys	Asp 250	Pro	Lys	Phe	Thr	Ala 255	Ala	
Leu	Ala	Thr	Ala 260	Ile	Ser	Gly	Arg	Leu 265	Ile	Glu	His	Ser	Arg 270	Thr		
<210 <211 <212 <213	l> : !> !	57 1230 DNA Arab	idopa	sis '	thal	iana										
<220 <221 <222 <223	L> ( 2>	CDS (1). G134	. (10: 9	89)												
	0> gct Ala	ant	cgg Arg	aga Arg 5	gaa Glu	gta Val	cgg Arg	tgc Cys	cgg Arg	tgc Cys	ggc	aga Arg	cgg Arg	atg Met 15	tgg Trp	48
gtt Val	caa Gln	cca Pro	gac Asp 20	gcc	cgt Arg	acc Thr	gto Val	caa Gln 25	tgc Cys	tca Ser	acc Thr	tgc Cys	cac His 30	acc Thr	gtc Val	96
acg Thr	cag Gln	Cto Lev 35	tac Tyr	tcg Ser	cta Leu	gtg Val	gac Asp 40	ata Ile	gct Ala	cgc Arg	ggt Gly	gca Ala 45	aac Asn	cgc Arg	ata Ile	144
Ile	His 50	Gly	Phe	Gln	Gln	55	Leu	ı Arg	j Gir	1 1119	60	PIC	GIII	nis	cat His	192
gaa Glu 65	caa Glr	caa Glr	caa Glm	caa Glr	caa Glr 70	atg Met	ato Met	g gct : Ala	a Gir	r ccg Pro 75	Pro	cca Pro	cgg Arg	ctg Lev	ctt Leu 80	240
Ğlu	Pro	Let	ı Pro	85	Pro	) Phe	e G13	y Lys	90 90	s Arg	J Ala	ı val	. Leu	95	ggc Gly	288
Val	Ası	ту:	100	Gly	y Ly:	s Sei	с Ту	109	r Lei	т гу	s GI	y Cyt	110	)	gat Asp	336
Ala	Ly:	3 Se:	r Met 5	; Ar	g Se:	r Lei	12	u va. O	1 G1:	n GII	1 ME	125	5	;	att o Ile	384
gac Asp	Se:	r Il	t cto e Leo	ate 1 Me	g cto	aca u Th: 13!	r GI	a ga u As	t ga p Gl	a gce u Ala	a Sei	r Pro	g cag Gli	g aga	a ata g Ile	432
ccé	ac	g aa	g aga	a aa	c at	t ag	g aa	g gc	g at	g ag		g tta	a gti	ga:	a ggg	480

PCT/US00/31418 WO 01/35726

Pro	Thr	Lys	Arg	Asn	Ile 150	Arg			eque: Met					Glu	Gly 160	
aac	aga Arg	gca Ala	agg Arg	gac Asp 165	tca	cta Leu	gtg Val	ttc Phe	cat His 170	ttc	tct Ser	ggt Gly	cat His	gga Gly 175	tct Ser	528
														gaa Glu		576
ttg Leu	tgc Cys	cct Pro 195	tta Leu	gac Asp	cat His	gaa Glu	aca Thr 200	gaa Glu	gga Gly	aaa Lys	atc Ile	att Ile 205	gat Asp	gac Asp	gag Glu	624
att Ile	aac Asn 210	cgg Arg	ata Ile	ctc Leu	gtg Val	agg Arg 215	cct Pro	ctc Leu	gtc Val	cat His	gga Gly 220	gct Ala	aag Lys	ctt	cac His	672
gct Ala 225	gtc Val	atc Ile	gac Asp	gcc Ala	tgt Cys 230	aac Asn	agc Ser	999 Gly	act Thr	gtc Val 235	ctt Leu	gat Asp	tta Leu	ccc Pro	ttc Phe 240	720
att Ile	tgc Cys	agg Arg	atg Met	gag Glu 245	agg Arg	aat Asn	ggt Gly	tct. Ser	tat Tyr 250	gaa Glu	tgg Trp	gaa Glu	gac Asp	cat His 255	aga Arg	768
tca Ser	gtc Val	aga Arg	gct Ala 260	tac Tyr	aaa Lys	gga Gly	aca Thr	gat Asp 265	ggt Gly	gga Gly	gca Ala	gct Ala	ttc Phe 270	tgt Cys	ttc Phe	816
agt Ser	gct Ala	tgt Cys 275	gac Asp	gat Asp	gat Asp	gaa Glu	tcc Ser 280	agt Ser	ggt Gly	tac Tyr	act Thr	cct Pro 285	gtg Val	ttc Phe	acg Thr	864
999 Gly	aag Lys 290	aac Asn	aca Thr	gga Gly	gcc Ala	atg Met 295	act Thr	tat Tyr	agc Ser	ttc Phe	ata Ile 300	aag Lys	gcg Ala	gtg Val	aag Lys	912
aca Thr 305	gct Ala	gga Gly	cca Pro	gca Ala	ccc Pro 310	acg Thr	tat Tyr	ggc Gly	cac His	ctg Leu 315	ctt Leu	aac Asn	ctt Leu	atg Met	tgt Cys 320	960
tct Ser	gca Ala	ata Ile	cga Arg	gag Glu 325	gcc Ala	cag Gln	tct Ser	cgc Arg	ctc Leu 330	gcc Ala	ttt Phe	aac Asn	999 Gly	gac Asp 335	tac Tyr	1008
aca Thr	agc Ser	tct Ser	gat Asp 340	gca Ala	tcc Ser	gcg Ala	gag Glu	cca Pro 345	ctg Leu	cta Leu	aca Thr	tca Ser	tct Ser 350	gag Glu	gaa Glu	1056
ttt Phe	gac Asp	gtg Val 355	tac Tyr	gcg Ala	aca Thr	aag Lys	ttt Phe 360	gta Val	ctc Leu	tga	atg	ctgt	aca	tatgi	atgctg	1109
caa	atag	ctc 9	ggaa	acgt	tt c	tatg	tgta	t gt	atca	tgta	atg	atta	tgt	tgca	tagcct	1169
ctc	tctt	ctt a	acga	gcaa	ta ag	gcta	tgaa	a ta	attg	attc	gct	aaga	aat	ttaa	aatgaa	1229
a																1230

<400> 58

Met Ala Ser Arg Arg Glu Val Arg Cys Arg Cys Gly Arg Arg Met Trp 1 5 10 15

Val Gln Pro Asp Ala Arg Thr Val Gln Cys Ser Thr Cys His Thr Val 20 30

<sup>&</sup>lt;210> 58 <211> 362 <212> PRT <213> Arabidopsis thaliana

- Thr Gln Leu Tyr Ser Leu Val Asp Ile Ala Arg Gly Ala Asn Arg Ile 35 40 45
- The His Gly Phe Gln Gln Leu Leu Arg Gln His Gln Pro Gln His His 50 55
- Glu Gln Gln Gln Gln Met Met Ala Gln Pro Pro Pro Arg Leu Leu 65 70 75 80
- Glu Pro Leu Pro Ser Pro Phe Gly Lys Lys Arg Ala Val Leu Cys Gly 85 90 95
- Val Asn Tyr Lys Gly Lys Ser Tyr Ser Leu Lys Gly Cys Ile Ser Asp 100 105 110
- Ala Lys Ser Met Arg Ser Leu Leu Val Gln Gln Met Gly Phe Pro Ile 115 120 125
- Asp Ser Ile Leu Met Leu Thr Glu Asp Glu Ala Ser Pro Gln Arg Ile 130 135 140
- Pro Thr Lys Arg Asn Ile Arg Lys Ala Met Arg Trp Leu Val Glu Gly 145 150 155 160
- Asn Arg Ala Arg Asp Ser Leu Val Phe His Phe Ser Gly His Gly Ser 165 170 175
- Gln Gln Asn Asp Tyr Asn Gly Asp Glu Ile Asp Gly Gln Asp Glu Ala 180 185 190
- Leu Cys Pro Leu Asp His Glu Thr Glu Gly Lys Ile Ile Asp Asp Glu 195 200 205
- Ile Asn Arg Ile Leu Val Arg Pro Leu Val His Gly Ala Lys Leu His 210 215
- Ala Val Ile Asp Ala Cys Asn Ser Gly Thr Val Leu Asp Leu Pro Phe 225 230 235 240
- Ile Cys Arg Met Glu Arg Asn Gly Ser Tyr Glu Trp Glu Asp His Arg 245 250 255
- Ser Val Arg Ala Tyr Lys Gly Thr Asp Gly Gly Ala Ala Phe Cys Phe 260 265 270
- Ser Ala Cys Asp Asp Asp Glu Ser Ser Gly Tyr Thr Pro Val Phe Thr 275 280 285
- Gly Lys Asn Thr Gly Ala Met Thr Tyr Ser Phe Ile Lys Ala Val Lys 290 295 300
- Thr Ala Gly Pro Ala Pro Thr Tyr Gly His Leu Leu Asn Leu Met Cys 305 310 315 320
- Ser Ala Ile Arg Glu Ala Gln Ser Arg Leu Ala Phe Asn Gly Asp Tyr
  Page 76

MBI15 Sequence Listing.ST25 330 335

Thr Ser Ser Asp Ala Ser Ala Glu Pro Leu Leu Thr Ser Ser Glu Glu 340 345 350

Phe Asp Val Tyr Ala Thr Lys Phe Val Leu 355

325

# INTERNATIONAL SEARCH REPORT

Interna al application No.
PCT/US00/31418

A. CLAS	SSIFICATION OF SUBJECT MATTER										
IPC(7)	US CI 435/320 1 419 468: 800/278, 279, 287, 301, 305-310, 312, 314, 317, 320, 322										
US CL	International Patent Classification (IPC) or to both nat	tional class	ification and IPC								
	DS SEARCHED										
Minimum do	ocumentation searched (classification system followed b	y classific	ation symbols)								
U.S. : 4	135/320.1, 419, 468; 800/278, 279, 287, 301, 305-310,	312, 314,	317, 320, 322								
Documentat	ion searched other than minimum documentation to the	extent that	such documents are included	I in the fields searched							
Electronic d EAST, USP	lata base consulted during the international search (name AT; STN, Agricola, CaPlus, Biosis, Embase	e of data b	ase and, where practicable, s	earch terms used)							
C. DOC	CUMENTS CONSIDERED TO BE RELEVANT										
Category *	Citation of document, with indication, where app	propriate, e	of the relevant passages	Relevant to claim No.							
X	WO 97/47183 A1 (PURDUE RESEARCH FOUNDA	ATION) 18	December 1997	1-9, 12, 13, 25							
 Y	(18.12.1997), entire reference.			10, 11, 26, 27							
x	US 5,939,601 (KLESSIG et al) 17 August 1999 (17.	entire reference.	1-9, 12, 13, 25								
 V				10, 11, 26, 27							
Y A	Database Genbank on NCBI, US National Library of No. AB009055, SATO, S. et al 'Strucural analysis of IV. Sequence features of the regions of 1,456,315 by assigned P1 and TAC clones. 27 December 2000, D 41-54, see bases 16,003-16,490, 16,571-16,683 and	of Arabido; p covered t ONA RES.	os is thaliana chromosome 5. by nineteen physically 1998, Vol. 5, No. 1, pages	1-13, 25-27							
Funt	ner documents are listed in the continuation of Box C.		See patent family annex.  later document published after the im-	annutional filing data or priority							
	Special categories of cited documents: tent defining the general state of the art which is not considered to be ticular relevance	*T*	date and not in conflict with the appl principle or theory underlying the in- document of particular relevance; the	ication but cited to understand the vention   e claimed invention cannot be							
"E" earlier	r application or patent published on or after the international filing date		considered novel or cannot be considered when the document is taken alone	lered to involve an inventive step							
establ specif	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "Y"  document of particular relevance; the claimed inventions cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combined.										
1	nent referring to an oral disclosure, use, exhibition or other means		being obvious to a person skilled in								
"P" docum	nent published prior to the international filing date but later than the ny date claimed	"&"	document member of the same pater								
Date of th	e actual completion of the international search	Date of	mailing of the international se	earch report							
23 Februa	ry 2001 (23.02.2001)	Authoria	ed officer	A)							
Name and	I mailing address of the ISA/US Commissioner of Patents and Trademarks	1.	TE	ARY T DEA 1019							
1	Box PCT	David F	LAGARTIC .	AL SPECIALIST							
Facsimile	Washington, D.C. 20231 P.No. (703)305-3230	Telephone No. 703-308-TECHNOLOGY CENTER 1600									

Form PCT/ISA/210 (second sheet) (July 1998)

## INTERNATIONAL SEARCH REPORT

Internal application No.
PCT/US00/31418

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claim Nos.:  because they relate to subject matter not required to be searched by this Authority, namely:
Claim Nos.:  because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claim Nos.: 14  because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows: Please See Continuation Sheet
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-13 & 25-27 and SEQ ID NOs 1&2
Remark on Protest
No protest accompanied the payment of additional search fees.

#### INTERNATIONAL SEARCH REPORT

lme......nal application No.

PCT/US00/31418

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Groups I-XXIX, claim(s) 1-14 and 25-27, drawn to a transgenic plant having modified seed characteristics, polynucleotides and vectors for producing said transgenic plant and a method of making said transgenic plant. Applicant must elect one pair of sequences (one nucleic acid and the corresponding amino acid translation) to be examined, i.e. SEQ ID NO: 1 and 2 in Group I, SEQ ID NO: 3 and 4 in Group II, SEQ ID NO: 5 and 6 in Group III, etc.

Group XXX, claim(s) 15-17, drawn to a method of identifying a factor that is modulated.

Group XXXI, claims(s) 18, drawn to a method of identifying a molecule that modulates activity or expression of a polynucleotide or polypeptide.

Group XXXII, claims(s) 19 and 20, drawn to an integrated computer system.

Group XXXIII, claim(s) 21-24, drawn to a method for identifying a polynucleotide sequence comprising selecting a nucleic acid sequence from a database that meets a selected sequence criteria.

The inventions listed as Groups I-XXXIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions listed as Groups I-XXXIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Groups I-XXIX are drawn to a transgenic plant and a method of producing said plant with a nucleic acid sequence. The methods of Groups I-XXIX differ from each other in that they are directed to a plant transformation method and transgenic plant with a structurally and functionally distinct nucleic acid sequence which encodes a structurally and functionally distinct amino acid sequence. In addition, Groups XXX, XXXI and XXXIII are different methods from any of Groups I-XXIX in that they have different method steps and different end products, and Group XXXII requires a computer system. Thus, there is no single special technical feature, which links the inventions of Groups I-XXXIII under PCT Rule 13.2.